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Abstract 
 
cAMP is a secondary messenger that is involved in a variety of signalling 
pathways through its effectors including EPAC, PKA and ion channels. cAMP 
signalling regulates processes such as memory, muscle contraction and 
inflammatory responses. PDE enzymes offer a mechanism to negatively 
regulate elevated cAMP levels elicted by activators of adenylyl cyclase. 
Studies have shown that cAMP signalling is compartmentalised through 
binding of PDEs to A-kinase anchoring proteins (AKAPs) that scaffold PKA 
regulatory subunits.  
 
In this study post-translational-modification of PDE4 isoforms is investigated. 
SUMOylation is a relatively newly identified post-translational modification that 
is known to regulate the structure and function of its substrates. PDE4 
isoforms of the PDE4A and 4D subfamilies are SUMOylated by an E3 ligase, 
PIASy. SUMOylation alters the rolipram sensitivity and potentiates the PKA 
mediated activation of the isoforms whilst it confers protection from ERK-
mediated inhibition of PDE4 activity. SUMOylation alters the association of 
PDE4 isoforms with binding partners like β-Arrestin, AKAP18 δ and UBC9.  
 
Rolipram is an archetypal PDE4 specific inhibitor. In this study it is shown that 
in cells expressing a GFP tagged form of PDE4A4 undergoes redistribution 
into accretion foci upon chronic treatment with rolipram. Data suggests that 
foci formation requires protein turnover and is regulated by signalling 
pathways such as PI3 kinase pathway, p38 MAP kinase pathway and PKC 
pathways. Further, the Immunomodulatory drug Thalidomide® also inhibits 
foci formation.  
 
PDE4 isoforms have isoforms specific N-terminal regions, which play a crucial 
role in sub-cellular localisation and protein-protein interactions. It is shown 
here that PDE4D5 interacts with a novel RhoGAP called ARHGAP21 which 
has been previously reported to bind β-arrestins. This interaction is 
independent of GAP activity of ARHGAP as well as PDE4 activity. Previous 
 iv 
reports have indicated a role of β-Arrestin, PDE4 and ARHGAP21 in 
regulation of actin cytoskeleton dynamics. Hence complex β-Arrestin-PDE4-
ARHGAP21 may play a crucial role in regulating actin dynamics.  
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Chapter 1 General introduction 
 
1.1 Cell Signalling 
 
In multi-cellular organisms various organ systems rely on complex cell-cell 
communication to attain co-ordination. Biological mediators such as peptide 
hormones, cytokines and growth factors, also known as first messengers, 
carry out this communication. First messengers cannot penetrate the cells so 
they need an effective messenger to communicate their signal from the 
plasma membrane through to the cell interior. The signals can be transduced 
to the interior of the cell by plasma membrane receptors and ion channels 
which elicit a specific and complex signalling response leading to the 
production of second messengers, which generate the desired intracellular 
response (Houslay and Milligan, 1997). 
 
1.2  G-protein coupled receptors 
 
G-protein coupled receptors (GPCRs) are the largest family of plasma 
membrane receptors and comprise nearly 1000 receptor variants which relay 
the signal from plasma membrane to the interior of the cell. Binding of ligands 
such as peptide hormones initiates conformational changes in the receptor 
which leads to activation of the one or more members of the guanine-
nucleotide-binding signal transducing proteins (G-proteins) which 
consequently generate an intracellular signal affecting a complex network of 
pathways within the cell (Luttrell, 2006 and Hollmann et al; 2005).  
 
GPCRs possess hepta-helical transmembrane structures (7 TM). The 
transmembrane (TM) domains are connected to each other by alternating 
extracellular and intracellular loops. GPCRs have an extra-cellular N-terminal 
tail and an intra-cellular C-terminal tail. The N-terminal region can vary in 
length from 4-50 amino acids and most GPCRs exhibit at least one 
consensus sequence (Asn-X-Ser/Thr) for N-linked glycosylation within this 
region. The C-terminal region varies considerably in length (12-359 amino 
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acids) with the exception of the mammalian GnRH receptor, which completely 
lacks an intracellular C-terminal domain (Sealfon et al., 1997). The C-tail is 
usually rich in serine and threonine residues that are potential sites for 
phosphorylation by GRKs and second messenger kinases for receptor 
desensitisation (Freedman and Lefkowitz, 1996). The C-terminal tail may also 
possess consensus sequences for palmitoylation and ubiquitination, which 
regulate the signalling of GPCRs (Milligan et al; 2004, Hollmann et al, 2005, 
Yin et al; 2004). Each TM domain ranges from 20-27 amino acids in length 
and the orientation of TM domains in the plasma membrane is highly 
conserved. Various amino acids in TM domains are highly conserved and 
they specify the ligand specificity and receptor activation of the GPCR. The 
TM III region contains a crucial amino acid residue immediately after a 
conserved cysteine residue, which determines the nature of the ligand binding 
to the GPCR. If the amino acid is acidic then the ligand is more likely to be a 
biogenic amine. However, if the amino acid is basic then a peptide ligand can 
be expected (Hollmann et al; 2005 and Yin et al; 2004). The binding of 
biogenic amines to their receptors is characterised by a complex of 
interactions involving key residues in TMs III, V and VI (Strader et al., 1987). 
In these receptors, the amine of the ligand interacts with the carboxyl group of 
an aspartate residue in TM III, whereas the catechol ring interacts with 
residues in TMs V and VI. Interactions of the ligand with TMIII are important 
for binding, while interactions with TMs V and VI are more important for 
receptor activation (Strader et al., 1997). 
 
Various mechanisms have evolved to terminate the signalling cascades 
through GPCRs. Agonist activation of GPCRs initiates a series of reactions 
which result in the “turn off” of the GPCR signal, a process known as 
desensitisation, thus preventing continuous receptor-mediated signalling 
through chronic ligand stimulation. Receptor level regulation, also known as 
homologous desensitisation, is mediated by phosphorylation of the receptor 
within its intracellular domains, via G-protein coupled receptor kinases (GRK) 
and second messenger kinases such as cAMP-activated Protein Kinase A 
(PKA) (Vaughn et al; 2006). GRK phosphorylation marks the receptor for β-
arrestin-mediated internalisation, which can lead to long-term desensitisation 
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if the receptor is degraded and thereby down-regulated. β-arrestin is recruited 
to the preferentially GRK-phosphorylated receptors and acts as a physical 
barrier thereby preventing the interaction between the GPCR and coupling G-
protein.  The N-terminus of β-arrestin binds to phosphate groups of the 
phosphorylated receptors (Vaughn et al, 2006) and aids in internalisation by 
associating with endocytotic machinery including proteins like clathrin with the 
help of an α-helical motif present on arrestin (Wolfe and Trejo, 2007). 
Endocytosed receptors can either be returned to the plasma membrane in a 
resensitised state or targeted for degradation. The mechanisms of GPCR 
resensitisation are thought to involve the internalisation of agonist-activated 
receptors into endosomal compartments which contain a GPCR-specific 
phosphatase. Endosomal acidification promotes the association of the 
receptor with the GPCR phosphatase and dephosphorylation of the receptor. 
Dephosphorylated GPCRs are subsequently recycled back to the cell surface 
where they can be again activated by agonist (Simaan et al; 2005). 
Alternatively, activated receptors can be targeted for degradation via a 
process known as down regulation, which will lead to sorting of receptors for 
degradation by proteasomal/lysosomal pathway. Receptors are ‘marked’ for 
proteasomal degradation following ubiquitination, which is mediated through 
the action of an E3-ligase that interacts with β-arrestin 2 thereby ubiquitinating 
the receptor (Shenoy and Lefkowitz, 2005, Shenoy and Lefkotwitz, 2005).  
 
Heterotrimeric G proteins are guanosine nucleotide binding proteins and 
couple to agonist-occupied GPCRs. The complex comprises α, β and γ 
subunits which are 40-46kDa, 35kDa and 8kDa, respectively.  Gα subunits 
contain two domains, a domain involved in binding and hydrolysis of GTP that 
is structurally homologous to the GTPases of monomeric G proteins and 
elongation factors, and a unique helical domain, which buries the bound GTP 
in the protein core. Gα subunits undergo lipid modification, which allows for 
the attachment to the intracellular membrane and also free movement along 
the membrane. Four distinct classes of Gα proteins have been identified 
namely, Gs, Gi/o, Gq/11 and G12/13 (Hollmann et al; 2005 and Javitch et al; 
1997). Each class of Gα subunit shows varying affinity for a wide variety of 
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GPCRs and G-proteins have been shown to lose or gain affinity due to 
various post-translational modifications such as phosphorylation and 
palmitoylation. When inactive, the guanosine diphosphate (GDP)-bound α-
subunit is tightly bound to βγ subunits and is not associated with the GPCR. 
Upon ligand binding to the GPCR, the transmembrane loops of receptors 
undergo conformational changes, thereby projecting out the sites that show 
high affinity for G-proteins. A GDP/GTP exchange factor (GEF) converts GDP 
on the α subunit to a GTP (guanosine triphosphate) there by activating the G-
protein complex. The activated heterotimeric complex then dissociates into α-
GTP and βγ subunits (Javitch et al; 1997). These two active complexes alter 
the activity of various effectors thereby initiating a range of downstream 
signaling events (Li et al; 2006). The self-regulatory GTPase activity within the 
α subunit hydrolyses the GTP into GDP and leads to re-association of the αβγ 
subunits, and thus terminating signalling (Brink et al; 2004 and Li et al; 2006). 
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Figure 1.1-Schematic representation of G-protein coupled receptor 
signaling  
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1.3  Adenylate Cyclases 
 
Adenylate cyclases (AC) are cAMP producing enzymes. They convert 
adenosine tri-phosphate (ATP) into 3’5’-cyclic adenosine monophosphate 
(cAMP).  Ten isoforms of AC have been identified and the isoforms have 
distinct distribution and are differentially regulated, as listed in table 1.1 
(Bundey and Insel, 2004). Nine of the isoforms are membrane bound while 
the other is a soluble cytosolic form (Sun et al; 2004). The membrane bound 
isoforms show distinct structural homology similar to DNA polymerase and 
possess a cyclase homology domain that plays a vital role in the catalytic 
activity of the isoforms (Cooper and Crosswaite, 2006). Regulation of 
adenylate cyclase isoforms is achieved by various mechanisms, which include 
binding of di-valent cations e.g. calcium, magnesium and manganese, binding 
of G-proteins and phosphorylation. Ca+2/calmodulin binding regulates the 
activity of isoforms 1, 3 and 8. Ca2+ inhibits AC5 and AC6 activity, whereas 
AC2, AC4 and AC7 are insensitive to Ca2+ (Cooper, 2003). Manganese-
dependent cytosolic AC10 is uniquely activated by bicarbonate ions (Sun et 
al; 2004).  
 
Phosphorylationn is another major regulator of adenylate cyclase activity. 
Various kinases are known to phosphorylate adenylate cyclases. The activity 
of AC1, AC2, AC3, AC5 and AC7 is enhanced by PKC phosphorylation 
whereas PKC action inhibits the activity of AC4 and AC6. Phosphorylation of 
AC5, AC6 by PKA, and AC3, AC1 by calmodulin kinases (CaMK) II and IV are 
known to have down-regulatory actions (Beazley and Watts, 2006). Nitric 
Oxide (NO) has also been reported to have regulatory affects on AC activity in 
that NO donors are known to inhibit the activity of AC5 and AC6 (Cooper, 
2003).  
 
Forskolin is a labdane diterpene from the plant Plectranthus barbatus and is 
known to augment the levels of cAMP in the cells by allosterically activating 
ACs in a mechanism similar to that achieved by activated Gsα (Hurley, 1999 
and Hurley 1998).  
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Isoform Cellular 
distribution 
                             Regulation 
AC1, 3 and 8 Lipid rafts Stimulated by 
calcium 
Inhibited by both 
Gβγ and Giα. 
Stimulated by Gsα 
AC2, 4 and 7 Non-rafts Calcium 
insensitive 
Stimulated by Gβγ 
and by Gsα 
Not effected by 
Giα 
AC5 and 6 Lipid rafts Inhibited by 
Calcium 
Stimulated by 
Gsα. Inhibited by 
Giα. Not affected 
by Gβγ 
AC9 Not known Inhibited by 
Calcineurin 
     ------ 
Soluble 
Isoform  
Cytosol Not known      ------ 
 
 
 
Table 1.1- The adenylate cyclase isoforms, their cellular distribution and 
regulatory mechanisms.  
 
1.4  cAMP  
 
The discovery of the signal functioning of 3’, 5’ cyclic adenosine mono-
phosphate (cAMP) led to the now widely accepted concept of a secondary 
messenger system (Beavo and Brunton, 2002). Cyclic AMP has been 
implicated in various metabolic activities, such as ion-channel regulation, cell 
growth and differentiation (Beavo and Brunton, 2003, Houslay and Milligan, 
1997).  
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The levels of cAMP within cells are under stringent control, which if not 
maintained can lead to erroneous signalling events and subsequently disease 
e.g. cholera. Cholera toxin catalyses the ADP ribosylation of α-Gs leading to 
constitutive adenylyl cyclase activation (Houslay and Milligan, 1997). Various 
signalling complexes as discussed below tightly regulate cAMP levels. 
 
1.5  Effectors of cAMP signalling 
 
1.5.1 Protein kinase A (PKA) 
 
Protein phosphorylation is one of the most important post-translational 
modifications. Protein kinases are a class of enzymes that phosphorylate their 
target proteins at Ser, Thr or Tyr residues (Krebs and Beavo, 1979). Protein 
kinase A provides the classic downstream effector of cAMP action (Taylor et 
al; 2005, Taylor et al; 1990, Kim et al; 2006).  
 
Protein kinase A is a tetrameric holoenzyme complex (R2C2) in its inactive 
state comprises of two catalytic(C) subunits and two regulatory (R) subunits 
(R2C2).  
 
The binding of two cAMP molecules to each of the R (regulatory) subunits 
leads to a conformational change in the tetrameric holoenzyme complex 
subsequently allowing the separation of the regulatory subunits from the 
catalytic subunits (Daniel et al; 1998, Johnson et al; 2001, Tasken and 
Aandahl, 2004) (figure 1.2).  
 
There are four genes RIα, RIβ, RIIα, and RIIβ encoding the regulatory 
subunits. Similarly, there are three genes for encoding the catalytic subunit, 
namely, Cα, Cβ, and Cγ (Tasken and Aandhal, 2004). A further C-subunit has 
been identified recently, known as PrKX and is encoded by human X-
chromosome. This subunit binds RI regulatory subunits but not RII subunits 
(Zimmermann et al; 2000). 
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The C-subunit contains a core catalytic site flanked by amino-terminal and 
carboxyl-terminal tails varying between 39-50 aminoacids in length. These 
two tail regions maintain the stability of the core (Taylor et al; 2005). The N-
terminal tail of C-subunit is known to undergo post-translational modifications 
including phosphorylation and myristoylation. The amino-terminus of C-
subunit is also known to interact with AKIP (A-kinase interacting protein), 
which promotes the transportation of C-subunit into nucleus (Taylor et al; 
2005) 
 
Regulatory subunits (R-subunits) play a key role in interacting with A-kinase 
anchoring proteins (AKAPs). AKAPs interact with R-subunits through their N-
terminal region, which has a dimerization/docking domain whereas the C-
terminus portions of the R-subunits contain the sites for cAMP binding (Taylor 
et al, 2005). Dimerization of RII subunits is a prerequisite for their interaction 
with AKAPs (Tasken and Aandhal 2004). 
 
Two different isoforms of PKA are reported to exist in cells. Isoform I, 
comprises RIα and RIβ subunits whereas isoform II possesses RIIα, and RIIβ 
subunits. PKA-I is mostly cytosolic while PKA-II is known to associate with 
AKAPs and is predominantly localized within sub-cellular compartments 
(McConnachie et al; 2006, Michel and Scott, 2002, Taylor et al, 1990). PKA 
phosphorylates Ser/Thr residues within various consensus sites. The most 
stringent PKA consensus motif is Arg-Arg-X-Ser/Thr but motifs including Arg-
Lys-X-Ser/Thr or Arg-Lys-X-X-Ser/Thr where X is a hydrophobic amino acid 
can also serve as PKA substrates (Kennelly and Krebs, 1991, Zetterqvist et 
al; 1976).  
 
Protein Kinase I is an endogenous inhibitor of PKA. Isoforms of PKI bind to 
and inhibits the activity of various catalytic subunits of PKA.  
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Figure 1.2: Schematic representation of activation of Protein Kinase A 
 
1.5.2 Exchange Protein Activated by cAMP (EPAC) 
 
In 1998, De Rooij and coworkers (De Rooij et al, 1998) identified an 881 
amino acid protein with distinct regions for cAMP binding and GEF activity 
naming it Exchange Protein Activated by cAMP (EPAC) thus identifying 
another effector of the cAMP signaling cascade (Kraemer et al; 2001, 
Kawasaki et al; 1998).   
 
Two isoforms of EPAC have been identified, namely EPAC1 and EPAC2. 
Both the isoforms activate the Ras-like G-protein Rap, which in turn has two 
isoforms, namely Rap1 and Rap2.  
 
EPAC has an N-terminal DEP (Dishevelled, Egl-10, Pleckstrin) domain, a 
cyclic nucleotide-binding domain, a Ras exchange motif (REM) and catalytic 
domains from the N-terminal towards C terminal regions in the same order. 
The DEP domain is known to be involved determining localization of EPAC 
within the cell. EPAC is generally associated with mitochondrial and peri-
nuclear regions of the cell (Magiera et al; 2004). EPAC2 differs from EPAC1 
in that it has an extra cAMP-binding region in its extreme N-terminus and a 
Ras binding domain between REM and catalytic regions (Rehmann et al; 
2003). Cyclic AMP binds EPAC and induces conformational changes in the N-
terminal region eventually leading to the activation of GEF domain. The EPAC 
GEF activity promotes the exchange of GDP for GTP on Rap. EPAC-cAMP 
complex therefore leads to activation of Rap1 and Rap 2 in a PKA-
independent manner.  
PK
A 
R 
subunits 
C 
subunits 
cAMP  
Substrate 
phosphorylation 
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EPAC plays a major role in integrin-mediated cell adhesion by interacting with 
Rap1 and light chain 2 of Microtubule associated Protein 1A (MAP1A-LC2) 
(Yarwood et al; 2005, Borland et al; 2006), Rangarajan et al; 2003). It has 
also been reported that EPAC is able to interact with AKAP6, which suggests 
the role of EPAC in spatial and temporal aspects of cAMP signaling 
(McConnachie et al, 2006). 
 
EPAC has also been shown to be involved in elevating intracellular calcium 
levels via Rap2B activation subsequently leading to the activation of 
Phospholipase Cε (PLCε) (Keiper et al; 2004, Vom et al; 2004). EPAC has a 
similar role in activation of PKCε, through PLC and PKD. This pathway is 
suggested to be involved in inflammatory pain (Hucho et al; 2005). The 
elevation of intracellular calcium by EPAC has been shown to have a role in 
regulating the secretory activity of pancreatic acinar cells (Chaudhari et al; 
2007).  
 
1.5.3 Cyclic nucleotide gated ion channels (CNG ion channels) 
 
CNG ion channels are regulated by cyclic nucleotides like cAMP and/or 
cGMP. They were first discovered in vertebrate retinal rods and olfactory 
sensory neurons (Bradley et al; 2005, Pifferi et al; 2006). There are six genes 
that encode four A subunits and two B subunits of CNG. They exist in either 
homo- or hetero-tetrameric states and the cyclic nucleotide binding occurs 
within their C-terminal region (Young and Krougliak, 2004, Bradley et al, 
2005). Activation of a GPCR coupled adenylyl or guanylyl cyclase leads to 
increase in levels of cyclic nucleotides, which can then bind and regulate CNG 
ions channel activity. For example, CNG (A2)2-A4-B1b is present in olfactory 
sensory neurons and is sensitive to cAMP where by elevated levels of cAMP 
increase the activity of the CNG. However, CNGs are not inactivated by cyclic 
nucleotides. CNG ions channels are non-specific cation channels and their 
activity is regulated by calcium-calmodulin cascade (Bradley et al; 2005).   
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1.6  The cyclic Nucleotide phosphodiesterase (PDE) superfamily 
 
Cyclic Nucleotide phosphodiesterases (PDEs) are a class of enzymes that 
catalyse the hydrolysis of cyclic nucleotides into their respective 5` 
mononucleotides. PDEs are localised in various cellular compartments and 
they regulate the basal levels of cyclic nucleotides in the cells (Houslay and 
Adams; 2003). The PDE superfamily constitutes 11 subfamilies that differ in 
their sequence homology, substrate specificity, regulation and selective 
inhibition (Lynch et al; 2006 Houslay and Adams; 2003, Houslay; 2001 and 
Houslay and Milligan 1997). Despite their differences, all PDE subfamilies 
share a highly conserved catalytic region with some structural differences 
generated by the substrate specificity. In the nomenclature of PDE 
superfamily, an Arabic numeral is used to indicate the family, then a capital 
letter indicating the gene within the family followed by a numeral indicating the 
splice variant are used. For example, PDE4B1 indicates subfamily 4, gene B 
and splice variant 1 (Lynch et al; 2006). Isobutylmethylxanitine (IBMX) inhibits 
all PDE enzymes except isoenzymes of PDE subfamilies 8 and 9, which are 
insensitive to it.  Table 1.2 depicts various features of PDE subfamilies. 
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Dipyridamole 
and Zaprinast 
GAF cAMP and cGMP A PDE11 
Dipyridamole 
and Zaprinast 
GAF cAMP and cGMP A PDE10 
Zaprinast and 
SCH51866.IBMX 
insensitive 
___ cGMP A PDE9 
Unknown and 
IBMX insensitive 
___ cAMP A PDE8 
BRL 50481 and 
ICI 242  
___ cAMP A and B PDE7 
Zaprinast and 
Sildenafil 
GAF cGMP A, B, and C PDE6 
Sildenafil GAF cGMP A PDE5 
Rolipram and 
Ariflo® 
UCR  cAMP A, B, C and D PDE4 
Cilostimide  cAMP   A and B PDE3 
EHNA GAF cAMP and cGMP A PDE2 
Nicarpidine and 
Vinopectine 
CaM binding cAMP and cGMP A, B, C PDE1 
Selective 
inhibitors 
Regulatory 
domains 
Substrate Genes PDE 
Table 1.2 Classification of Cyclic nucleotide PDE superfamilies. 
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1.6.1 Phosphodiesterase-1 
 
Phosphodiestarase1 family of enzymes are calcium-calmodulin dependent 
dual specificity phosphodiesterases. Three genes A, B and C encode both 5’ 
and 3’ mRNA splice variants of PDE1 isoenzymes (Lugnier; 2006, Goraya 
and Cooper; 2005, Snyder et al; 1999). PDE1A and PDE1B genes encode 
two splice variants PDE1A1, 2 and PDE1B1, 2 respectively and preferentially 
hydrolyse cGMP whereas PDE1C gene encodes five splice variants 1-5 and 
hydrolyses both cAMP and cGMP (Giembycz; 2005)  
 
PDE1 isoforms are dimers and although they have been found in the 
cytosolic, some studies suggest that they can exist in particulate fractions of 
olfactory neurons and plasma membrane (Goraya and Cooper; 2005, Francis 
2001). PDE1 activity can be inhibited by vinopectine and nicardipine (Houslay 
2001). PDE1 activity can be regulated by PKA and Cam Kinase II 
phosphorylation (Lugnier; 2006).  
 
1.6.2 Phosphodiesterase-2  
 
Beavo and coworkers (Beavo et al, 1971) first discovered phosphodiesterase 
2 in 1971 in rat liver preparations where they showed that the enzyme 
hydrolysed cAMP more effectively in the presence of cGMP.  Three splice 
variants; PDE2A1 PDE2A2 and PDE2A3 respectively are generated from 
PDE2 gene. PDE2A2 is more hydrophobic than the other two splice variants 
of the family. PDE2 enzymes, like PDE1, are dual-specific and hydrolyse 
cGMP and cAMP with Km values 10µmol/ L and 30µmol/ L respectively 
(Zaccolo and Movsesian; 2007).  
 
cGMP plays an important role in the regulation of PDE2 activity. cGMP 
activates PDE2 in all or none fashion by binding to its GAF domain located 
between the N-terminal region and catalytic region of the enzymes. At higher 
concentrations cGMP inhibits cAMP hydrolysis of PDE2 by competitive effects 
at the catalytic site (Wu et al; 2004). PDE2 isoforms have been shown to 
localise to sub-cellular membrane structures such as Golgi and perinuclear 
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membranes. Phosphorylation by PKC α-isoform has been shown to activate 
the PDE2 enzymes in live rat Golgi endosomal fractions under PMA 
stimulation (Geoffroy et al; 1999). PDE2 enzymes can be selectively inhibited 
by EHNA and non-selectively by IBMX (Lugniere et al, 1986).  
 
1.6.3 Phosphodiesterase-3 
 
PDE3 isoforms show high affinity to both cAMP and cGMP and are inhibited 
by cilostamide and milrinone. Two genes A and B encode different PDE3 
isoforms which are different from other PDEs in that they have a 44 amino 
acid insert in their catalytic region and determine their affinity to cGMP 
(Manganiello et al; 1995). PDE3 isoforms show high affinity to cGMP but 
hydrolyse cAMP at a 10-fold greater rate than cGMP and are therefore 
classed as being inhibited by cGMP (Beavo; 1995).   
 
PDE3A isoforms are expressed widely in muscle tissue, myocardium and 
platelets. However, PDE3B isoforms are expressed in adipocytes and 
hepatocytes (Beavo, 1995). PDE3 enzymes are regulated by various kinases 
as well as by hormones. They are phosphorylated by both PKA and PKB/Akt. 
Phosphorylation by either kinase has been shown to activate the enzymes. 
Also, hormones such as insulin and glucagon are known to activate the 
enzyme in Golgi-Endosomal fractions of rat liver tissue by the action of PKB 
and PKA, respectively (Zaccolo; 2007, Geoffroy et al, 2001, Kitamura et al; 
1999, Beavo; 1995).  PDE3B is expressed in pancreatic islets where it is 
known to mediate the effects of leptin on insulin release. Furthermore, PDE3B 
inhibitors have been shown to increase glucose-mediated insulin release. This 
effect is attributed to the function of cGMP in islet cells. Inhibition of PDE3B in 
beta cells leads to elevation of cGMP levels which in turn leads to elevation of 
cAMP levels and Ca+2-mediated exocytosis. However, PDE3B-mediated 
cross talk between cAMP-cGMP pathways in islet beta cells has not been well 
documented (Pyne and Furman, 2003). 
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1.6.4 Phosphodiesterase-5 
 
PDE5 is a cGMP-specific, rolipram-insensitive phosphodiesterase that can be 
inhibited by zaprinast (Hamet and Coquil; 1978, Lugnier et al; 1986).  PDE5 
gene encodes three splice variants from two alternate promoters (Lin et al; 
2002, Loughney et al; 1998). PDE5 isoforms are expressed in lung , kidney, 
brain and platelets where they contribute to regulation of cGMP levels (Pyne 
and Burns, 1993, Giordano et al; 2001, Kameni Tcheudji et al; 2001). 
Expression of PDE5A1 and A2 in pulmonary artery smooth muscle cells is 
elevated by hypoxic conditions (Murray et al; 2002).  
 
PDE5 activity has a vaso-relaxing effect that is mediated through nitric oxide 
(NO) and cGMP (martin et al; 1986, Schoeffter et al; 1987, Prickaerts et al; 
2004). PDE5 activity is shown regulate object and spatial memory in rodents. 
Elevation of cGMP levels by inhibiting PDE5 isoforms led to enhanced 
memory performance which was mediated through hippocampal regions in 
rodents (Prickaerts et al; 2004).   
 
Cellular cGMP levels and PKA phosphorylation regulate PDE5 activity. 
Binding of cGMP to PDE5 is required for its phosphorylation by PKA, which in 
turn leads to increased affinity for cGMP (Burns et al; 1992 and Francis et al; 
2002). Hanson et al; 1998, have shown that PDE5 plays a crucial role in 
perinatal vascular resistance (PVR) in ovine and murine prenatal development 
by regulating the cGMP levels. They have also shown that mRNA and protein 
levels of PDE5 decrease within the one hour of birth when PVR decreases. 
However, mRNA and protein levels of PDE5 undergo a secondary increase 
between the 4-7days after birth.  PDE5 has also been shown to be involved in 
fluid transport in malphigian tubules that form a part of arthropod excretory 
system by regulating cGMP levels (Broderick et al, 2004). 
 
PDE5A1 is known to interact with the pro-apoptotic protease caspase-3 upon 
an apoptotic stimulus both in vitro and in vivo. This interaction leads to 
cleavage and subsequent inactivation of the enzyme (Frame et al, 2003). In 
the presence of the gamma subunit of PDE6 the proteolysis of PDE5A1 by 
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caspase-3 is increased, contrary to the action of caspase on PDE6 isoforms 
in the presence of its gamma subunit (Frame et al; 2001).  
  
1.6.5 Phosphodiesterase-6 
 
Phosphodiesterase 6 was first discovered in retinal rods. It hydrolyses cGMP 
specifically and is zaprinast inhibited (Beavo, 1995, Goridis and Viramaux, 
1974). PDE6 is a heterodimer complex containing two catalytic subunits (α in 
rods and ά in cones and a β subunit), two inhibitory subunits (γ in rods and γ’ 
in cones), and a δ prenyl binding protein (PrBP) subunit, all of which are 
encoded by separate genes, A for α subunit, B for β subunit, C for ά, D for δ 
subunit, G for γ and H for γ’ subunits (Lugnier, 2006). As well as  binding to 
prenylated photoreceptor proteins such as  GRK7 and Rab8, PrBP binds to 
the catalytic subunits of membrane bound PDE6 and has been suggested to 
reduce transducin-mediated activation of the phosphodiesterase in frogs 
(Norton et al; 2005).  
 
PDE plays a major in visual cycle. Briefly, activated rhodopsin activates 
transducin molecules, which are G protein heterotrimers, which exist in GDP-
bound inactive and GTP-bound active states. Activated, GTP-bound 
transducin binds to catalytic subunits of PDE6 and increases affinity of the 
enzyme for cGMP and leads to hydrolysis of the cyclic nucleotide. A decrease 
in cGMP concentration activates the CNG, which leads to sensory responses 
through the optic nerve (Ionita and Pittler, 2007). PDE6 is negatively regulated 
by individual phosphorylation of PKC and CDK-5 (Hayashi et al; 2002, 
Udovichenko et al; 1994, Udovichenko et al, 1996). The degradation of PDE6 
by caspase-3 is modulated by gamma subunit of the PDE (Frame et al. 2001). 
In the presence of PDE6 rod gamma subunit casapse-3 was shown to exhibit 
reduced PDE6 proteolysis.  
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1.6.6 Phosphodiesterase-7 
 
In 1993, Michael and workers (Michaeli et al; 1993) isolated and characterised 
a cAMP phosphodiesterase different from both PDE3 and PDE4 isoforms and 
called it HCP1 (High affinity cAMP-specific PDE). It was later re-named as 
PDE7 (Beavo, 1995). PDE7 is not sensitive to cGMP and is not inhibited by 
the PDE3 and/or PDE4 selective inhibitors like milrinone and rolipram.  
 
The PDE7 family comprises two different subfamilies of isoforms, 7A and 7B 
(Han et al 1997, Gardner et al; 2000, Sasaki et al; 2000). PDE7A was initially 
thought to be crucial in T-cell function. T-Cell receptors, Cd23 and CD28 
when stimulated increase the expression of PDE7A and thus decrease cAMP 
levels and PKA activity in T-cells (Li et al, 1999). PDE7A is also known to be 
involved in T-cell proliferation and regulating the production of chemokines 
such as IL-2, 4 and 7 (Li et al; 1999 and Nakata et al; 2002). However, further 
studies (Yang et al 2003) showed that PDE7A is not necessary for T-cell 
function. Indeed, transgenic mice lacking PDE7A gene were found to have 
functional T-cells. The absence of PDE7A did not affect the IL-2 production 
driven by Cd23 and cd28 or T-cell proliferation suggesting that T-cell function 
is not regulated by PDE7A (Yang et al; 2003)  
 
PDE7B is implicated in dopaminergic signalling. Primary striatal cells treated 
with dopamine showed elevated levels of PDE7B, which is believed to 
mediate through a cAMP-PKA-CREB cascade, which promotes PDE7B 
transcription (Sasaki et al; 2004).   
 
1.6.7 Phosphodiesterase-8 
 
Two different subfamilies of PDE8, namely A and B, were first identified and 
cloned by three different groups from both mouse and human (Fisher et al; 
1998, Hayashi et al; 1998 and Soderling et al; 1999).  
 
PDE8A and PDE8B have 5 and 4 splice variants, respectively (Hayashi et al; 
2002, Wang et al, 2001). The PDE8 family is insensitive to the PDE4 cAMP 
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specific selective inhibitor, rolipram and, surprisingly, the non-selective PDE 
inhibitor, IBMX. However, PDE8B subfamily is sensitive to EHNA and 
inhibitors of PDE5 (Fisher et al, 1998). PDE8 isoforms have an N-terminus 
that is homologous to PAS domain of many signalling protein (Soderling et al 
1998). The role of the PAS domain is not known but it has been suggested it 
may be involved in either PDE dimer formation or promote protein-protein 
interactions.  
 
1.6.8 Phosphodiesterase-9 
 
In 1998, Fisher and coworkers (Fisher et al 1998) identified 
Phosphodiesterase 9. Although the PDE9A family was originally thought to 
have only 4-splice variants (Guipponi et al; 1998, Rentero et al; 2003) at least 
20 mRNA splice variants have identified have since been identified. PDE9A1 
specifically hydrolyses cGMP and is insensitive to IBMX and the PDE5 
selective inhibitor, sildenafil. However, it is sensitive to the PDE5 inhibitor 
SH51866, which is also a PDE1 inhibitor (Soderling et al; 1998). PDE9 
isoforms show varied localisation within the cell (Renetero et al; 2006). 
PDE9A1 isoform is exclusively localised to the nucleus whereas PDE9A5 
isoform is cytoplasmic (Wang et al, 2003).   
 
1.6.9 Phosphodiesterase –10 
 
PDE10 is dual-substrate specific enzyme family. It has two mRNA alternative 
splice variants, PDE10A1 and PDE10A2 (Kotera et al; 1999). PDE10A 
contains two GAF domains although its structure is significantly different from 
other cGMP-specific PDEs like PDE5 and PDE6. PDE10 hydrolyses both 
cGMP and cAMP. However, it shows more affinity to cAMP (Fujishige et al; 
2000). PDE10A is inhibited by IBMX, zaprinast, SCH51866 but is not inhibited 
by sildenafil and EHNA (Soderling et al; 1999). PDE10A2 is known to localise 
to intracellular membrane fractions like Golgi apparatus (Kotera et al; 2004). 
However upon PKA phosphorylation at Thr16, PDE10A2 was shown to 
localise to cytosol suggesting the role of PKA in determining the sub-cellular 
localisation of the isoform (Kotera et al; 2004). 
 21 
1.6.10 Phosphodiesterase-11 
 
PDE11 is also a dual-substrate specific family of PDEs and is sensitive to 
IBMX, dipyridamole and zaprinast (Fawcett et al; 2000). Despite the dual 
substrate specificity and presence of GAF domains these enzymes are not 
activated by either of the cyclic nucleotides. (Yuasa et al, 2000). So far, four 
splice variants have been identified of which PDE11A3 and PDE11A4 are well 
characterised. Interestingly, PDE11A4 contains two complete GAF domains 
whereas PDE11A3 contains one complete and one incomplete GAF domains. 
Also, PDE11A4 contains putative phosphorylation sites for both PKA and 
PKG. However, PDE11A3 lacks phosphorylation sites for both the kinases 
suggesting that these isoforms differ in their N-terminal regions, which is a 
common phenomenon observed on PDE superfamily (Hetman et al; 2000 and 
Yuasa et al, 2000).   
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Figure 1.3 Modular structures of PDE enzyme-superfamily (Adapted 
from Lynch et al, 2006) 
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1.7 cAMP Phosphodiesterase 4  
 
1.7.1 Phosphodiesterase gene and structure 
  
Phosphodiesterase-4 (PDE4) enzymes are a family of more than 20 isoforms 
encoded by four genes A, B, C and D (Conti et al 2003, Houslay et al; 2005, 
Houslay et al, 2004). The dunce+ PDE4 gene was cloned from Drosophila 
melanogaster (Davis et al; 1989) and was used to identify the mammalian 
homologues by Swinnen and coworkers (Swinnen et al; 1989). They also 
showed that the different PDE4 isoforms arise by alternative mRNA splicing 
which was confirmed and extended in studies of the human forms (Bolger et 
al; 1996).  
 
Genes encoding PDE4 isoforms are located on various chromosomes. 
PDE4D subfamily is located on chromosome 5 in humans and chromosome 2 
in rats, whereas PDE4B subfamily is located on human chromosome 1 and 
rat chromosome 5 (Szpirer et al, 1995). PDE4A and PDE4C are located on 
chromosome 19 at 19p13.2 and p13.1 respectively (Engels et al; 1995, 
Horton et al; 1995, Sullivan et al; 1994). The mRNA splice variation generates 
PDE4 isoforms each possessing a unique N-terminal region with two 
upstream conserved regions (UCR1 and UCR2) and a highly conserved 
catalytic unit (Bolger et al; 1996). The residues of the extreme C-terminal 
region of the catalytic unit are unique to each of the four sub families (Bolger 
et al; 1996).  The UCR1 is 60 amino acids in length and the UCR2 has 80 
amino acids long. The UCR1 domain is linked to the UCR2 by linker region 
1(LR1) which is 24 amino acids long and UCR2 is linked to the catalytic unit 
(320-350 amino acids in length) by LR2, which is 10-28 amino acids long 
(Conti and Jin; 1999, Houslay and Adams, 2003, Lynch et al 2006).  
 
 PDE4 isoforms can be classified into three groups; Long, short and super-
short forms. Long forms have a unique N-terminal region, complete UCR1 
and UCR2 regions, catalytic region and a C-terminal region. Short forms lack 
the UCR1 region while super-short forms lack UCR1 and have an N-terminally 
truncated UCR2. A representation of PDE4 structure is shown in Figure 1.4.  
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Figure 1.4 Schematic of modular structures of PDE4 isoforms 
 
1.7.2 Catalytic Domain 
 
          Interpreting the mechanisms involving the catalytic activity of PDE4 
isoforms requires knowledge of PDE4 structure. Xu and coworkers (Xu et al; 
2000) were the first to determine the structure of a PDE catalytic domain, 
namely the catalytic unit of PDE4B. It was determined that catalytic domain of 
the PDE4 has 17α helices, which form 3 distinct sub domains. The first sub-
domain contains four α helices connected by two inter-connecting loops. The 
second sub-domain contains two α helices that are oriented perpendicular to 
two anti-parallel α helices. The third sub-domain is composed of five of α 
helices and an extended β-hairpin loop (Xu et al 2000). 
 
          A deep pocket of 21 residues in the COOH-terminal sub-domain 
extends into the junction of the three sub-domains. All 21 residues are highly 
conserved in all the 11 PDE families. Twenty of these residues lie near the 
pocket and 12 lie within the pocket.  The pocket accommodates a molecule of 
either cAMP substrate or 5’AMP product and is lined with negatively charged 
and hydrophobic amino acids (Xu et al 2000).  The deep pocket serves as a 
substrate-binding site and has two divalent cation binding sites. Metal binding 
site 1 (Me1) is the deeper set and holds the ion by four direct interactions with 
His238, His274, Asp275, and Asp392. Metal binding site 2 is slightly superficial in 
location and is close to the Me1. The Me1 is usually occupied by a Zn+2 ion 
and is very tightly held. The Me2 can bind Mn+2, Mg+2 or Zn+2. However, the 
Short 
Super- short 
Long 
Catalytic unit 
Isoform-specific 
N-terminal region 
UCR1
1 
UCR2 
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physiologically relevant ion is thought to be Mg+2 (Houslay MD and Adams 
DR; 2003).  
 
Depending upon the kinetics of rolipram binding to the catalytic unit, the PDE4 
isoforms can exist in two conformational states namely a high affinity rolipram 
binding site (HARBS) and or a low affinity rolipram binding site (LARBS) 
(Souness and Rao; 1997). The LARBS conformation is seen in the inactive 
enzyme and the HARBS is seen in catalytically active enzyme. Divalent cation 
binding plays an important role in releasing the product of cAMP hydrolysis 
from the catalytic site (Laliberte et al; 2002, Liu et al; 2001). PDE4 isoforms 
upon phosphorylation and activation by PKA change their affinity to rolipram 
and convert to a HARBS conformation (Hoffmann et al, 1998). PDE4 
interaction with various binding partners such as SRC tyrosyl kinases, XAP2, 
RACK1 has has also been shown to change the rolipram affinity of the 
isoforms (Bolger et al; 2003 and McPhee et al; 1996, Yarwood et al 1999). 
(Please refer to appendix II for an Image of catalytic subunit) 
 
1.7.3              PDE4 isoforms 
 
1.7.3.1 Phosphodiesterase- 4A 
 
PDE4A isoforms differ from other PDE4 subfamilies in that they their C 
terminus is not conserved and that they are not inhibited by ERK 
phosphorylation (Mackenzie et al, 2000). PDE4A1 is a super-short form 
(Sullivan et al; 1998). PDE4A4 is human homologue of rat PDE4A5 both of 
which are long forms. PDE4A7 is the only PDE4 isoform that is spliced both 
on the 3’ and 5’ ends of the mRNA transcript (Sullivan, 1998) and it lacks the 
residues that confer catalytic activity (Johnston et al, 2004). PDE4A10 and 
4A11 are also long forms (Wallace et al; 2005 and Rena et al 2001). 
PDE4A10 is known to be upregulated in differentiated monocytes and 
macrophages (Shepherd et al; 2004). PDE4A11 is localised to both 
particulate and soluble cellular fractions (Wallace et al; 2005).   
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1.7.3.2 Phosphodiesterase -4B 
 
PDE4B1, 4B3 and 4B4 are long forms so far reported from PDE4B subfamily. 
PDE4B1 is a human isoform whereas B3 and B4 are expressed in rat 
(Shepherd, 2003 and Huston et al; 1997). PDE4B2 is a short form that is 
expressed in both humans and rat. PDEB5 is a super-short form expressed 
only in brain and its N-terminal region is identical to that of  PDE4D6 (Cheung 
et al; 2007), the first time, to date, this phenomenon has been noted. 
 
1.7.3.3 Phosphodiesterase-4C 
 
Three isoforms have been reported from PDE4C family by various groups 
(Engels, et al; 1995 Owens et al, 1997 and Obernolte et al, 1997), all of which 
are long isoforms. It has been argued that it is unlikely for a PDE4C short form 
to exist because of the lack of space between long form exons (Sullivan et al; 
1999). However, other studies (Obernolte et al; 1997) have identified four 
splice variants. Isoforms PDE4C-791 and 426 were isolated from foetal lung 
whereas PDE4C delta-54 and delta 109 were isolated from testis mRNA.  
 
1.7.3.4 Phosphodiesterase-4D 
 
PDE4D encodes 9 isoforms 4D1-4D9 (Bolger et al; 1997). PDE4D1 is a short 
form and PDE4D2 is super-short form (Nemoz et al; 1996). PDE4D3, 4D4 and 
4D5 are long forms (Bolger et al; 1997). PDE4D6 is a brain-specific super-
short form and PDE4D7 is a long form (Wang et al; 2003). PDE4D8 and 
PDE4D9 are long forms that are closely related to PDE4D3 (Richter et al; 
2005).  
 
1.7.4 Regulation of PDE4 isoforms 
 
1.7.4.1 Transcriptional regulation of PDE4 isoforms  
 
             Cyclic AMP sensitive promoters regulate cellular PDE4 activity at a 
transcriptional level. Follicle stimulating hormone (FSH)-mediated elevation of 
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cAMP levels in sertoli cells were shown to elevate the mRNA transcripts and 
protein levels of PDE4D family enzymes particularly PDE4D1 and PDE4D2 
(Vicini and Conti; 1997) This elevation in protein levels was due to cAMP-
mediated activation of promoters of PDE4D1 and 4D2.  Similarly, Jurkart-T 
cells pre-treated with 8-bromo-cAMP or with Prostaglandin E2 increased the 
protein levels of PDE4D1-D3, PDE4A4 and PDE3 in a protein synthesis 
sensitive manner as confirmed by using Actinomycin D to inhibit transcription 
and Cycoheximide to inhibit translation suggesting that elevated cAMP levels 
directly impact cellular PDE4 expression (Seybold et al; 1998). Furthermore, 
Oxo-7-prostacyclin-treated rats exhibited a marked change in expression 
profile of the PDE4 isoforms in heart tissue. Forty-eight hours post-treatment, 
levels of mRNA transcripts of PDE4B3 were elevated while the levels of 
mRNA transcript levels of isoforms D1, D2 and D3 Kosti et al; 1997). The 5` 
flanking sequence of PDE4A10 exon-1 is shown to have cell type-specific 
promoter-like activity (Rena et al; 2001). Furthermore, two regions upstream 
to exon-14A10 identified in mouse, namely A and B, were shown to bind 
transcription factors. Region B has binding sites for transcription factors 
CREB, GATA, Nuclear factor-κB and H2O2-activated USF suggesting that 
PDE4A10 might be involved in inflammatory response (Rena et al; 2001). 
Similar studies on PDE4A11 (Wallace et al; 2005) of a region 1 Kb upstream 
of exon-14A11 identified a potential transcription binding site as identified by an 
increase in luciferase activity in reporter construct assays The PDE4D 
subfamily has also been shown to be subject to transcriptional regulation. 
Exons encoding isoform-specific N-terminal regions of PDE4D5 were shown 
to exhibit promoter activity (Le Jeune et al; 2002). This transcriptional 
regulation is reported to be driven by cAMP due to the presence of a CRE site 
upstream of the exon (Le Jeune et al; 2002). Transcriptional regulation of 
PDE4D1 and PDE4D2 has also been noted (Vicini and Conti, 1997). 
 
1.7.4.2 Regulation by Protein Kinase A 
 
 In 1996, Sette and Conti reported that PDE4 isoforms are activated upon 
phosphorylation by cAMP dependent protein Kinase (PKA) from observations 
of rat thyroid cells stimulated with TSH. PDE4D3 was the first studied isoform 
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for PKA phosphorylation. The target sites were mapped within two PKA 
consensus sites at Ser13 and Ser 54. Ser13 is located with PDE4D3’s unique N-
terminal region while Ser 54 is in the UCR1 region (Alvarez et al; 1995, 
Hoffmann et al; 1998, Sette and Conti, 1996). Although there are two PKA 
phosphorylation sites on PDE4D3 only Ser54 is required for the activation of 
the enzyme (Sette and Conti 1996).   
 
PKA phosphorylation occurs at the R-R-E-S-F motif in UCR1 region, which is 
conserved in long PDE4 isoforms. PKA phosphorylation at this site activates 
the enzymes (MacKenzie et al 2002). The glutamate residue present in PKA 
consensus site is highly conserved in all PDE4 long forms and has an 
inhibitory affect on PKA phosphorylation (Hoffman et al; 1998). Mutational 
analysis of the glutamine preceding the Ser in PKA consensus site was 
shown to increase PDE4 activity, which was further increased by PKA 
phosphorylation (Hoffmann et al; 1998).  
 
UCR1 and UCR2 bind with each other by electrostatic interactions between 
positively charged amino acids in UCR1 and negatively charged amino acids 
in UCR2, an interaction which is modulated by PKA phosphorylation (Beard et 
al; 2000). The intramolecular association of UCR1 and UCR2 is known to 
form a module that has an inhibitory affect on catalytic unit. This inhibitory 
effect is abolished by phosphorylation of PKA on UCR1 region, which opens 
the module and thereby activates the enzyme (Lim et al, 1999).  
 
PKA phosphorylation is also known to have an affect on rolipram sensitivity of 
PDE4 long forms. PKA phosphorylation increases the rolipram-binding affinity 
of certain long-forms by switching on the HARBS conformation (Mackenzie et 
al; 2002 and Hoffman et al; 1999). 
 
1.7.4.3 Regulation by Extra-cellular signal regulated kinase 
 
            The ERK-MAP kinase family is a family of serine-threonine kinases 
and is one of the most important signalling cascades that can regulate the 
activity of the cAMP messenger system through crosstalk (Mackenzie 2000). 
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ERK1 and ERK2 are members of MAP Kinase family. Phosphorylation by 
ERK requires three motifs, a kinase interaction motif (KIM), FQF domain and 
a proline-directed serine consensus motif found in all authentic ERK 
substrates.  The KIM domain is located upstream of the target Ser/Thr and 
has a consensus sequence [Leu/Val]-Xaa-Xaa- [Arg/Lys]-[Arg/Lys]-Xaa (6)-
Leu-Xaa- [Leu/Ser]. FQF domain is downstream of the target Ser/Thr and has 
a consensus of Phe-Glu-Phe (Lynch et al; 2006, Houslay and Adams; 2003 
and Mackenzie et al, 2000).  
 
It has been shown that PDE4 isoforms are substrates for the ERK-MAP 
kinases. ERK2 is known to associate with the PDE4 catalytic subunit by 
binding to the KIM domain and FQF site on an exposed β hairpin loop and α 
helix respectively. These two sites flank an ERK phosphorylation site. 
Phosphorylation of long, short and super short forms of PDE4 enzymes by 
ERK leads to either the activation or inhibition of the particular isoform 
depending upon the presence or absence of UCR1/2 regulatory modules 
(Hoffmann et al 1999 Mackenzie et al; 2000, Baillie et al; 2000, Baillie et al; 
2001) 
 
Ser579 in PDE4D3 isoform is a target site of phosphorylation by ERK, which 
leads to the inhibition of the activity of PDE4D3. Interestingly, isoforms of the 
PDE4B, 4C and 4D subfamilies, but not the PDE4A subfamilies, are ERK 
substrates. This is due the presence of a target Ser/Thr in a P-x-ser/Thr-P 
motif in the PDE4B, 4C and 4D families. In the PDE4A subfamily, one of the 
proline residues in the motif is replaced by and arginine. PDE4A subfamily of 
isoforms are therefore not inhibited by ERK2 (Baillie et al; 2000, Baillie et al; 
2001).  
 
As mentioned, PDE4D3 is also regulated by the PKA-mediated 
phosphorylation at Ser54 within UCR1, which leads to activation of the enzyme 
(Mackenzie et al; 2000). The phosphorylation events regulating PDE4D3 
counteract each other as PKA-mediated activation is ablated by the ERK-
mediated inhibition of PDE4D3. This provides a regulatory system whereby 
ERK-mediated inhibition leads to an increase of cAMP levels which triggers 
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the subsequent PKA-mediated phosphorylation and activation of PDE4D3 
(Hoffmann R, 1999). PDE4D3 therefore provides a point of cross talk between 
the ERK MAP kinase pathway and cAMP pathway.  
 
Hill and coworkers (Hill et al, 2006) showed that PDE4D3 is activated rapidly 
and phosphorylated at Ser579 and Ser239 upon challenging RAW macrophages 
with hydrogen peroxide (H2O2). Phosphorylation at Ser579 was revealed to be 
mediated by ERK whereas phosphorylation at Ser239 occurred by as yet 
unidentified kinase downstream of PI3 kinase. Phosphorylation at Ser239 
reverses the inhibitory effect caused by phosphorylation at Ser579 by ERK. It is 
proposed that phosphorylation at Ser239 might reverse the inhibitory effect of 
ERK phosphorylation by inhibiting the interaction of UCR1-UCR2-catalytic 
region.  
 
1.7.4.4 Regulation by Phosphatidyl Inositol Kinase-3 
 
PDE4A5, a rat homologue of human PDE4A4, is activated and 
phosphorylated by an unknown kinase downstream to PI3 kinase in F442-pre-
adipocytes activated by Growth hormone stimulation and contributed to 
differentiation of the pre-adipocytes into adipocytes (Mackenzie et al, 1998). 
Activation and differentiation were not seen when the cells were treated with 
PI3-kinase inhibitors such as wortmannin and Ly294002. In further studies 
(Yarwood et al; 1999) differentiation was reported to be transduced through a 
Janus Kinase–2 and Signal Transducer and activator of Transcription-5 
(STAT5) pathway.  
 
1.7.4.5 The action of Phospholipids 
 
It has been suggested that certain PDE4 long forms can be activated by 
acidic phospholipids. This activation is not seen in short and super-short 
forms. Lysophosphatidic acid and phosphatidyl-serine, but not phosphatidyl 
choline, increase the activity of PDE4D3 activity up to 3-fold (Disanto et al, 
1995 and Nemoz et al, 1997). Subsequent work (Garange et al; 2000) 
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showed that phosphatidic acid failed to activate a UCR1 deletion mutant of 
PDE4D3.  
 
Studies from our group (Baillie et al; 2002) identified a novel phosphatidic acid 
binding domain in the N-terminus of PDE4A1. This domain was named 
TAPAS1 (tryptophan anchoring phosphatidic acid selective domain). The 
sequence of the TAPAS domain is LVXaaWWDXaaXaa K/R, where residues 
LVXWW are needed for membrane insertion and residues DXXK/R are 
needed for calcium binding. The TAPAS domain uses submicromolar free 
calcium ions to bind to Asp21 in PDE4A1, allowing insertion of this isoform 
into membranes. This feature is analogous to that of annexin whereby calcium 
binding switches on a conformation that exposes the tryptophan residues in 
the protein such that they can be inserted into the membrane (Campos et al; 
1998).  
 
1.8 Targeting of PDE4 isoforms to signalling complexes 
 
It is now widely appreciated that cAMP signalling is compartmentalised within 
cells (Houslay et al; 2007, Zaccolo 2006, Zaccolo et al; 2006, Lissandron et 
al; 2006, Terrin et al; 2006, Houslay and Adams, 2003). Buxton and Brunton, 
in 1983, for the first time showed that ventricular myocytes challenged with 
isoprenaline and prostaglandin E1 produced different responses on glycogen 
phosphorylase activity suggesting that their cAMP responses are 
compartmentalised. Recently, Zaccolo and Pozzan; 2002 have demonstrated 
the presence of distinct pools of cAMP in live neonatal cardiomyocytes using 
fluorescence resonance energy tranfer (FRET) technology.  
 
PDE4 isoforms have been shown to contain regions that confer a high degree 
of specificity in allowing them to interact with a wide variety of signalling 
complexes. This allows PDE4 isoforms to regulate the cAMP levels in specific 
intracellular compartments (Lynch et al; 2006, Houslay and Adams, 2003). 
The following section discusses the various signalling PDE4 binding proteins 
which have been shown to regulate compartmentalisation of cAMP signalling. 
A schematic of cAMP signalling is shown in Figure 1.5.  
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1.8.1 β-arrestins 
 
           Arrestins are ubiquitously expressed scaffold proteins and are of two 
types, visual arrestins and β-arrestins. Visual arrestins are expressed only in 
retinal tissue (Yamaki et al, 1987 and Shinohara et al 1987), whereas the β-
arrestins are expressed in all tissues particularly in the brain and spleen 
(Attramadal et al; 1992). Visual arrestins play an important mechanistic role in 
the visual responses whereas β-arrestins are involved in complex signalling 
pathways including GPCR desensitisation (Lefkowitz and Shenoy; 2005 and 
Luttrell and Lefkowitz, 2002).  
 
           Recently, it has been demonstrated that PDE4D5 interacts with β-
arrestins (Bolger G. B et al, 2003). PDE4D isoforms are ubiquitously 
expressed in a wide range of cell types and PDE4D3 and PDE4D5 are the 
most predominant isoforms (Conti M; 2003). Specifically, the interaction 
appears to involve amino acid residues 70-88 within the unique N-terminal 
region of PDE4D5 (Bolger et al, 2006). Two hybrid assays show that both the 
unique N-terminal region and a portion of catalytic region are required for the 
interaction PDE4D5 with β-arrestins. Most probably the two different domains 
of βarrestins interact with the two interaction sites of PDE4D5. Indeed, the site 
within the conserved PDE4 catalytic region allows PDE4s from all subfamilies 
to interact with β-arrestin (Baillie et al; 2007 and Bolger G. B et al; 2003). β-
arrestins have two domains, N- and C- domains each of which are composed 
of seven-stranded β helix loops. Truncation experiments show that the amino 
terminal regions of both domains are required to interact with PDE4 isoforms. 
Also, residues K25 and R26 within a β helix loop of the N-terminus of arrestin 
have been shown to be crucial for interaction with the FXFELXL and 
FQFELTLEED motifs present in the catalytic site of the PDE4 isoforms (Baillie 
et al; 2007 and Bolger et al 2003). It is through this site in the catalytic unit 
that all the PDE4 isoforms can potentially interact with β-arrestin. In case of 
PDE4D5, an additional β-arrestin binding site is present in the N-terminal 
region of the isoform. Whether the site within the specific amino terminal 
region of PDE4D5 facilitates the binding of common binding site in catalytic 
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site, or allows other proteins that interact with β-arrestin to bind is unknown. 
However, it is known that β-arrestin does not affect the enzymatic activity of 
the PDE4 enzymes (Bolger G. B et al, 2003).  
 
It has been recently reported that desensitisation of β2 adrenergic receptor 
involves the β-arrestin mediated recruitment of PDE4D5, thus leading to 
decrease in cAMP levels around the receptor and eventually leading to re-
coupling of G proteins to the receptor. In contrast, the β1 adrenergic receptor 
shows very low affinity to β-arrestins. This is in accordance with the 
observation that stimulation of cardiac contraction by β2-adrenergic receptor is 
transient and that the receptor undergoes desensitisation very quickly. 
However, the stimulation of cardiac contraction by β1 adrenergic receptor 
recovers very slowly. Furthermore, the activity of β1 adrenergic receptor is not 
affected by inhibiting PDE4D in β2-AR knockout murine myocytes, indicating 
that PDE4D is involved in regulating the activity of β2 AR, but not that of the 
β1-AR, thereby contributing to the differential regulation of cardiac contraction 
by adrenergic agonists (Xiang Y et al, 2005 and Lynch et al; 2005).  
 
Agonist-induced β2-AR desensitisation is also mediated by second messenger 
responses. PKA tethered to AKAP5 is constitutively bound to the receptor and 
subsequently phosphorylates the receptor upon ligand activation. Similarly, an 
agonist-mediated PKA-AKAP79 complex is recruited to the receptor inducing 
receptor phosphorylation eventually leading to receptor desensitisation 
(Willoughby et al; 2006, Houslay and Baillie; 2005, Lynch et al; 2005, Fraser 
et al; 2000, Tao et al; 2003). PKA-mediated phosphorylation of the receptor 
leads switching of receptor coupling from Gs to Gi. This Gs to Gi switching now 
allows for ERK1/2 activation through Src recruitment to the complex (Baillie et 
al; 2003).  
 
PKA (Cong et al; 2001) or PKC (Krasel et al; 2001) -mediated phosphorylation 
and activation of GRK2 leads to its increased interaction with Gαβγ subunits 
and desensitisation of the β2-AR receptor by GRK2 phosphorylation (Li et al; 
2006). This activation and recruitment of GRK2 to the β2 AR is reversed by 
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ERK phosphorylation of GRK2, which decreases its affinity for Gαβγ. Li and 
coworkers (Li et al. 2006) showed that PKA phosphorylation of the receptor 
and its subsequent switching from Gs to Gi signalling is controlled by 
recruitment of a β-arrestin-PDE4D5 complex to the receptor where PDE4D5 
regulates the levels of cAMP and thereby PKA activity and prevents 
inappropriate recruitment of GRK2 to the membrane.  
 
Abrahamsen and coworkers (Abrahamsen et al; 2004) showed that T cell 
activation is initiated in lipid rich membrane micro-domains known as lipid 
rafts and leads to the production of cAMP within these lipid rafts. Concomitant 
stimulation of CD-28 (cluster of differentiation), induces β-arrestin dependent 
recruitment of PDE4 enzymes to the lipid rafts The long isoform PDE4A4, the 
short isoforms PDE4B2, and PDE4D1/2 were all found to rapidly recruited to 
lipid rafts in a β-arrestin dependent process. This recruitment of PDE4 
enzymes to lipid rafts offers a way to downregulate the inhibitory affects of 
cAMP elevation on T-cell activation, which is mediated by PKA through a Csk-
Lck pathway (vang et al, 2003). The process of cAMP elevation in lipid rafts 
and PDE4 recruitment achieved only by activation of the T-cell receptor (TCR) 
and concomitant activation of CD28 as upon TCR stimulation alone, there is 
insufficient PDE4 to reduce the cAMP levels and therefore maximal T- cell 
activation cannot be achieved due to the inhibitory effects of cAMP signalling 
(Abrahamsen et al; 2004).   
Apart from GPCR desensitisation, β-arrestins are also involved in receptor 
internalisation. After receptor activation and desensitisation, β-arrestins binds 
to adaptor protein-2 (AP-2), which concentrates the receptor–βarrestin 
complex to clathrin-coated pits (Laporte et al; 1999 and Goodman et al; 
1996). Once the receptor-arrestin complex reaches the clathrin-coated pits, 
the pits will be pinched off by the Src-phosphorylated G protein dynamin 
(Sever, 2002).  Arrestin then dissociates from the internalised receptor 
complex which will be either degraded via proteasomal/lysosomal complex or 
recycled back to membrane after dephosphorylation by phoshphatase PP2A 
(Vaughan et al; 2006 and Oakley et al; 1999).  
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1.8.2 RACK1 
 
RACK1-Receptor of Activated C-kinase is a 36 KDa protein with a seven 
bladed propeller structure, each blade consisting of β sheets. RACK1 has Trp-
Asp 40 (WD40) repeats. These repeats are highly conserved in a range of 
species. RACK1 serves as a binding protein for Protein kinase C. However, 
other proteins like Src, integrin β subunits, and γ-aminobutyric acid (GABA) 
are also known to interact with RACK1 (McCahill et al, 2002). RACK1 
associates with proteins in either a constitutive or stimulus-dependent 
manner. RACK1 has multiple independent protein binding sites, which 
suggest the individual blades of RACK1 may be able to interact with specific 
protein classes. Similar to its interaction with the Gβ and Gα subunits, the 
RAID1 (RACK1 Interaction Domain) within the N-terminal region of PDE4D5 
interacts with WD repeats on RACK1 (Bolger et al; 2006 and Yarwood et al; 
1999).  Recent work (Bolger et al. 2006) showed that RACK1 has a further 
PDE4 binding site within the catalytic unit suggesting that RACK1 might 
interact with other isoforms of other PDE4 subfamilies. The functional 
consequences of RACK1-PDE4 interaction are not yet known but it is 
predicted that PDE4D5 interacting with RACK1 controls the cAMP levels 
within its immediate surroundings and alter the sensitivity of the RACK1-
interacting proteins to PKA phosphorylation (McCahill et al, 2002). In support 
of this, it has been reported that RACK1 has a role in regulating the PKA 
activity of the defective CFTR chloride channel in cystic fibrosis. However, 
The regulatory mechanisms of this process are still unknown. Its been 
showed that activation of adenylyl cyclase and subsequent production of 
cAMP by forskolin caused the translocation of RACK1 to nucleus without 
altering the location of PKC βII (McCahill et al; 2002). This indicates that 
RACK1 might be involved in shuttling of proteins into nucleus.  It has also 
been shown that inhibition of ethanol-induced compartmentalisation of RACK1 
is inhibited by cAMP analogues that prevent activation of PKA by cAMP 
(McCahill et al; 2002). Thus PDE4-RACK1 interaction may have a role in 
regulating the PKA activity within the environment of this scaffold.  
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1.8.3 AKAPs 
 
A Kinase Anchoring Proteins, known as AKAPs for short, are a family of 
proteins that can bind directly to regulatory subunit II of PKA (McConnachie et 
al; 2006 and Newlon M. G. et al, 1999) and thus generate a 
compartmentalized PKA response to various intracellular gradients of cAMP. 
Although all most all AKAPs have been shown to bind RII subunit of PKA, 
some AKAPs like AKAPCE bind to RI subunit (Angelo et al; 2000). The 
interaction of AKAPs with PKA is disrupted by peptide likes Ht31 
(McConnachie et al; 2006, Carr et al; 1992). Interestingly, some AKAPs like 
AKAP250, also known as gravin, are PKA phosphorylated. PKA 
phosphorylation is crucial for association of gravin to β2 AR and subsequent 
resensitisation of the receptor (Tao et al; 2003). To date more than 50 AKAPs 
have been identified and they show sparse homology. However, they share 
some a common RII subunit-binding domain (Wong and Scott; 2004).  
 
PDE4 isoforms have been shown to interact with certain AKAPs (Dodge K. L., 
et al 2001 and Asirvatham A. L et al. 2004). PDE4D3 has been reported to 
bind mAKAP (muscle–selective) and AKAP 450. AKAP 450 interacts with the 
UCR2 of PDE4D3, whereas mAKAP interacts with the N-terminal region of 
PDE4D3 (Dodge K. L., et al 2001).  
 
As mentioned previously, PDE4D3 can be phosphorylated by PKA at two 
sites, namely Ser13 and Ser54 (Sette and Conti 1996). Phosphorylation of 
PDE4D3 at Ser54 by PKA bound to mAKAP leads to activation of the enzyme. 
This results in increased activity of PDE4D3, which decreases the local cAMP 
levels. This in turn, leads to deactivation of the mAKAP bound PKA, leading to 
the dephosphorylation and deactivation of PDE4D3 itself. Thus these 
components form a signalling complex with unique feedback control (Dodge 
K. L., et al 2001). PKA phosphorylation at Ser 13 of PDE4D3 increases the 
affinity of the isoform for mAKAP (Carlisle Michel et al; 2004) but does not 
alter the activity of PDE4D3.   
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 It has been shown that mAKAP recruits PDE4D3 to the nuclear envelope 
where the isoform is shown to be in a complex with PKA, the ryanodine 
receptor (RyR) and protein phosphatase 2A. This complex is believed to 
regulate the function of RyR by modulating PKA phosphorylation of the 
receptor as shown by elevated PKA phosphorylation of the receptor in PDE4D 
deficient-mice cardiac tissue (Lehnart et al; 2005 and Kapiloff et al; 2001). 
 
PDE4A interacts with AKAP95 and AKAP149 in T lymphocytes (Asirvatham et 
al. 2004).  AKAP95 has been identified in the nucleus of T lymphocytes and is 
known to interact with c-Myc binding protein. AKAP149 is known to be present 
in cytoplasm of the T cells and binds to phosphatase PP1 (Asiravatham et al. 
2004).  Since these AKAPs are organelle-specific and they bind to PKA and 
specific forms of PDE4s, it is likely these interactions play an important role in 
regulating cAMP homeostasis in T cells. 
 
AKAPs have been shown to be involved in a wide range of functions. They 
are involved in sperm mobility; aquaporin-mediated water reabsorption in 
renal collecting ducts; cell cycle progression and gene regulation (Bajpai et al; 
2006, McSorley et al; 2006, Tasken and Aandhal; 2004).  
 
1.8.4 XAP2 immunophilin 
 
Immunophilins are key targets for immunosuppressive drugs including 
cyclosporin and rapamycin. Most immunophilins are known to have a 
characteristic amino acid sequence known as the Immunophilin Domain 
(Bolger et al; 2003). This domain in many immunophilins has a rotamase 
activity, which is targeted by the drugs. Rotamases are those enzymes that 
enhance the rate of protein folding (Avramut and Achim, 2002). 
Immunophilins are also known to have protein chaperone function (Bolger et 
al; 2003). XAP2 (AIP/Ara9) is an immunophilin that does not have these 
general functions (Bolger, G.B. et al 2003). 
 
XAP2 or Hepatitis B virus X-associated protein, also known as ARA9 or Aryl 
hydrocarbon receptor (AhR) Interacting Protein (AIP), has been shown to form 
 38 
a complex with Hsp90 and the dioxin receptor regulating the stability of the 
complex (Meyer and Perdew; 1999 and Kuzhandaivelu et al; 1996). XAP2 is 
also associated with regulation of transcriptional activity of both X-HBV and 
AhR (Meyer et al; 2000 and Meyer et al; 1998). XAP2, along with Hsp90, 
regulates the transcription of other proteins such as the peroxisome 
proliferator in association with peroxisome proliferator-activated receptor 
alpha (PPARalpha) (Sumanasekera et al; 2003).  
 
PDE4A5 is targeted to both insoluble and soluble fractions of the cell (Beard, 
M.B. et al, 2002). Bolger and coworkers (Bolger et al 2003) showed that XAP2 
specifically interacts with PDE4A5. This interaction requires the 
tetratricopeptide repeat (TPR) within the N-terminal region of XAP2, which 
interacts, with the unique N-terminal region of PDE4A5 and a motif within 
UCR2. Arg271 within XAP2 TPR interacts with an EELD motif in UCR2 of 
PDE4A5. The functional significance of this interaction is inhibition of PDE4A5 
activity by XAP2 in a non-competitive way. This is mediated through a 
regulatory region extended to the cAMP-binding site in PDE4A5, presumably 
UCR2. This interaction also evokes a decrease in sensitivity of the isoform 
towards inhibition by the specific PDE4 inhibitor, rolipram. Furthermore, 
binding of XAP2 acts to inhibit PKA phosphorylation of PDE4A5 at Ser140 in 
UCR1. This indicates that XAP2 and UCR2 bind to similar regions within 
UCR1 of PDE4A5. This suggests that XAP2 blocking of PKA phosphorylation 
of UCR1 leads to changes in the conformation in UCR1 thereby preventing it 
from interacting with UCR2. The functional significance this interaction and 
subsequent effects on PDE4A5 activity are yet to be fully appreciated. 
However, given the expression profiles of PDE4 isoforms, particularly the 
PDE4A subfamily in inflammatory cells and the role of AhR and complexes 
containing AhR in inflammatory diseases like COPD, it could be argued that 
PDE4A and XAP2 might play an important role in mediating inflammatory 
responses (Wallace et al; 2005, Teske et al; 2005, Matinez et al; 2002). In 
support of this, the PDE4A4 isoform has been reported to be significantly 
elevated in monocytes from smokers (Barber et al; 2004).  
 
 
 39 
1.8.5 SH3 binding domains 
 
           Src, Lyn and Fyn are Src homology 3 (SH3) domain containing 
tyrosine kinases that regulate the function of a wide variety of cellular 
proteins.  They are globular proteins and can be divided into two classes 
depending upon their binding consensus motifs. Class I SH3 binding domains 
have a P-X-X-P motif, and confer specificity to interaction with Src Kinases 
(Ramos-Morales et al; 1994). Class II SH3 binding sites are variable and bind 
to motifs such as X-P-X-X-P-R and confer specificity to interactions with 
proteins including Crk and abl (Alexandropoulos et al; 1995). In some 
instances, SH3 binding domains are known to bind proteins that do not 
contain this consensus sequence but have positively charged sequences (Jia 
et al; 2005 and Pawson; 1994).   
 
           PDE4A5 and PDE4D4 have been shown to be able to bind to SH3 
domains of Lyn, Fyn and Src kinases. PDE4D4 has also been identified to 
bind the SH3 domains of fodrin and abl tyrosine kinases. PDE4A5 has a P-X-
X-P motif whereas PDE4D4 has polyproline stretches (Beard M.B et al, 1999, 
McPhee et al; 1999 and O’Connell, 1996). The interaction was mapped to the 
N-terminal region PDE4A5, the truncation of which prevented the tyrosyl 
kinase interaction. The probable function of such an association may be is to 
provide a means of regulating the affinity of PDE4A5 for cAMP and PDE4 
inhibitors. It is suggested that SH3 domains bound to PDE4A5 initiate 
conformational changes in LR2 region of the enzyme thus increasing its 
affinity to rolipram thereby converting it to the HARBS conformation (McPhee 
et al; 1999). The interaction of PDE4A5 with SH3 binding domains is also 
known to change the subcellular localisation of PDE4A5 (Beard et al; 2002 
and Huston et al; 2000).  
 
Caspases are enzymes involved in initiating apoptotic cell death and their 
substrates have a consensus motif Asp-Xaa-Xaa-Asp within which cleavage 
by caspase occurs. Caspase-3 cleavage of PDE4A5 N-terminal region 
prevents its interaction with Lyn and ablates the ability of the isoform to 
localise to the perinuclear region (Huston et al; 2000). Caspase cleavage is 
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specific to PDE4A5 and is not seen in other PDE4A isoforms (Wallace et al; 
2005). 
 
Since PDE4A5 is localised to membranes, it is also possible that PDE4A5-Src 
interactions might contribute to a reduction of local concentrations of cAMP 
surrounding the tyrosyl kinase and other proteins recruited to complexes at 
the plasma membrane. This would provide local and specific control of actions 
of cAMP, possibly mediated through PKA action, on such tyrosyl kinases and 
their associated complexes. The association of PDE4A5 N-terminal region 
with SH3 domains might also help in regulating the activity of the PDE4A5 
and targeting PDE4A5 to membrane and cytoskeletal fractions of the cell 
(O’Connell, 1996). 
 
1.8.6 Myomegalin 
 
Myomegalin is a scaffold protein related to Drosohphila centrosomin protein. 
The C-terminus of Myomegalin interacts with UCR2 region of PDE4D3 in 
yeast-two hybrid assays (Verde et al; 2001). Myomegalin is composed of α-
helical and coiled-coil structures and shares domains with microtubule 
associated proteins. It co-localises with PDE4D3 at the sarcoplasmic 
reticulum in cultured skeletal muscle cells and is though to anchor the 
PDE4D3 to golgi/centrosomal regions in Cos cells (Verde et al; 2001).  
 
1.8.7 Disrupted in Schizophrenia-1 
 
Disrupted-in-Schizophrenia 1(DISC1) was first reported to be linked to 
schizophrenia upon the observation that the DISC1 was disrupted by 
translocation, leading to DISC1 haploinsufficiency in cases of familial 
schizophrenia (Millar et al; 2000). More recently, a translocation within the 
PDE4B gene has been linked to instances of inherited schizophrenia (Millar et 
al; 2005).  
 
DISC1 is thought have as many as 5-7 isoforms that  differ from each other in 
their C-termini and share a common N-terminal region although some 
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isoforms like c-75kDa lack N-terminal regions that are shared among the 
isoforms and is thought to exist as homodimer. DISC1 expression is 
cytoplasmic but can also be detected at the mitochondria and nucleus (James 
et al; 2004).  
 
The N-terminal region of DISC1 has been shown to interact with the UCR2 
region of isoforms from all PDE4 subfamilies with subfamily-specific 
differences in sensitivity to dissociation from DISC1 in the presence of 
elevated cAMP (Millar et al; 2005; Murdoch et al; 2007). An N-terminal 
truncated DISC1 was found to interact with PDE4B1 dynamically whereby its 
interaction with PDE4B1 was attenuated by elevating cellular cAMP levels or 
by PKA activation (Murdoch et al; 2007). However, this dynamic interaction 
was not observed for full-length DISC1, where cAMP elevation failed to 
dissociate the PDE4B1-DISC1 whilst allowing for the release of isoforms 
PDE4D3 and PDE4C2. The possible reason for this is that the full length 
DISC1 isoform has extra binding sites for PDE4B1 within its N-terminal region 
which is not present in the shorter–isoform, thus making it insensitive to the 
actions of cAMP/PKA (Murdoch et al. 2007).  
 
Missense mutations within in the DISC1 gene, which were found to elicit 
schizophrenia-like phenotype in mice, were revealed to be located within 
DISC1’s PDE4B1-specific binding regions (Clapcote et al. 2007). This would 
suggest that alterations in PDE4B1-DISC1 interactions, and associated cAMP 
signalling, might confer susceptibility to schizophrenia (Millar et al; 2007).  
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Figure 1.5 - Schematic presentation of the cAMP signalling system 
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1.8.8 PDE4 oligomerisaton 
 
The concept of PDE4 oligo/dimerisation has been proposed by various 
studies (Richter and Conti, 2004, Richter and Conti; 2002 and Lee et al; 2002, 
Rocque et al; 1997).  Rocque and coworkers suggested that purified PDE4B2 
exists as a dimer and showed that it exhibited different affinity for rolipram 
compared to its monomeric form. Mutating the N-terminal region the isoform 
drastically reduced its ability to dimerise.  
 
PDE4 oligomerisation was further characterised by Richter and Conti who 
showed that UCR1 and UCR2 might also have a role in oligomerisation of 
PDE4 long forms.  Studies from our group (Beard et al 2000) originally 
showed that the C-terminal half of UCR1 and the N-terminal half of UCR2 of 
PDE4D3 interact with each other internally. Richter and Conti suggested that 
this interaction might be switched from internal to external allowing UCR1 to 
interact with UCR2 on a dimer and vice versa. Considering positively charged 
residues Arg-98 and 101 contained within the UCR1 domain of PDE4D3 
interact with negatively charged residues Glu146, Glu147, and Asp149 present 
within the UCR2 domain of the same molecule (Beard et al 2000), Richter and 
Conti proposed that these interactions may also occur between two molecules 
of PDE4 isoforms thus leading to dimerisation (Richter and Conti, 2004). 
Richter and Conti demonstrated that PDE4D3 can dimerise and that 
disruption of dimerisation ablates the PDE activity of the isoform mediated by 
either PKA phosphorylation or by phosphatidic acid binding (Richter and 
Conti; 2004).  
 
Others (Lee et al; 2002) have suggested that the PDE4 C-terminal region is 
necessary for oligomerisation. It was shown that C-terminal truncates of 
PDE4D failed to oligomerise whereas full-length PDE4D and the Catalytic 
domain were able to oligomerise. Arg358 was identified as a crucial residue in 
dimer interface which when mutated, prevented dimerisation. This finding was 
also supported by gel filtration chromatography analysis, where full-length 
isoforms existing as oligomers eluted first, followed by the Arg358 mutant, 
which was present as a monomer. Mutational analysis identified key residues 
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putatively involved in dimerisation, namely Glu315, Asn321, Asp322, Asn328, 
Arg358, and Ile362. These residues are highly conserved in PDE 1, 3, 4, 8 and 9 
subfamilies. These observations are contradictory to the model for PDE4 
dimerisation as suggested by Richter and colleagues (Richter and Conti; 
2002) in which it is argued that the upstream conserved regions are involved 
in dimerisation. Although further investigation is needed to confirm the sites of 
dimerisation, it is likely that UCR1, UCR2 and catalytic regions contribute to 
dimerisation of PDE4 isoforms. 
 
Functional significance of PDE4 dimerisation is yet unknown. Beard and 
coworkers (Beard et al, 2000) showed that UCR1 and UCR2 interact with 
each other to form a regulatory module, which has a role in the activation of 
PDE4 long forms upon PKA phosphorylation. The long form splice variants of 
PDE4 as discussed above are proposed to exist as dimers due to inter-
molecular interaction of UCR1-UCR2 regions; they show higher sensitivity to 
inhibitors like rolipram after phosphorylation by PKA. This is in agreement with 
the previous findings that purified PDE4B2 and PDE4A isoforms show a 
higher affinity to rolipram when present in oligomeric state (Rocque et al, 1997 
and Jacobitz et al 1996). The formation of this high affinity state for rolipram 
binding has been shown to involve residues outside the catalytic region 
towards the N-terminal region of the protein (Rocque et al, 1997).   
Dimerisation helps in stabilising the PDE4 long forms, so that they exhibit a 
high affinity for rolipram binding state. However, it has been suggested that 
although dimerisation stabilises the long forms and helps in maintaining the 
high affinity rolipram binding state, it is not required for the HARBS 
conformation as there are fewer rolipram binding sites in the monomeric state 
compared to the dimeric form (Richter and Conti 2004).  
 
It has been shown that dimerisation modulates the activity of long PDE4 forms 
upon modifications including phosphorylation, ligand binding, and protein-
protein interaction (Richter and Conti 2004) and that dimerisation may be a 
requirement for enzyme activation.  
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1.8.9 Foci formation  
 
PDE4 isoforms PDE4A4B and to some extent PDE4A5, have been shown to 
undergo dynamic redistribution and form accretion foci after chronic treatment 
with the PDE4 selective inhibitor rolipram (Terry et al; 2003). This process is 
triggered by HARBS-sensing PDE4 inhibitors such as rolipram and RO 20-
1724 but not by LARBS-sensing inhibitors such as Ariflo®. Protein synthesis 
is crucial for formation and maintenance of foci (Terry et al; 2003).  It is 
thought PDE4A4 foci formation is mediated by conformational changes 
produced upon binding of the inhibitor.  The unique N-terminal region of 
PDE4A4 is also thought to contribute to the process, as other isoforms of the 
PDE4A subfamily are not known to form foci.   
 
It has been noted that the triggering of HARBS conformation upon PDE4 
inhibitor binding is associated with the side effects produced upon treatment 
with PDE4 inhibitors (Martin et al; 2002 and Souness et al; 1997). The ability 
of a PDE4 inhibitor to induce PDE4A4 foci formation may therefore serve as 
an important screen for identifying potentially therapeutic PDE4 inhibitors.  
 
1.9 PDE4 isoforms in diseases- PDE4 inhibitors as therapeutics agents 
 
PDE4 inhibitors may serve as therapeutic agents in diseased states. PDE4 
inhibitors are known to elicit anti-inflammatory effects (Cheng and Grande; 
2007) and have also been used in the treatment of many CNS disorders such 
as depression (Cheng and Grande; 2007, Dastidar et al; 2007, Houslay et al; 
2005). The potential therapeutic value of selective PDE4 inhibitors has been 
assessed in PDE4 knockout studies. In mice the knock down of the PDE4B 
gene decreased production of tumour necrosis factor (TNF) upon exposure to 
lipopolysaccharide (LPS) (Jin and Conti; 2002). However, knockdown of 
PDE4D in mice did not alter TNF production. However, PDE4D knockdown 
has been shown to attenuate the muscarinic-cholinergic response leading to 
the loss of hyper-reactivity of the airways (Hansen et al in 2000). These 
studies indicate that there is little or no redundancy in the roles of the PDE4 
subfamilies and pave the way for development of PDE4 inhibitors that can 
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selectively inhibit the activity of the isoforms in various inflammatory tissues 
thus offering a promising treatment for inflammatory diseases including 
arthritis and asthma. The sequence similarity of the catalytic sites for these 
enzymes will make it difficult to design sub-family or isoform specific inhibitors 
successfully. However, a recent study (Wang et al; 2007) has shown the 
PDE4 inhibitor NVP {4-[8-(3-nitrophenyl)-[1, 7] napthyridin6-yl]benzoic acid} 
binds the same conformation in the cAMP and inhibitor binding pocket of all 
PDE4 subfamilies but the PDE4A and PDE4C subfamilies show significant 
differences in key residues that are displaced by inhibitor binding. This 
indicates that there is a possibility to design subfamily-specific PDE4 
inhibitors.  
 
It has been reported that the PDE4B2 isoform inhibits the cAMP-induced 
apoptotic cell death in B cells, thus leading to Diffuse Large Cell B Cell 
lymphoma (Smith et al; 2005). It is therefore possible that inhibition of this 
isoform may induce death of the malignant cells and serve as a therapeutic 
agent in the treatment of lymphomas.  
 
Follicle stimulating hormone (FSH), Human chorionic Gonadotropin (hCG) 
and Luteinizing hormone (LH) are the principal hormones that regulate 
ovulation. It was noted that PDE4 inhibition in FSH-primed rats, untreated with 
LH and hCG, stimulated ovulation indicating that PDE4 function modulates 
the signalling mechanisms involved in the ovulation (McKenna et al, 2005). 
The rat oocytes produced thus were found to be as equally fertile as oocytes 
produced by untreated rats. PDE4 inhibitors may therefore be useful as 
therapeutic agents in infertility conditions with hCG and LH defects (McKenna 
et al 2005). 
 
It is now well established that smooth muscle contraction and relaxation is 
regulated by cyclic nucleotides cAMP and cGMP which act as secondary 
messengers and regulate many downstream pathways and are associated 
with many physiological responses (Abdel-latif AA 2001). Myometrial smooth 
muscle cells express five different types of PDEs (1-5), of which, PDE4 family 
is the most predominant with PDE4 activity comprising 75% of the cAMP -
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specific PDE activity in late pregnancy.  PDE4D and PDE4B are the most 
predominant PDE4 isoforms expressed in human myometrium; especially 
PDE4B2 is selectively induced in the myometrium at the late stage of 
pregnancy (Mehats et al; 2005). Elevation of cAMP levels led to increase of 
PDE4 activity due to induction of PDE4B2, PDE4D1 and PDE4D2.  β-agonists 
can relax a non-pregnant myometrium but not that of a pregnant myometrium, 
indicating the β adrenergic receptors of pregnant myometrium are 
desensitized. However, PDE4 inhibitors can reverse this effect and potentiate 
the relaxant functions of β-agonists. It is therefore likely that selective PDE4 
isoforms are involved in regulating the contractile functions of myometrium 
and altered PDE4 activity/expression within the myometrium may induce pre-
term labour (Méhats et al. 2004).  
 
Prostaglandin E2 (PGE2) induces PDE4B2, PDE4D1 and PDE4D2 expression 
in a cAMP-dependent manner. PGE2 also mediates heterologous 
desensitisation of β-adrenergic receptors inhibiting their relaxant functions, an 
effect which is reversed by the presence of PDE inhibitors. PDE4 inhibitors 
may therefore be of use to increase the tocolytic efficiency with β-mimetics so 
as to prevent premature births (Méhats et al, 2004). 
 
Bones are formed through the action of three important cell types, 
osteoblasts, osetoclasts and osetocytes respectively. Osteoblasts are 
involved in bone formation. Osteoclasts are involved resorption and 
osteocytes comprise the ossified part of the bone. Osteoblasts when 
stimulated by factors such as 1, 25(OH)2D3, parathyroid hormone, interleukin-
6, prostaglandin E2 stimulate production of a cytokine known as TNF-Related 
Activation Induced Cytokine (TRANCE). TRANCE then activates the 
signalling pathways leading to differentiation of osteoblasts to osteoclasts. 
This process is inhibited by osteoprotergerin (OPG), a decoy receptor for 
TRANCE, which is also produced in osteoblasts (Takami M et al, 2005).   
Recent studies have revealed that PDE4 enzymes are involved in regulating 
the expression of TRANCE, as determined by increased levels of TRANCE 
after treatment of osteoblasts with PDE4 inhibitor rolipram (Takami et al; 
 48 
2005). The effect of PDE4 inhibition appears to be mediated through a PKA-
dependent pathway as PKA inhibitors were shown to attenuate IBMX-induced 
TRANCE expression in osteoblasts (Takami et al; 2005). Furthermore, it was 
shown that the PDE inhibitor-treated osteoblasts elicited increased activity of 
ERK and p38 MAPKand that treatment with ERK inhibitor PD98059 and p38 
MAPK inhibitor SB 203580 reduced the rolipram-induced TRANCE 
expression in osteoblasts. These findings are indicative of a cAMP-PKA-
PDE4 pathway regulating the expression of TRANCE via ERK and p38 
activation (Takami M et al, 2005). PDE4 activity may therefore regulate bone 
cell differentiation induced by TRANCE.  
 
PDE4 genes have also been implicated in osteoporosis, a disease associated 
with a decrease in osteoblast levels (Reneland et al; 2005). Rolipram-
mediated inhibition of PDE4 leads to elevation of alkaline phosphatase 
activity, a marker for the differentiation of osteoblasts to osteoclasts 
(Reneland et al; 2005). Inhibition of PDE4 also induces increased expression 
of osteopontin, osteocalcin and collagen type I which mark osteoblast 
differentiation suggesting a role of PDE4 enzymes in bone disorders including 
osteoporosis (Reneland et al; 2005). 
 
Glucocorticoids and Parathyroid hormone (PTH) play a crucial role in 
regulating bone metabolism. PTH is known to decrease bone resorption (loss) 
by reducing osteoblastic (bone forming cells) apoptosis via a cAMP-
dependent pathway (Ahlstorm, M. et al, 2005). Glucocorticoids, in contrast, 
decrease osteoblast levels, potentially leading to osteoporosis (Ahlstorm, M. 
et al, 2005).   
 
Evidence also suggests that PDE4 may mediate the effects of 
dexamethasone-regulated cAMP signalling in the osteoblasts. Synthetic 
glucocorticoid Dexamethasone is known to a decrease cAMP-specific PDE 
activity in MG-63 and SaOS-2 osteosarcoma cells (Ahlstorm, M. et al, 2005). 
Dexamethasone treatment also leads to reduced rolipram sensitivity of the 
total cAMP-PDE activity (Ahlstorm, M. et al, 2005). The reduction in cAMP 
response and the decrease in sensitivity to rolipram indicate an altered PDE 
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profile in the osteosarcoma cells. In support of this, it was noted that there is a 
massive decrease in the expression of PDE4A4 and PDE4B1 isoforms in 
these cells (Ahlstorm, M. et al, 2005).  
 
Glucocorticoids act as anti-inflammatory and immuno-suppressive agents by 
inhibiting prostaglandin biosynthesis (Ahlstorm, M. et al, 2005). They mainly 
inhibit the cyclo-oxygenase activity thereby reducing the levels of PGE2 
whose functions are mainly anabolic. However, PDE4 inhibitors rolipram and 
denbufylline have been shown to increase the PGE2-mediated anabolic 
effects and subsequent bone formation in rat bone marrow cells (Ahlstorm, M. 
et al, 2005). All these studies indicate glucocorticoid-induced bone loss is 
mediated through a PDE4-dependent pathway (Ahlstorm, M. et al, 2005).  
 
Rolipram is the first generation PDE4 inhibitor to be used as an anti-
depressive agent (Scott et al; 1991). However, the side effects (e.g. nausea) 
associated with usage of rolipram have limited its role as a therapeutic agent 
(Scott et al; 1991). However, with the advent of second-generation PDE4 
inhibitors such as roflumilast and cilomilast, which exhibit anti-inflammatory 
and CNS effects, PDE4 inhibitors are emerging as potentially useful 
therapeutic agents (Houslay et al; 2005). However, neither of these 
compounds successfully passed phase-II clinical trials, revealing side effects 
and efficacy problems still need to be resolved in order to market PDE4 
inhibitors successfully for therapeutic use (Geimbycz, 2006).  
 
1.10 SUMOylation 
 
Ubiquitylation is a post-translational modification involving the attachment of 
the 76-amino acid protein ubiquitin to its substrate protein, which will then 
mark its substrate for proteasomal-degradation (Zhao et al; 2007).   
 
Small Ubiquitin-related Modifier (SUMO) belongs to a family of ubiquitin-like 
proteins that are closely related to ubiquitin and are covalently attached to 
substrates as a part of their post-translational modification (Kerscher; 2007 
and Johnson; 2004). SUMO was first discovered in mammalian cells and has 
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since been reported in all eukaryotic organisms where it is known to be 
involved in a wide range of functions. SUMO is also known as, Pmt2p, PIC-1, 
GMP-1, Ubl1 and sentrin (Johnson, 2004).  
 
1.10.1 Components of SUMO conjugation pathway 
SUMO conjugation pathway is very similar to ubiquitin pathway both in the 
process and in the components. However, many functional differences do 
exist between the ubiquitin and SUMO (Kerscher, 2006). Please refer to figure 
3.1 
 
1.10.1.1 SUMO genes and isoforms 
 
In mammals SUMO is encoded by four SUMO genes, which encode SUMO 
molecules 1-4 (Geiss-Friedlander and Melchior, 2007). SUMO-2 and 3 share 
95% sequence homology and 50% sequence homology with SUMO-1. 
SUMO-4 differs from the other three SUMOs in that it can form covalent 
bonds with its substrate.  (Owerbach et al 2005, Bohren et al; 2004, Johnson; 
2004, Melchior et al; 2003, Hayashi et al; 2002, Apionishev et al; 2001). 
SUMO-1 differs from SUMO-2 and SUMO-3 in that the latter two form poly 
SUMOylation chains whereas SUMO1 does not form poly SUMO chains. This 
unique ability of SUMO-2 and 3 is attributed to the presence of a consensus 
on the target molecule SUMO modification site ΨKXXE where Ψ is an 
aliphatic residue and X is any amino acid. This consensus sequence is not 
present in SUMO-1 suggesting that the differences within their primary 
structures contribute to their distinct functions (Tatham et al; 2001). In support 
of this, it was shown that in plant cells SUMO-2 and SUMO-3 levels were 
elevated in response to stress whereas SUMO-1 levels were unaltered under 
similar conditions (Lois et al; 2003).  
 
1.10.1.2 SUMO-activating enzyme (E1) 
 
SUMO molecules exist in an inactive state until processed by SUMO-
activating enzyme. SUMO-activating enzyme is a heterodimer consisting of 
two Aos1 (SAE1) and Uba2 (SAE2) units. Aos1 is structurally analogous with 
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the N-terminus of ubiquitin activating enzyme Ub E1, whereas Uba2 is 
structurally similar to the C-terminus of Ub E1, which contains the enzyme’s 
active site (Johnson et al; 1997).  
 
1.10.1.3 SUMO-conjugating enzyme (E2) 
 
UBC9 is the universal SUMO-conjugating enzyme in all organisms with a 
SUMO conjugation pathway (Hayashi et al; 2002). It is structurally and 
functionally similar to Ub conjugation enzyme Ub-E2 (Johnson and Blobel, 
1997).  
 
1.10.1.4 SUMO ligases (E3) 
 
There are three classes of E3 ligases, namely Protein inhibitor of Activated 
STAT (PIAS), RNBP2/NUP358 and polycomb group protein PC2 (Johnson; 
2004).  
 
PIAS proteins are inhibitors of the Signal Transducer and Activator 
Transcription (STAT) class of proteins, which are involved in the JAK-STAT 
signalling pathway. There are four different PIAS proteins PIAS1, PIAS3, 
PIASx and PIASy (Jackson; 2001 and Gross et al; 2001).  All PIAS proteins 
have been shown to possess SUMOylation (E3 ligase) activity and show 
substrate-specificity. (Chun et al; 2003 and Miyauchi et al; 2001). All PIAS 
proteins have a conserved N-terminus with a variable C-terminus. These 
proteins contain SAP, SP-ring and SIM domains from the N-terminus to the C-
terminus. The SAP domain (SAR, Acinus and PIAS domain), is involved in 
chromosomal organisation by interacting with DNA at AT-rich regions (Aravind 
et al; 2000). The SP-ring domain contains the E3 ligase activity. The SIM 
domain (SUMO interaction motif) contains an S/T-X-X-D/E consensus motif, 
which is thought to mediate interaction with SUMO. This SIM consensus 
sequence is also seen in SAE-2 and RanBP2 (Minty et al; 2000). 
 
RanBP2, also known as Nup358, is a nuclear GTPase that forms a complex 
with chromatin-bound guanosine nucleotide release factor RCC1. This 
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RanBP2-RCC1 complex pore protein localises to the cytoplasmic side of 
nuclear membrane. It possesses a leucine-rich N-terminal region and eight 
zinc finger motifs. The C-terminus contains regions homologous to 
cyclophilins (Yokoyama et al; 1995). RanBP2 was shown to have SUMO E3 
ligase activity similar to PIAS proteins. RANBP2 interacts with UBC9 bound 
SUMO-1 and transfers the SUMO to SP100. E3 ligase activity of the protein is 
evoked by two repeats of a unique 50-amino acid region known as internal 
repeat domain, IR0) which is not seen in any other E3 ligases (Pichler et al; 
2004 and Pichler et al; 2002).  
 
Pc2 is recently discovered E3 ligase and belongs to a class of proteins called 
polycomb groups that are known to be involved in gene repression. Pc2 does 
not share any homology with other E3 ligases (Kagey et al; 2003). 
 
1.10.1.5 SUMO deconjugating enzymes 
 
Seven genes encode various SUMO deconjugating enzymes that are known 
to cleave SUMO from SUMOylated proteins in mammals. Some cleave the 
SUMO precursor as well as SUMO from SUMOylated proteins (e.g.; Ulp1) 
while other members only function in latter process (Melchior et al; 2003). All 
SUMO cleavage enzymes have a conserved C-terminal domain named the 
Ulp (Ubiquitin like protease) domain, which has isopeptidase activity. The 
enzymes have a variable N-terminal domain that is regulatory in function and 
targets the enzyme to specific sub-cellular compartments (Johnson et al 
2004).  
 
1.10.2 SUMO conjugation pathway 
 
SUMOylation conjugation involves three enzymatic steps. In summary, a 
SUMO molecule is activated in an ATP-dependent manner by SUMO 
activating enzyme 1, with the SUMO deconjugating enzymes contributing to 
this process. This activation leads to maturation of the SUMO molecule. The 
SAE1/SAE2 complex then transfers the matured SUMO to conjugating 
enzyme E2, UBC9. It is then transferred from UBC9 to its substrate, a 
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process, which requires the substrate-specific E3 ligases (Kerscher; 2006). A 
more detailed explanation of this pathway is described in Chapter 3. 
 
1.10.3 Regulation of SUMO conjugation pathway 
 
The mechanisms regulating SUMO conjugation are poorly understood. There 
is no evidence for a common signalling pathway for SUMOylation of 
substrates. Most of SUMO consensus motifs in a vast number of proteins are 
sites for other post-translational mechanisms such as acetylation and 
ubiquitinylation. For example, the acetylation sites of Sp3, a transcription 
factor, are also a part of SUMO consensus motif thus acetylation and 
SUMOylation compete for the same sites and may have an inhibitory affect on 
each other (Braun et al; 2001). Similarly, ERK phosphorylation and 
SUMOylation of ELK-1 seems to elicit  opposing effects on each other as well 
as on the activity of the transcription factor (Yang et al; 2003).  
 
Gam1, an adenoviral gene product, is a unique protein that the inhibits 
SAE1/SAE2 heterodimer complex both in vivo and in vitro thus elevating 
unprocessed SUMO molecules and consequently inhibiting the SUMO 
conjugation pathway and promoting loss of SUMO-1 from the nucleus (Boggio 
et al; 2004 and Colombo et al; 2002). Gam1 forms a complex with 
SAE1/SAE2 in a dose-dependent manner and inhibits the de novo SUMO 
conjugation of substrates. Furthermore, it has been shown to decrease the 
levels of both SAE1/SAE2 and UBC9 proteins through regulation of 
transcription. Gam1 was found not to affect the conjugation pathway in the 
presence of preformed SAE1/SAE2 heterodimer complexes suggesting its 
inhibitory function is partially mediated through its ability to prevent the 
formation of heterodimer complexes in cells (Boggio et al; 2004).  
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1.11 Small GTPases  
 
Rho GTPases belong to Ras superfamily of GTPases along with other 
subfamilies including Ras, Rab, Ran and Arf. Rho GTPases are small 
GTPases that regulate actin cytoskeletal system in all eukaryotes 
(Aspenstrom et al; 2004). So far, 22 different Rho GTPases have been 
identified that can be divided into 8 groups, of which Rho, Cdc42 and Rac1 
are the most studied (Jaffe and Hall; 2005). Classification and groups of Ras 
and Rho GTPases are shown in Table 1.3.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.3 Groups of Ras and Ras like GTPases 
 
 
 
 
 
 
Cdc42 
TC10 
TCL 
Chp 
Wrch1 
 
Ras Superfamily of GTPases 
Ras           Rab          Ran             Rho            Arf              Rap            Sar 
   Rho          Rac           Rnd     RhoD & Rif    RhoH/TFF    Rho BTB       Miro    RhoG    Cdc42 
   (A-C)         (1-3)         (1-3)                                    (1 & 2)       (1 & 2)        
 55 
1.11.1 GTPase cycle and regulation of Rho GTPases  
 
Rho GTPases cycle between a GTP-bound active and GDP-bound inactive 
state. Rho GTPase cycle is regulated by various proteins including GEFs 
(Guanine exchange factors), GAPs (GTPase activating proteins) and GDIs 
(Guanine nucleotide dissociation inhibitors). GEFs exchange GDP for GTP 
thereby activating Rho; GAPs switch on the intrinsic GTPase activity of Rho 
thereby inactivating Rho. GDIs block the dissociation of GDP from Rho thus 
blocking their activation (Jaffe and Hall; 2005, Aspenstrom; 2004, Luo; 2000 
and Olofsson; 1999). In resting cells, Rho exists in a complex with GDI, which 
can be dissociated from Rho upon appropriate stimulation (Saski and Takai; 
1998). Two regions called switch-I and switch-II play a crucial role in 
activation, inactivation and protein interactions of Rho GTPases (Dvorsky and 
Ahmadian, 2004). Figure 1.5 is a diagrammatical representation of the 
GTPase cycle of RhoGTPases.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 Schematic of GTPase cycle. Rho GTPase cycle is regulated by 
GAPs, GEFs and GDIs. 
 
GEF  
Rho GDP 
Rho GDP 
GD
I 
Rho GTP 
Cellular responses through 
effectors  
GAP 
Pi 
GTP GDP 
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1.11.2 Guanine exchange factors (GEF) 
 
Guanine exchange factors or GEFs, act by nucleotide exchange and 
GTPases are subsequently activated by the virtue of the higher levels of 
cellular GTP. GEFs lack preference for GDP or GTP and modify the 
nucleotide-binding site of G-proteins, thereby accelerating the release of the 
nucleotide from the G-protein so that GTP can replace it. The guanine 
nucleotide and GEF also compete for binding to the G protein thereby 
promoting the binding of the nucleotide to the G-protein (Bos et al; 2007).   
 
GEF activity is regulated by various mechanisms including protein-protein/lipid 
interactions, secondary messengers and Post-translational modifications 
(Garcia-Mata and Burridge; 2006, Bos et al; 2007 and Ebinu et al; 1998).  
Most Rho-GEFs have been shown to contain a putative PDZ domain 
(Postsynaptic density protein PSD95; the Drosophila septate junction protein 
Discs-large; tight junction protein, ZO-1). PDZ domains mediate protein 
targeting and allow for the formation of multi-protein complexes thus providing 
a mechanism to limit individual GEF activity to various sub-cellular 
compartments.  This has been reported for GEFs including Kalirin-7 and 
betaPIX exchange factor (Liu and Horowitz; 2006, Garcia-Mata and Burridge; 
2006).  
 
Second messengers including cAMP, calcium and DAG have all been shown 
to modulate the function of various GEFs as discussed previously in 1.5.2, 
cAMP is a regulator of EPAC; Ca+2 and DAG regulate Ras GEFs, Ras GRP1 
and 2, which activate golgi-localised Ras in response to elevated levels of 
either of these second messengers (Bos et al; 2007 and Ebinu et al; 1998).  
 
Tyrosine phosphorylation of the RhoGEF Vav by Lck and Src kinases within 
its Dbl homology (DH) domain is shown to disrupt the auto-inhibitory effect of 
the intra-molecular interaction of the Ac-DH domain leading to activation of 
the GEF (Aghazadeh et al; 2000).  
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1.11.3 GTPase activating proteins 
 
GTPase activating proteins (GAPs) are regulators of G-protein signalling 
(RGS) and contain a 120 amino acid homologous RGS domain (Willars; 2006 
and Popov et al; 1997). Approximately, 70 putative GAPs specific for 
RhoGTPases have been identified, 30 for Ras GTPases, five for Rap and one 
for Ran-GTPases (Bernards and Settleman; 2005).  
 
The catalytic domains of GAPs from any two families are very different 
although GAPs of same subfamily share similar sequences (Boguski and 
McCormick; 1993).  GTP hydrolysis by GTPases is very slow and requires a 
GAP to hasten the process. GAP-assisted GTP hydrolysis has been 
explained by two different models; in the first model, GAPs help stabilise the 
catalytic machinery of a GTPase that otherwise performs the hydrolysis at a 
slower rate (Moore et al; 1993 and Eccleston et al; 1991). In the second 
model, GAPs provide GTPases with an arginine finger residue (Arg789), which 
stabilises the transition states of the active site (Scheffezek and Ahmadian, 
2005 and Scheffezek et al; 1997).  
 
RasGAPs contain a catalytic domain, PH domain and a C-2 domain 
(Conserved domain 2 in PKC). Some RasGAPs, like P120GAP, also contain 
SH2 and SH3 domains (Bernards and Settleman; 2004). Various regulatory 
mechanisms have been reported for individual RasGAPs. Serth and 
coworkers (Serth et al; 1991) showed that p21 is inhibited by lipid micelles in 
vitro. The PH domain of some RasGAPs, including GAP1m and GAPIP4BP, 
has been reported to induce translocation of the GAPs to plasma membrane 
(Lockyer et al; 1997).  
 
RhoGAPs possess a conserved catalytic domain. Different RhoGAPs have 
various regulatory domains such as a BCR (Breakpoint Cluster Region) 
domain. RhoGAPs including RasGAPs can be regulated by phospholipids 
such as phosphotidylserine. In case of p190, a RhoGAP as well as a 
RacGAP, phospholipid binding has been shown to switch the GTPase 
preference with phospholipid binding inhibiting theRhoGAP activity of p190 
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and subsequently activating its RacGAP activity (Ligeti and Settlemen, 2006 
and Ligeti et al; 2004).  
 
RhoGAPs and other Rho proteins have been shown to play a significant role 
in pathogen invasion. Bacterial toxins pumped into host cell cytoplasm modify 
the Rho proteins and alter the dynamics of actin cytoskeleton to aid pathogen 
uptake into host cells (Scheffzek and Ahmadian; 2005).  
 
RapGAPs contain RapGAP domain and differ from GAPs of other families in 
that they do not use arginine finger residue in regulating GTPase activity and 
utilise two lysine residues (Daumke et al; 2004 and Brinkmann et al; 2002). 
Some RapGAPs contain PDZ domains, which may serve to target this protein 
to specific subcellular locations like cytoskeleton as well as to other signalling 
molecules (Schefzek and Ahmadian, 2005) 
 
RabGAPs are involved in vesicle trafficking. All Rabs identified share similar 
primary sequence but exhibit different substrate specificities. They function to 
regulate the activity of Rab GTPases within the same sub-cellular location 
(Bernards; 2002).  
 
Arf GAPs are GAPs for ADP ribosylation factors (ARF). One of the major roles 
of ARFs is in regulating vesicle/endosomal trafficking in conjunction with the 
Rab proteins (Gaynor et al; 1998). ArfGAP activity is regulated by 
phosphorylation and phospholipid interaction (Menetrey et al; 2007).  
 
RanGAP is a GAP for the Ran G protein, which is involved in 
nucleocytoplasmic shuttling of proteins. RanGAP1 is one of the first proteins 
identified to become SUMOylated. RANGAP1 associates with the nuclear-
pore complex upon SUMOylation (Mahajan et al; 1998).  
 
1.11. 4 Guanine dissociation inhibitors (GDI) 
 
Guanine dissociation inhibitors (GDI) bind to GTPases and prevent the 
dissociation of GDP from the inactive GTPase. GDIs in turn, are regulated by 
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GDI dissociation factors (GDFs) (Dermardrossian and Bokoch; 2005, 
Olofsson; 1999). So far, three Rho GDIs have been identified that function to 
regulate the activity of Rho GTPases (Olofsson; 1999), RabGDIs function in a 
similar manner in regulating the RabGTPase cycle (Olofsson; 1999). It has 
been shown that RhoGDI is a substrate for phosphorylation by p21-activated 
kinase 1 (Pak1) leading to the dissociation of RhoGDI from RacGTPase. Pak1 
action therefore indirectly promotes Rac activation (Dermardrossian et al; 
2004).   
 
1.12 Thesis Aims 
 
The data presented in this thesis is divided into three distinct chapters. Each 
chapter focuses on different aspects of PDE4 function. Previous unpublished 
work from our group has shown that certain PDE4 isoforms can be 
SUMOylated in vitro. Chapter 3 aims to characterise the SUMOylation of 
PDE4 isoforms both in vitro and in vivo and to examine the effects of 
SUMOylation on PDE4 signalling and compartmentalisation of PDE4 
signalling.  
PDE4A4 has been shown to form accretion foci reversibly only in the 
presence of rolipram and its analogues and that this process is dependent 
upon protein synthesis (Terry et al; 2003). Considering that only PDE4 
inhibitors that cause emesis lead to PDE4A4 foci formation and not the non 
emetic ones, PDE4A4 foci formation may be important in understanding the 
side-effects elicited upon treatment with PDE4 inhibitors. Chapter four 
therefore aims to indentify the signalling pathways involved in foci formation 
and maintenance. 
PDE4 isoforms and their interacting partners like β-arrestins have been shown 
to play an important role in cell migration and stress fibre formation (Flemming 
et al; 2004 and Barnes et al; 2005). Chapter 5 describes the preliminary work 
in characterising the interaction of novel RhoGAP ARHGAP21/10 with 
PDE4D5 and β-arrestin.  
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Chapter 2 Materials and Methods 
 
2.1 Materials 
 
Throughout the following methods the names of the companies used for the 
purchase of specific reagents are given in parentheses. Where no company is 
mentioned, the reagent was purchased from Sigma-Aldrich. All reagents were 
of analytical grade.  
 
2.2 Methods 
 
All molecular biology techniques were undertaken in DNAase and RNAase 
free environment using sterilised equipment and aseptic technique. Buffers 
were of molecular biology grade and were sterilised by autoclaving or 
sterilised filtration. 
 
2.2.1 Large scale production of plasmid DNA 
 
A sample of E.coli bacteria carrying a plasmid containing the DNA of interest 
was taken from a frozen glycerol stock and transferred to a 2 L flask of culture 
medium (LB broth- 1% (w/v) Bacto-tryptone, 0.5% (w/v) Bacto-yeast extract, 
1% (w/v) NaCl distilled H20) supplemented with antibiotic ampicillin or 
kanamycin (100µg/ml final concentration) depending upon the antibiotic 
resistance of the plasmid by means of a sterile pipette. The culture was 
incubated at 37ºC overnight in an orbital shaking incubator. The cells were 
harvested the next day by centrifugation at 6000 x g for 15 minutes using the 
JA-14 rotor in a Beckman refrigerated centrifuge. The plasmid DNA was 
extracted from the cell pellet using the Wizard maxi-prep kit (Promega®, UK) 
according to manufacturer’s instructions. The principle of the method involves 
precipitating of DNA from cell lysates by isopropanol treatment followed by its 
purification using a silica resin.  
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DNA was precipitated from the eluted solution by addition of room 
temperature isopropanol followed by centrifugation at 15000 x g for 30 
minutes at 4ºC. DNA pellet was then washed with 5 ml of room temperature 
70% ethanol and air dried for 5-10 minutes before resuspended in 500 µl of 
distilled H2O.  
 
2.2.2 Small-scale production of DNA 
 
QIAprep® Spin miniprep kit was used for this procedure. The principle of this 
method involves alkaline lysis of bacteria followed by adsorption onto a silica 
resin from which the DNA will be extracted by water. A sample of E.coli 
bacteria carrying a plasmid containing the DNA of interest was taken from a 
frozen glycerol stock was cultured in 5 ml of LB broth containing appropriate 
antibiotic was incubated at 37ºC overnight in an orbital shaking incubator. The 
cells were harvested the next day by centrifugation at 3000 x g for 10 minutes 
using a Jouan tabletop centrifuge. Pelleted cells were resuspended and 
subjected to alkaline lysis by lysis buffer provided by the manufacturer. DNA 
was adsorbed onto a silica spin column followed by a wash with ethanol. The 
column was air-dried and the DNA was eluted into sterile distilled H2O.  
 
2.2.3 Quantification of DNA 
 
Both DNA and RNA concentrations were measured using a WPA lightwave 
spectrophotometer. 5 µl of DNA was diluted into 1ml distilled H2O and the 
absorbance measurements were taken at 260 and 280 nM against distilled 
water as blank.  
 
The concentration of nucleic acid was calculated using the following 
approximations: 
An absorbance of 1 at 260 nM corresponds to 50 µg/ml double stranded DNA, 
37 µg/ml single stranded DNA, 40 µg/ml single stranded RNA.  
 
The ratio between the absorbance measurements at 260nM and 280nM 
provided an indication of the purity of the nucleic acid. In solution RNA and 
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DNA have A260: A280 ratios of 1.8 or 2.0 respectively. If the absorbance ratio 
is significantly less than this it indicates that the nucleic acid may be impure. 
 
2.3 Site-directed mutagenesis                
 
2.3.1 Primer designs     
 
Site-directed mutagenesis is altering parental DNA by incorporating designed 
changes using engineered primers and polymerase chain reaction. While 
designing the 5’-primer the nucleotide bases that encode new amino acid 
were kept as close to the original sequence as possible. Depending upon the 
length of each primer varied between 45-50 nucleotides in length containing 
both desired mutation and flanked unmodified sequence in total. A melting 
temperature of 75ºC was considered good. 3’ primer is reverse complement of 
5’ primer to amplify the other strand. G or C was always chosen for the first 
and last nucleotide of the primer as it ensures efficient bonding.  
 
The following formula is commonly used for estimating the melting 
temperature Tm of the primers: 
 
Tm (°C) ≈ 2 (NA+NT) + 4 (NG+NC) 
 
 N equals the number of adenine (A), thymidine (T), guanidine (G), or cytosine 
(C) bases in the primer. 
 
The 5’ and 3’primers are designed for PDE4D5 SUMO K mutant 
(PDE4D5K323R) are shown below. 
 
5’-primer CCCAAGGTTTGGAGTTCGAACTGAACAAGAAGATGTCC 
3’-primer GGACATCTTTCTTGTTCAGTTCGAACTCCAAACCTTGGG 
 
The base substitutions made to the K323R mutation are shown underlined.  
 
2.3.2 Mutant strand synthesis reaction  
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Site directed mutagenesis was performed using the Quickchange site-directed 
mutagenesis kit according to manufacturer’s instructions (Stratagene, UK). 
Primers designed in section 2.3.1 were custom synthesised and purified by 
HPLC by Thermo scientific®. The sample reactions then prepared in thermo-
tubes (Abgene, UK) as below: 
 
5 µl of 10x reaction buffer (supplied with the kit); 
x µl (5-50 ng)of dsDNA template (See below); 
x µl (125 ng) of oliconucleotide primer #1 (sense primer); 
x µl (125 ng) of oligonucleotide primer #2 (antisense primer); 
1 µl of dNTP mix (supplied with the kit); 
Sterile, deionised H2O to a final volume of 50µl                                                                
 
A series of sample reactions were set up with various amounts of dsDNA 
template while the primer concentration was kept constant. Once the 
reactions were set up 1µl of pfu turbo DNA polymerase (2.5U/µl) was added 
into each tube and mixed by vortexing. The reactions were cycled in a PTC-
200 Peltier thermo cycler PCR machine using the parameters indicated below 
in table 2.1 
Segment Cycles Temperature Time 
1 1 95°C 30 seconds 
95°C 30 seconds 
55°C 1 minute 
2 12 
68°C 2 minutes/kb of 
plasmid length 
 
Table 2.1 Cycling Parameters for the QuickChange Site-Directed 
Mutagenesis Method.  
 
Following temperature cycling, the reactions were placed on ice for 2minutes 
to cool the reaction to below 37°C.  
2.3.3 Dpn I digestion of parental plasmid  
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1µl of the Dpn I restriction enzyme (1U/µl) (Stratagene, UK) directly was 
added to each amplification reaction and the samples were thoroughly mixed 
by pipetting the solution up and down. Then the reaction mixtures were 
centrifuged at 18,000 x g in a Heraeus microcentrifuge for 1 minutes and 
immediately incubated at 37°C for 1 hour to digest the wild type parental 
super coiled ds DNA.  
 
2.3.4 Transformation of XL1-Blue supercompetent cells 
 
The XL1-Blue supercompetent cells (Stratagene, UK) were gently thawed on 
ice. For each transformation 50µl of the supercompetent cells were aliquoted 
to a pre-chilled Falcon polypropylene tube. 1µl of each DpnI treated DNA 
was then added to separate aliquots of the supercompetent cells, swirled 
gently to mix and were incubated on ice for 30 minutes. Transformation 
reactions were then heat shocked by incubating the samples at 42°C for 45 
seconds in a water bath with and the samples were immediately transferred 
on to ice for 2 minutes.  0.5 ml of LB broth preheated to 37°C was added to 
transformation reactions and then incubated at 37°C for 1 hour. 250µl of each 
transformation reaction was spread onto an agar plate containing 100 ug/ml 
final concentration of ampicillin and incubated at 37°C for 16 hours. A number 
of single colonies were selected for analysis by plasmid preparation followed 
by DNA sequencing to verify successful mutagenesis.  
 
2.3.5 Sequence analysis 
 
Samples of DNA obtained from mutagenesis were sent to Baseclear® 
sequencing centre, The Netherlands. Routine DNA and deduced aminoacid 
sequence analysis were performed on the Genejockey II programme. 
 
 
 
2.3.6 Glycerol stocks 
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A single colony was picked from an agar plate and for long term storage of 
E.coli containing a plasmid of interest was used to inoculate 5 ml of LB broth 
supplemented with appropriate antibiotic. The culture was grown overnight at 
37°C overnight in an orbital shaking incubator. 1 ml of the overnight culture 
was transferred into a sterile eppendorff® tube with 500µl of sterile glycerol 
(Riedel-DeHaën, Germany). The glycerol stock was immediately frozen to  
-70°C using dry ice and then stored at -80°C until required. To revive the cells, 
cells from glycerol stock were picked using a nichrome wire near a Bunsen 
flame and were streaked onto an LB plate and incubated at 37°C over night. 
Single colonies from the picked plate were used in further experiments.  
 
2.3.7 Agarose Gel analysis of DNA 
 
DNA was visualised using agarose gel electrophoresis. 1% agarose was 
dissolved in 1 x TBE buffer (9M Tris base, 20mm EDTA, 0.9M Boric acid) by 
heating in the microwave with occasional swirling to reduce air bubbles in the 
solution. To agarose solution, 0.01% Ethidium bromide was added to enable 
the visualisation the DNA under UV light. A comb and end stoppers were set 
up into the gel apparatus and the agarose solution was poured into it. Once 
the gel was set, the comb and end stoppers were removed and the gel tank 
was filled with 1 x TBE buffer until the gel was immersed in the buffer. 5µl of 1 
Kb DNA ladder (Roche®, UK) was added to the first lane to enable prediction 
of size of the DNA fragments. All the samples were then diluted 5:1 by adding 
6 x DNA blue/orange loading dye (Promega®, UK). The samples were then 
loaded onto the gel which was then run at 50V until the dye front migrated 
along the gel to ensure sufficient separation of the fragments. The gel was 
then carefully removed from the tank and examined under UV light.  
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2.4 Expression and purification of proteins 
 
2.4.1 Maltose Binding Proteins (MBP) fusion proteins 
 
E.coli BL21 pLys (DE3) cells transformed with the appropriate pMAL plasmid, 
as described in Table 2.2 were grown in 30ml of LB broth supplemented with 
100 ug/ ml ampicillin, overnight in an orbital shaking incubator at 37°C. 450ml 
of sterilised LB broth supplemented with 100 ug/ ml ampicillin, was inoculated 
with overnight culture and grown in the orbital shaker at 37°C for 1-2h. A 1 ml 
sample of culture was removed to a plastic cuvette and the optical density 
measured at 600nm (OD600) against a rich media control. Expression of the 
fusion protein was induced with 0.2mM isopropyal-β-D-thiogalactopyranoside 
(IPTG) when an OD600 of 0.6-1 was achieved. An OD600 at this level ensured 
that the culture was in the logarithmic phase, where bacteria will grow 
exponentially. Expression of the target protein was undertaken for 4h in an 
orbital shaker set at 30°C. 1 ml samples of culture were removed hourly to 
monitor protein expression. These samples, including the sample used for 
OD600 measurement were centrifuged at 13000 x g and the pellet was re-
suspended in 100 µl 1x SDS sample buffer for analysis by SDS-PAGE and 
Coomassie® staining, as described in section 2.10. Four hrs post-induction 
the cells were harvested by centrifugation at 4000 x g for 10 minutes. The 
cells were re-suspended in resuspension buffer (50mm Tris-HCl; pH 8.0, 
10mM NaCl and 10mm β-mercaptoethanol). The re-suspended cells were 
then frozen at -80°C and thawed on ice. Lysozyme was added at a final 
concentration of 1mg/ml and the cell suspension was subjected to sonication 
three times for 30 seconds each with an interval of 30 seconds in between to 
achieve cell lysis. NP-40 was added to a final concentration of 0.05% to aid 
cell lysis and the subsequent cell debris removed by centrifugation at 13000 x 
g for 15 minutes. 1 ml of amylose resin (New England Biolabs, UK) was pre-
equilibrated with re-suspension buffer containing 0.05% NP-40. The fusion 
protein was eluted from the amylose resin with 500 µl of 10mM maltose, 
50mM Tris-HCl; pH 8.0 by incubating end-over-end for 20 minutes at 4°C. 
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This was repeated up to three times, if necessary. The eluted fractions were 
pooled and dialysed using a slide-A-lyser dialysis cassettes (Pierce Rockford, 
USA) against three 650ml volumes of dialysis buffer (100mM NaCl, 50mM 
Tris-HCl, pH 8.0, 5% glycerol) for 1h each at 4°C. The purified fusion protein 
was frozen in aliquots on dry ice and stored at -80°C. The expression time 
course and final purification to homogeneity was analysed by SDS-PAGE and 
Coomassie® staining, described in section 2.10.  
 
2.4.2 Glutathione-S-Transferase (GST) Fusion proteins 
 
Recombinant GST fusions proteins were expressed and purified from E.coli 
essentially as described for MBP fusion proteins (section 2.4.1). Competent 
E.coli BL21 pLys (DE3) cells were transformed with appropriate pGEX 
plasmid (Table 2.2). GST fusions proteins were purified using glutathione 
sepharose resin (Amersham Biosciences, UK) and eluted using 10mM 
glutathione following the sample protocol as described in section 2.4.1.  
 
2.4.3 In vitro transcription and translation (TnT®) of recombinant proteins 
 
TnT®, Promega kit is a system designed for expression of proteins through in 
vitro transcription and translation of PCR generated templates using rabbit 
reticulocyte lysates. The reactions were performed as described in 
manufacturer’s instructions (Promega® TB126). Briefly, 40µl of rabbit 
reticulocyte TnT Sp6® quick master mix, 0.5ug of DNA template, 2µl of amino 
acid mixture were mixed in an eppendorff® tube and the total volume was 
made upto 50µl with nuclease free water. Reaction tubes were incubated at 
30°C for 2 hours. Transferring the tubes to 4°C terminated the reactions and 
the resulting recombinant proteins were stored at -80°C.  
 
2.4.4 Purification of TnT® yields 
 
Reaction samples from TnT® were mixed with equal volumes of 4M saturated 
ammonium sulphate in TE buffer (10mM Tris, pH 7.5, 1mM EDTA) at room 
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temperature. Samples were then incubated in ice water for 20 minutes and 
then centrifuged for 20 minutes at 14,000 x g at 4°C. The supernatant was 
removed and the pellets were washed with ice-cold TE buffer containing 2M 
ammonium sulphate and 2mM Dithiothreitol. The samples were centrifuged 
and the pellets were resuspended in modified TE buffer.  
 
2.5 Maintenance of cell lines  
 
2.5.1 COS1 and COS7 cell lines  
 
Cos1 and Cos7 cell lines are derived from African green monkey kidney cells 
and have been transformed with SV40 virus. The cells were propagated in 
complete DMEM (DMEM supplemented with 10% FBS, 0.1% Penicillin and 
Streptomycin (10000U/ml), 2mM Glutamine). The cell line was maintained at 
37°C in an atmosphere of 95% air and 5% CO2. The cells were passaged 
when approximately 90% confluence was reached. This was carried out in a 
laminar flow hood to maintain sterility. To passage the cells the growth media 
was removed and 5 ml of pre-warmed sterile phosphate buffered saline (PBS) 
was added. The cells were washed by gentle agitation with sterile PBS, which 
was then aspirated. 1 or 2ml of Trypsin-EDTA solution was added and cells 
were incubated for 5min at 37°C. The cells were vigorously agitated and then 
analysed under a microscope to check for efficient cell detachment. Once this 
state was achieved, 10ml of growth media was added to inactivate the trypsin-
EDTA solution. The cells were collected by centrifugation at 1000 x g for 3 
minutes. The growth media supernatant was removed and the cell pellet re-
suspended in the appropriate volume of fresh media. Cells were routinely split 
1:5 into fresh media in sterile flask. The cells were returned for incubation at 
37°C in atmosphere of 95% air and 5% CO2 until confluent.  
 
2.5.2 HEK293 cells 
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The human embryonic kidney-293 cell line has epithelial cell morphology. 
These cells were maintained as described in section 2.5.1 for COS1 and 
COS7 cells 
2.5.3 CHO cells  
 
CHO cells were cultured in HAM’s F12 nutrient mix with Glutamax-1 10% 
foetal bovine serum (FBS) plus 0.1% Penicillin / streptomycin (10,000U/ml).  
 
2.5.4 HEK293 cells with inducible (Flp-In-T-Rex) At1a receptor 
 
HEK293 cells stably expressing At1a receptor were maintained in complete 
DMEM supplemented with 200 ug/ml Hygromycin (Calbiochem, UK). Cells 
were treated with 1 ug/ml doxycycline 24-96 hours before assays to induce 
expression of receptors cloned into Flp-In- locus.  
 
2.5.5 Freezing and Thawing of cell lines 
 
The storage of cells with a low passage number at -200°C in liquid nitrogen 
vats ensured the long-term integrity of the specific cell line. To revive cells 
from this temperature the individual vial was quickly thawed and added 
directly to 10ml of pre-warmed fresh growth media, under sterile conditions. 
Once the cell line was established and confluent, further 1ml aliquots of cells 
were re-suspended in freezing media. These were initially frozen at -80°C 
before being transferred to -200°C for long-term storage.  
 
2.6 Transfection of mammalian cell with plasmid DNA 
 
Transfection is a process of introducing foreign DNA into mammalian cells to 
allow the expression of recombinant proteins.  
A list of DNA plasmids used for the transfection of mammalian cell lines is 
described in table 2.2 
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2.6.1 DEAE-dextran transient transfection 
 
This method of mammalian cell transfection was used for the transfection of 
COS1 and COS7 cell lines only. Flasks of confluent cells were passaged the 
day prior to transfection and plated to ensure 70% confluence on the day of 
transfection. These plates were incubated overnight at 37°C in an atmosphere 
of 95% air and 5% CO2.  The amount of DNA required for each transfection 
plate is dependent on the number of cells to be transfected and should be 
scaled accordingly. This protocol is accurate for 100mm plates of 70% 
confluent cells in 10ml of growth media. 10ug of desired plasmid DNA was 
diluted in 10mM Tris-Cl, pH 7.6, 0.1mM EDTA to a final volume of 250 µl. 
200µl of 10mg/ml DEAE-Dextran was added to the DNA solution, mixed and 
incubated for 15 min at room temperature. Where co-transfection of two DNA 
plasmids was required 10ug of each plasmid in final 250 µl of 10mM Tris-Cl, 
pH 7.6, 0.1mm EDTA was added to 200µl of 10mg/ml DEAE-Dextran. During 
the incubation period the growth media was removed from the plates and 
replaced with 10ml of fresh growth media supplemented with 100µM sterile 
chloroquine. The DNA-DEAE-Dextran solution was added directly to the 
appropriate transfection plate and incubated for 3-4hrs at 37°C. The growth 
medium was removed from the plates and 10ml of sterile PBS containing 10% 
Di-methyl sulphoxide (DMSO) added and aspirated immediately. The plates 
were washed twice with 10ml of sterile PBS before the introduction of 10ml of 
fresh growth media. The plates were incubated for approximately 2 days at 
37°C in an atmosphere of 95% air and 5% CO2 prior to any cell treatments 
and harvesting.  
 
2.6.2 Polyfect® transient transfection 
 
The Polyfect® method of mammalian cell transfection from QIAGEN® U.K, was 
used for transfection of COS1, COS7, and HEK293 cell lines. Cells were 
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cultured and prepared for transfection essentially as described in section 2.6.1. 
4ug of the desired plasmid DNA for the transfection was mixed with 25µl of 
Polyfect for HEK 293 cells (80µl for COS cells) and the final volume of the 
mixture was made up to 300 µl with serum free growth media. The reaction 
mixture was incubated at room temperature for 5-10 minutes to allow complex 
formation. During incubation growth medium was removed from the plates 
and replaced with 7ml of fresh complete DMEM. Post-incubation, 1 ml of 
complete DMEM was added to reaction mixture, which was then gently mixed 
and added to the appropriate trasnfection plate. The plates were then 
incubated for approximately 2 days at 37°C as described in section 2.6.1 
 
2.6.3 FuGENE® 6 transient transfection  
 
The FuGENE®6 method of mammalian cell transfection, from Roche® 
diagnostics, Germany was used for the trasnfection of COS1, COS7 and 
HEK293 cell lines that were used for confocal microscopy analyses for better 
morphology. Cells were grown and prepared as described in section 2.6.1. 
This protocol is accurate for one well of a 6-well plate containing 70% 
confluent cells in 2ml of growth media. 5µl of FUGENE®6 transfection reagent 
was added to 95µl of serum free growth media and incubated at room 
temperature for 5minutes. 1ug of the desired plasmid DNA for cell transfection 
was added to reaction mixture and were further incubated for 15-45 minutes 
allowing the complex formation. The transfection reagents were then added 
directly to the appropriate well of the transfection plate. The plates were 
incubated as described in section 2.6.1 prior to harvesting.  
 
2.6.4 Generation of stable cell lines 
 
Chinese hamster ovarian cells (CHO) and HEK293 cells were transfected with 
plasmids as described in Table 2.2 using the transfection agent FUGENE® 6 
(Roche® diagnostics, USA). Cells were allowed to grow for further 48-72 
hours before starting the selection system.  
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After transfection, cells were split to 1:10, 1:20, and 1:50 into 15 cm dishes 
and were selected by growing them in media containing selection antibiotic. 
The choice of selection antibiotic was determined by the plasmid DNA used 
for transfection. For example, G418 was used for all plasmid DNAs cloned 
into pcDNA. An appropriate concentration (lowest concentration) of drug that 
gave massive cell death within 3 days was used.  Cells were left in the 
selection medium for a week with occasional topping of selection medium. 
After the first week, any dead floating cells were removed, fresh selection 
media was added and the cells were replaced in the incubator for further 
selection. The process was repeated for 2-4 weeks until single isolated 
colonies started appearing. Single colonies were scraped carefully into 1ml of 
fresh medium with a micropipette. Cells were then plated into a 24-well plate 
and 1 ml of fresh selection media was added to them. Once the cells reached 
70% confluency, they were trypsinised and then they were plated into a 6-well 
plate.  Once the cells were confluent, they were split into a 75-cm2 flask. Once 
confluent, cells were tested for protein expression and were stored at -200°C.  
 
2.7 Immunocytochemistry 
 
COS1 or COS7 cells were plated on to cell culture treated cover slips and 
transfected in 6-well plates with the appropriate plasmid DNA using FUGENE® 
6 (Roche® diagnostics, USA) as described in 2.6.3. Following protein 
expression for 24h and any subsequent cell treatments the cells were fixed in 
sterile PBS containing paraformaldehyde (4% Paraformaldehyde with 10mM 
MgCl2 and 150mM NaOH pH 7.5). The cells were then washed three times 
with 2ml of sterile PBS. Cells were then permeabilised with 200µl of 0.2% 
TritonX-100. This was repeated three times and the excess TritonX-100 
removed by blotting with napkins. The proteins were then blocked using 10% 
goat serum (dependent upon the primary antibody) and 2% BSA diluted in 
20mM Tris-HCl, pH 7.5 and 150mM NaCl. The protein of interest was 
detected using specific primary anti-serum. If staining for two different proteins, 
the cells were first stained for the protein with monoclonal anti-sera followed 
by polyclonal. Appropriate dilution of 200µl of primary anti-serum in 1:1 TBS 
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and blocking solution was added to cover slips for 2h at room temperature. 
The cover slips were washed three times with 200µl of blocking solution and 
incubated with 200µl of secondary antibody conjugated to Alexa® 594/495 
from Molecular Probes (Eugene, OR, USA). The cells were then fixed to a 
microscopic slide using immuno-mount and observed using Zeiss® Pascal 
laser-scanning microscope (Jena, Germany).  
 
2.8 Preparation of cell extracts 
 
2.8.1 Preparation of nuclear extracts 
 
Cells were grown and transfected using appropriate methods as described in 
section 2.6. Forty-eight hours post-transfection, cells were washed with cold 
sterile PBS and they were scraped into 500µl of hypotonic buffer (1M HEPES 
pH 7.0, 1M KCl, 1M MgCl2, 1M DTT, 10% Triton X-100, 100% Glycerol, 
500mM PMSF, 1mg/ml Aprotinin, 1mg/ml, Leupeptin). The cells were 
disrupted with 10-20 strokes of a Dounce homogeniser (Wheaton #357542, 
USA) and centrifuged at 3000-x g for 5 minutes. The supernatant was the 
cytoplasmic fraction. The pellet was resuspended in 100µl cold extraction 
buffer (Hypotonic buffer with 5M NaCl). Resuspended pellets were then 
incubated on an end over end rotating wheel for 20 minutes at 4°C. Cells 
were then centrifuged at 13,000 x g, for 10 minutes. The supernatant was 
used as nuclear extract and the pellet or nuclear matrix was resuspended in 
100µl extraction buffer. The fractions were all subjected to SDS-PAGE and 
immunoblotting as described in section 2.10 
 
2.8.2 Sub-cellular fractionation 
 
Cells were grown and transfected using appropriate methods as described in 
section 2.6. Post-transfection, cells were washed with sterile PBS and they 
were scraped into 500µl of KHEM buffer (50mM KCl, 50mM HEPEs; pH7.2, 
10mM EGTA, 1.92mM MgCl2, and 1mM DTT) and 1x protease inhibitors 
(Roche® Diagnostics, Germany). Cells were then passed through brown 
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gauge needle for 10 minutes and were centrifuged at 2000 x g for 10 minutes.  
The pellet was P1 fraction and supernatant was removed into another 
eppendorff® tube and was centrifuged at 75000 x g for 30 minutes at 4°C. The 
supernatant obtained was S fraction and the pellet was resuspended in 750µl 
of KHEM buffer and centrifuged at 75000 x g for 30 minutes at 4°C. The pellet 
was retained as P2 fraction. P1 and P2 fractions were resuspended in the 
same volume of buffer as that of S fraction.  The fractions were all subjected 
to SDS-PAGE and immunoblotting as described in section 2.10.  
 
2.8.3 Whole cell lysate 
 
Confluent cells were harvested at temperatures less than 4°C using buffers 
that had been previously chilled to minimise protein degradation in the whole 
cell extract. The cell culture media was aspirated and the cells were washed 
twice with ice cold sterile PBS. The cell plates were drained thoroughly and 
the appropriate volume of cell lysis buffer added. For a 6-well plate 100µl of 
cell lysis buffer was added whereas a 100mm plate received 500µl of cell lysis 
buffer. For the production of whole cell lysate, 3T3 lysis buffer (25mM HEPES, 
pH 7.5, 50mM NaCl, 10% glycerol, 1% triton, 50mM NaF, 30mM Na 
pyrophosphate, 5mM EDTA) and 1x protease inhibitor cocktail (Roche® 
diagnostics, Germany) was used.  
 
2.9 Determination of protein concentrations  
 
The protein concentration of purified recombinant proteins or cell lysates was 
determined using bovine serum albumin (BSA) as a standard in a 
spectrophotometric assay. The assays were undertaken in a clear 96-well 
micro-titre plate. A standard curve of known proteins concentrations was 
generated using a series of BSA standards of 0-5 ug in a final volume of 50µl.   
Protein assay reagent (BioRad®, UK) was diluted 1:5 with sterile water and 
200µl of diluted reagent was added to each well of 96-well micro-titre plate. 
The intensity of the colour change (Brown to blue) was directly proportional to 
the protein concentration of the sample.   The 96-well plate was analysed with 
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a 590nm test filter using Dynex MRX micro-titre plate reader controlled 
through Dynex Revelation, version 3.04-computer software. A standard curve 
was generated by plotting A590 of the BSA standards against their protein 
concentrations, with least squares regression used to obtain the best-fit line. 
The protein concentration of cell lysates was determined by comparison of 
their A590 with the standard curve.  
 
2.10 Protein analysis 
 
2.10.1 SDS-PAGE 
 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) is 
a method that is routinely employed to separate proteins by virtue of their 
molecular weight (Schägger and von Jagow, 1987). Protein samples of 1-
100ug were denatured and reduced by dilution in 1x SDS sample buffer (10% 
SDS, 300mM Tris-HCl; pH 6.8, 0.05% bromophenolblue, 50% glycerol and 
10% β-mercaptoethanol).  The samples were boiled for 5 minutes and the 
loaded directly to an appropriate well of an Invitrogen™ UK protein gel. 
NuPAGE® 4.12% Bis-Tris polyacrylamide gel immersed in Invitrogen™ 
NuPAGE® MES or MOPS SDS running buffer. 5µl of Bio-Rad®, UK pre-
stained molecular weight protein marker was also loaded to an appropriate 
well of the gel to allow the molecular weight of the proteins within the sample 
to be estimated. The gels were run at 200V for 1 hr. For more detailed 
description of Invitrogen NUPAGE® pre-cast gels and associated Xcell II™ 
apparatus please consult the manufacturer’s instructions.  
 
2.10.2 Visualisation of electrophoreses proteins by Coomassie® staining 
 
Proteins separated by SDS-PAGE can be visualised by a variety of methods. 
The limit of coomassie® staining is approximately 0.1-0.5ug of proteins per 
band on a polyacrylamide gel and detects all proteins within a sample. Gels 
that required Coomassie® staining were removed from the pre-cast gel 
cassette and washed with sterile water to remove residual running buffer. 
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Coomassie® stain (1.25g (w/v) of Brilliant blue R250, 44.4% Methanol, 5.6% 
acetic acid) was added to the gel with gentle shaking for 2h at room 
temperature. The gel was transferred from Coomassie® stain into de-stain 
(44.4% Methanol, 5.6% acetic acid). De-stain removed all background 
staining with Coomassie® stain remaining bound to the proteins resulting in 
the detection of all proteins present in the sample. The gels was then washed 
with sterile water and incubated with sterile water plus 10% glycerol to prevent 
the gel cracking during drying.  
 
2.10.3 Western Immuno-blotting  
 
Proteins separated by SDS-PAGE can be visualised by a variety of methods. 
Western immunoblotting allows the detection of the individual proteins with 
specific anti-sera. The proteins separated by SDS-PAGE were transferred to 
nitrocellulose membrane using the XCell™ blotting apparatus and NuPAGE® 
transfer buffer containing 20% methanol. The proteins were transferred with 
an applied voltage of 30V for 1h. For a more detailed description of XCell™ 
blotting apparatus setup and buffer compositions please consult the 
manufacturer’s instructions. Following the transfer of the sample proteins, as 
indicated by successful transfer of the pre-stained molecular weight markers, 
the nitrocellulose membrane was incubated or blocked in 5% milk (Marvel®, 
UK), reconstituted in TBST (20mM Tris-Cl pH 7.6, 150mM, NaCl and 0.1% 
Tween20) for 1h at room temperature with gentle agitation. The primary 
antibody was added at the appropriate dilution to a solution of 1% milk powder 
in TBST. Details of the primary antibodies used in the experiments are 
indicated throughout the text where they have been used. The blocked 
nitrocellulose membrane was then sealed in an airtight hybridisation bag 
containing the primary antibody solution and this was incubated for 1h at room 
temperature, or overnight at 4°C, with vigorous agitation. The membrane was 
then washed several times with TBST before the application of the 
appropriate horseradish peroxidase (HRP) conjugated anti immunoglobulin 
secondary antibody diluted 1:5000 in 1% milk powder in TBST in a sealed bag 
as before. Similarly, this was incubated for 1h at room temperature, or 
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overnight at 4°C, with vigorous agitation. The membrane was again washed 
several times with TBST before employing the Amersham Biosciences, UK 
enhanced chemiluminiscence (ECL) western blotting-kit as the visualisation 
protocol for detecting bound antibodies. Briefly, the bound antibodies were 
detected by exposure of the membrane to lumionol, a substrate for HRP that 
oxidises luminol in the presence of hydrogen peroxide. Luminol is converted 
to an excited stated which emits light that is received by blue-light sensitive X-
ray film and developed using the Kodak® X-Omat model 2000 processor.  
 
2.11 Fusion protein interactions 
 
2.11.1 GST-MBP pull-downs assays 
 
Appropriate amounts of MBP fusion proteins were mixed with 100µl of slurry 
50% (v/v) PBS-washed amylose resin (Amersham Biosciences, UK) for 2h at 
4°C. The beads were pelleted by centrifugation at 14,000 x g for 1 min and 
washed twice with PBS containing 1% Triton X-100 before the addition of 50 
ug of the required GST fusion protein in a 1ml solution of PBS and Triton x-
100 containing 5mM Dithiothreitol. After 2h incubation at 4°C, the beads were 
collected and washed three times with PBS and Triton x-100 solution and 
eluted in 100 µl of 1 x SDS sample buffer. Eluates were resolved by SDS-
PAGE and the bound GST fusion proteins were detected by immunoblotting 
as described in section 2.10.  
 
2.11.2 Peptide arrays 
 
Peptide arrays are Whatmann®50 cellulose membranes on which peptide 
sequences are directly synthesised (Reineke et al; 2001 and Frank; 2002). 
Each spot on a peptide array contains an overlapping 25mers spanning the 
entire protein sequence. These peptide arrays are able to bind purified 
recombinant proteins and provide evidence for direct protein interaction and 
the elucidation of the critical domains and the residues involved (Espanel and 
Hooft van Huijsduijnen; 2005 and Bolger et al; 2006). Substitution alanine 
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scans were also made where a particular amino acid is substituted by alanine 
to identify the critical residues involved in binding.  The peptide arrays used in 
the experiments detailed in the thesis were kindly produced by Dr. E. 
Klussmann (Forschungsinstiut FÜr Molekulare Pharmakologie, Berlin, 
Germany) using the Intavis Bioanalytical instruments (Köhn, Germany) 
Autospot-Robot ASS 222 and utilising Fmoc-Chemistry. Recombinant GST 
fusion proteins were produced homogeneity as described in section 2.4.2. 
The peptide arrays were activated by immersion in 100% ethanol and then 
washed in TBST for 10min at room temperature on an orbital shaker. The 
peptide arrays were then incubated or blocked with 5% milk powder (Marvel®), 
reconstituted in TBST for 1h at room temperature with vigorous agitation. 
Recombinant GST fusion protein or GST alone as control was then added to 
1% milk powder in TBST to a final concentration of between 3-10ug/ml and 
incubated with the peptide array in a hybridisation bag overnight at 4°C with 
vigorous agitation. The peptide array was then subjected to three 10 min 
washes in TBST. Binding of the GST fusion protein to the peptide array was 
detected by incubation of the membrane with protein or GST specific primary 
antibody, followed by a HRP conjugated secondary antibody followed by ECL 
as described in section 2.10.3. As a general rule the primary antibody was 
used at two-fold less than the recommended dilution for immuno-blotting. The 
resolution of spots, distinct from the GST control peptide array, on the blue 
light sensitive X-ray film were indicative of positive interaction of the 
recombinant fusion protein with the peptide array and the critical sequences 
were analysed for putative consensus or binding motifs using sites like 
Scansite (Scansite.mit.edu).  
 
2.11.3 GST-Rhotekin pulldown assays 
 
GST-Rhotekin beads were prepared as per manufacturer’s instructions 
(Millipore, UK) and as described by Barnes et al; 2005. Following the 
necessary cell treatments, cells were lysed in 1x ice-cold Mg2+ lysis buffer 
(125mM HEPES, pH 7.5, 750mM NaCl, 5%Igepal CA-630, 50mM MgCl2, 
5mM EDTA, 10% glycerol, 10ug/ml aprotinin and 10ug/ml leupeptin). Lysed 
cells were then incubated on ice for 10 min and then scraped into prechilled 
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1.5 ml eppendorff® tube. Lysates were centrifuged at 15000 x g for 5 min. 
Supernatant was then removed into a fresh tube and protein concentration 
was determined as described in section 2.9. A volume of lysate containing 
70ug of protein was then pipetted into a fresh prechilled 1.5 ml eppendorff® 
tube and mixed with 30ug of GST Rhotekin beads in a final volume of 300µl. 
Lysates with beads were allowed to rotate for 1h at 4°C before the beads 
were washed 3 times with 1 x Mg2+ lysis buffer. Following the last wash the 
majority of the supernatant was removed by pipette and the beads were 
aspirated to dryness with a flat gel-loading tip followed by SDS-PAGE and 
immuno-blotting to determine the Rho activity of the samples.  
 
2.12 Co-immunoprecipitation  
 
Mammalian cell lines were co-transfected, as described above in section 2.6 
and cell lysates were produced by sub-cellular fractionation as described in 
2.8. The protein concentrations of the samples were determined as described 
in section 2.9 and the concentrations equalised for all samples to contain 
approximately 250ug of protein in a 500µl volume of ice-cold KHEM. A 30µl 
sample of the diluted lysate was removed for western immunoblotting to 
determine he relative immuno-reactive inputs of the co-expressed proteins for 
the co-immunoprecipitation experiment. Anti-Flag or anti-VSV agarose beads 
pre-equilibrated in ice-cold KHEM to produce 50% slurry. 60µl of the slurry 
was added to each 500µl protein sample and these were incubated end-over-
end wheel for 2 h at 4°C. The samples were centrifuged at 13,000 x g for 1 
min at 4°C. Bound proteins were then eluted in 1x SDS sample buffer and 
subjected to SDS-PAGE and western immunoblotting as described in section 
2.10.2 and 2.10.3 respectively. The quantification by densitometry, of the 
immuno-reactive amounts of the co-expressed proteins, in both the initial cell 
lysate and following co-immunoprecipitation, was determined using the 
Discovery series Quantity one® software, version 4.4.0. These data were used 
to compare the interaction efficiency of the two proteins and assess conditions 
that may facilitate the specific interaction. Control immuno-precipitations were 
undertaken in a similar manner with cell lysates produced from cells singly 
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transfected with protein that was co-immunoprecipitated to screen for non-
specific binding to the chosen agarose bead conjugate.  
2.13 Phosphodiesterase activity assay  
 
To measure PDE activity a radioactive cAMP hydrolysis assay was employed. 
This procedure has been described previously (Marchmont and Houslay, 
1980) and is a modification of a historical two-step procedure (Thomson and 
Appleman, 1971). PDE enzymes hydrolyse cAMP, which results in the 
formation of 5’AMP. In this assay, both [8-3H] adenosine 3’, 5’-cyclic mono-
phosphate from Amersham Biosciences, UK and adenosine 3’, 5’-cyclic 
mono-phosphate are hydrolysed.  
 
2.13.1 Activation of Dowex 1x8-400 anion exchange resin 
 
Dowex 1x8-400 was prepared and activated by dissolving 400g of dowex 
resin in 4 litres of 1M NaOH. The solution was stirred for 15 min at room 
temperature and the resin was allowed to settle down. The supernatant was 
removed and the dowex resin extensively washed 30 times with 4 litres of 
distilled water and allowed to settle after each wash. After thirty washes the 
resin was washed with 4 litres of 1M HCl for 15 min at room temperature and 
allowed to settle. The resin was then washed a further 5 times with distilled 
water and stored at 4°C as 1:1 slurry with distilled water. This procedure 
generally produced approximately 1 litre of Dowex slurry. This Dowex slurry 
was utilised in the PDE assay as a 2:1 solution of slurry to 100% ethanol.  
 
2.13.2 Assay procedure 
 
The assay was performed 1.5ml eppendorff® tubes. The cAMP substrate 
solution for the assay was composed of 2µl of 1mM 3’, 5’ cyclic adenosine 
mono-phosphate 3µl of 740GBq/mM [8-3H] adenosine 3’, 5’-cyclic mono-
phosphate per millilitre of PDE substrate buffer (20mM Tris Cl; pH 7.4, 10mM 
MgCl2). The appropriate volume of purified protein or cell extract was diluted 
to a final volume of 50µl in PDE assay buffer (20mM Tris Cl; pH 7.4). 50µl of 
PDE assay buffer was used as a blank control. The exact volume of purified 
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protein or cell extract required in the assay was predetermined in a pilot assay 
using increasing concentrations of protein samples to ensure activity 
measurements were within detection range. 50µl of cAMP substrate was 
added to 50µl of PDE containing sample, mixed and these were then 
incubated in a water bath at 30°C for 10 min to allow hydrolysis. The samples 
were then placed in a boiling bath for 2 min to inactivate the PDE and stop the 
reaction. The tubes were then cooled on ice for a minimum of 15 min. 25µl of 
1mg/ml snake venom of Ophiphagus hannah was then added to the reaction 
tubes, mixed and incubated for a further 10min at 30°C. 400µl of Dowex-
ethanol mixture was added to each reaction tube, mixed and incubated on ice 
for a further 15min. Snake venom prevents re-circularisation of uncharged 5’ 
AMP by further hydrolysis to adenosine and the dowex slurry binds charged, 
unhydrolysed cAMP. Following incubation the tubes were then mixed again 
and centrifuged at 13000 x g for 3 minutes at 4°C in a refrigerated bench-top 
centrifuge. 150µl of supernatant from each reaction was added to 1ml of Opti-
Flow SAFE1 scintillant in a fresh 1.5ml eppendorff® tube and mixed well. The 
extent of cAMP hydrolysis by PDE was determined by measuring the 8-3H 5’-
AMP in 150µl of each supernatant using a Wallac® 1409 liquid scintillation 
counter. 50µl of cAMP substrate solution was also added to 1ml of Scintillant 
and counted to provide a total count for the calculation of PDE activity.  
 
2.13.3 Determination of phosphodiesterase activity 
 
To determine specific PDE activity contained within any reaction tube the 
following formula was applied 2.61x (value-blank/average total) x1011X1012 x 
(1000/ug protein) resulting PDE activity in pmoles/min/mg protein. To assess 
the effect of PDE inhibition, the activities of samples containing inhibitor were 
directly compared to an uninhibited control reaction and were expressed as 
the percentage of the aforementioned uninhibited control.  
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2.14 In vitro phosphorylation assays 
 
2.14.1 In vitro PKA phosphorylation assay  
 
All PKA phosphorylation assays were undertaken using Promega® purified 
PKA catalytic subunit. The expression and purification of MBP or GST fusion 
proteins in E.coli was undertaken as described in section 2.4 and the 
concentration of the purified protein determined as described in 2.9. 1ug of 
fusion protein and 10 units of Promega® recombinant protein kinase A were 
diluted in phosphorylation buffer (100mM Tris-HCl pH 7.5, 0.2mM ATP, 10mM 
MgCl2, 30mM β-mercaptoethanol, 20% glycerol, 10mM Calyculin A) (One unit 
of PKA is defined as an amount of enzyme required to incorporate 1pmol 
phosphate into casein in one minute).  The reaction was incubated at 30°C for 
30 min to allow phoshphorylation. A control was set up without PKA catalytic 
unit. The reaction stopped by the addition 1 x SDS sample buffer. The 
samples were then analysed by SDS-PAGE and immunoblotting. The extent 
of PKA phosphorylation was determined by using a PKA phosphosubstrate 
antibody that specifically recognises phosphorylated PKA substrates.  
 
2.14.2 In vitro ERK phosphorylation assay 
 
 All ERK phosphorylation assays were undertaken using purified recombinant 
MAPK-2 from Upstate cellular signalling®. The procedure was same as 
described in section 2.14.1.  
 
2.15 Foci-Plate reader assays 
This  procedure was followed as described in Terry et al. 2003  
CHO cells stably transfected with PDE4A4GFP were plated overnight onto 
96-well plates (Costar, UK) at a density of 1x106 cells/ml. Cells were then 
treated for 1-24h with a range of signalling inhibitors either with or without 
rolipram. PDE4A4-GFP accretion foci were quantified by measuring GFP 
fluorescence using a Packard Fusion Plate Reader equipped with appropriate 
filter set (GFP: exc 485nm, emi 527nm; Hoescht: exc 355nm, emi 460 nm). 
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Total GFP per well was measured first from live cells in full growth media, 
then cells were treated with an extraction buffer (0.4% formaldehyde in PBS 
with 1% tritonX-100) for 10 min at room temp. Full fixation and nuclear 
staining was completed with fixation buffer (4% formaldehyde with 10 uM 
Hoescht in PBS) and the cells were washed three times in PBS. PDE4A4 
accretion foci were quantified by calculating immobile GFP as percentage of 
the total GFP (mobile and immobile). Hoescht values were used to monitor 
cell numbers.  
 
2.16 In vitro SUMOylation assay  
 
GST or MBP fusion proteins were expressed and purified as described in 
section 2.4. The purified proteins were used in the in vitro SUMOylation 
assays (Biomol, UK) according to the manufacturer’s instructions. Briefly, the 
SUMOylation buffer, SUMO ligases, Mg-ATP mixture and 5ug of purified 
recombinant proteins were mixed in an eppendorff® tube and were incubated 
at 30°C for an hour. The SUMOylation assays were quenched using 25µl of 1 
x SDS sample buffer and the samples were analysed by SDS-PAGE and 
immunoblotting as described in section 2.10. The extent of SUMOylation was 
determined using a SUMO specific antibody as well as by band shift caused 
by SUMOylation.  
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Plasmid  Antiobiotic 
resistance 
Expression Description 
pcDNA 3.1 UBC9 Ampicillin Mammalian UBC9 
PcDNA3.0His SUMO Ampicillin Mammalian SUMO-1 
pKW HA PIASy Ampicillin Mammalian PIASy 
pcDNA3.1VSV 4D5  Ampicillin Mammalian PDE4D5 VSV tag 
pcDNA3.1VSV 4D5 
FQF mutant 
Ampicillin Mammalian PDE4D5 VSV tag-
FQF mutant 
pcDNA3.1VSV 4D5 
K323R mutant 
Ampicillin Mammalian PDE4D5 VSV tag-
K323R mutant 
pcDNA3.1FLAG 
βarrestin1  
Ampicillin Mammalian β-arrestin-1 Flag tag 
pEGFP RACK1 Kanamycin Mammalian RACK1 GFP fusion  
MycEXV3 ERK2 Ampicillin Mammalian ERK2 myc tag 
pEGFP AKAP18δ Kanamycin Mammalian AKAP18δ GFP 
pS462 4A4GFP Kanamycin Mammalian GFP PDE4A4 
pGEX3 UBC9 Ampicillin E.coli GST UBC9 
pGEX4 4D5 Ampicillin E.coli PDE4D5 with GST 
pGEX-4D5 K323R 
mutant 
Ampicillin E.coli K323R mutant of 
PDE4D5  
pGEX6 Arrestin Ampicillin E.coli β-arrestin-1 GST 
pGEX4T3 AKAP18δ Ampicillin E.coli AKAP18δ GST 
pGEX4T3 RACK1 Ampicillin E.coli RACK1 GST 
pGEXEV3 ERK2 Ampicillin E.coli ERK2 GST 
pGEX4T ARHGAP21 
1064-1346 
Ampicillin E.coli ARHGAP21(1064-
1346 a.acids) GST  
pGEX4T ARHGAP21 
1042-1346 
Ampicillin E.coli ARHGAP21(1042-
1346 a.acids) GST 
pGEX4T ARHGAP21 
929-1346 
Ampicillin E.coli GST of ARHGAP21 
fragment 929-1346 
a.acids 
pGEX4T ARHGAP21 
929-1096 
Ampicillin E.coli ARHGAP21(929-
1096 a.acids) GST 
pGEX4T ARHGAP21 
885-1096 
Ampicillin E.coli ARHGAP21(885-
1096 a.acids) GST 
pGEX4T ARHGAP21 
885-1052 
Ampicillin E.coli ARHGAP21(885-
1052) GST 
pGEX4T ARHGAP21 
929-1052 
Ampicillin E.coli ARHGAP21(929-
1052 acids) GST 
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pGEX4.0 UCR1 Ampicillin E.coli PDE4D UCR1 GST 
pGEX4.0 UCR2 Ampicillin E.coli PDE4D UCR2GST 
pGEX4.0 Catalytic 
region 
Ampicillin E.coli PDE4D Catalytic 
region GST 
pMALN Arrestin Ampicillin E.coli β-arrestin-1 MBP 
pMAL 4D5  Ampicillin E.coli PDE4D5 MBP 
pMAL 4A4B Ampicillin E.coli PDE4A4 MBP 
pMALC2 4B1 Ampicillin E.coli PDE4B1 MBP 
 
 
Table 2.2 cDNA plasmid constructs used for protein over-expression in 
either E.coli or mammalian cells.  
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Chapter 3 SUMOylation of PDE4 isoforms in HEK293 cells 
 
3.1 Introduction 
 
3.1.1 SUMO modification  
 
Small Ubiquitin-like Modifier proteins modulate the structure and subsequently 
the function of its target protein by covalently attaching to a lysine residue 
within the consensus motif ΩKXE/D, where Ω is a hydrophobic amino acid 
and X is any residue (Johnson, 2004).  
 
SUMO modification of proteins is known to regulate various cellular processes 
ranging from transcriptional activity (Motter and Castronovo, 2007, Yang et al; 
2003 and Zhao et al; 2005) to cell signalling such as regulation of mitotic 
check points (Bischof and Dejean; 2007, Gutierrez and Ronai 2007), Kerscher 
et al; 2006).  
 
3.1.2 SUMO conjugation pathway  
 
The SUMO conjugation pathway is very similar to ubiquitin pathway both in 
structure and function (summarized in Figure 3.1). The components of SUMO 
pathway are highly conserved in all eukaryotes. There are four different kinds 
of SUMO molecules 1-4, which are conjugated to various substrates by 
specific ligases (Johnson, 2004). 
 
Initiation of the SUMO conjugation pathway involves activation of a SUMO 
molecule by SUMO proteases. So far, six mammalian SUMO proteases have 
been identified and they have all been classed under ulp (Ubiquitin like 
protease) family. Human SUMO proteases SENP 1, 2, 3 and 5 are closely 
related to ulp1 in yeast whereas SENP 6 and 7 are related to ulp2 (Hay, 
2007). SUMO proteases have dual functions. Firstly, their C-terminal 
hydrolase activity processes the SUMO molecule leading to its maturation 
such that the two C-terminal diglycine residues are exposed. They also  
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function to cleave SUMO molecules from SUMO-conjugated proteins by their 
isopeptidase activity thus contributing to SUMO turnover in the cells (Li and 
Hochstrasser, 2003). 
 
SUMO maturation also involves the enzyme complex, SUMO activating 
enzyme E1 complex. Unlike ubiquitin E1, SUMO E1 enzyme is a heterodimer 
complex comprising the Aos1 and Uba2 proteins also known as SAE1 (SUMO 
Activating enzyme and SAE2 respectively. Both E1 subunits possess a 
nucleotide-binding motif, GXGXXG, which is able to form a thio-ester bond 
with the C-terminal glycine residue in SUMO molecules. This process is ATP-
dependent and is inherent for activation of the enzyme complex (Desterro et 
al; 1999). Activated SUMO-E1 enzyme subsequently transfers the SUMO 
molecule to a C-terminal cysteine residue of UBC9, a SUMO conjugating 
enzyme; this transfer involves the formation of thio-ester bond between the 
SUMO molecule and UBC9. To date, UBC9 is the only SUMO conjugating 
enzyme to be identified (Hayashi et al; 2002).  
 
Transfer of SUMO molecule from UBC9 to the target protein is achieved by 
E3 ligases. There are three different classes of E3 ligases as described in 
section 1.10.1.4. All classes of E3 ligases share three functional properties. 
Firstly, they all bind to E2 enzyme(UBC9). Secondly, they all bind to the 
SUMOylating target protein and thirdly, they all transfer SUMO from SUMO-
UBC9 complex to the ε-amino group of the lysine residue within SUMO 
consensus motif present on the substrate (Johnson, 2004). Interestingly, only 
the E1 and E2, but not E3, enzymes are required for SUMO conjugation in 
vitro. However, E3 enzymes have been shown to enhance the SUMOylation 
efficiency of their substrates both in vitro and in vivo (Okuma et al, 1999). 
Furthermore, the E3 SUMO ligase is essential for the SUMO conjugation 
pathway in yeast (Takahashi et al; 2003).  
 
Availability of SUMO molecules for conjugation is under stringent control as 
almost all of SUMO is present as protein conjugates (Desterro et al; 1999). 
The pathway is summarized in fig 3.1 and in the first paragraph of section 
3.1.2.  
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3.1.3 PDE4 isoforms and SUMO pathway  
 
Research within our group has shown that PDE4 enzymes can be 
ubiquitylated (unpublished data). Given the similarity of SUMO and Ubiquitin 
conjugation pathways a SUMOPLOT® analysis of PDE4 isoform sequences 
identified potential SUMOylation sites within members of the PDE4 family 
(www.abgent.com.cn/doc/sumoplot). This chapter focuses on the 
SUMOylation of PDE4 sub-familes.  
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Figure 3.1 Schematic of SUMO conjugation pathway 
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3.2.1 SUMOylation of PDE4 isoforms in HEK 293 cells  
 
Earlier work from our group and collaborators (unpublished data) had shown 
that PDE4D5 is SUMOylated on lysine 323 in vitro (unpublished results). In 
order to examine the effects of SUMOylation of PDE4D5 in vivo, HEK293 
cells were co-transfected with plasmids encoding an HA epitope-tagged 
PIASy E3 ligase and a VSV epitope tagged wild type PDE4D5 or a mutant of 
PDE4D5 in which residue K323 had been mutated to arginine by site-directed 
mutagenesis as described in section 2.3.. Expression of the transfected 
constructs in lysates was confirmed by SDS-PAGE and Western blotting. In 
figure 3.2 a 1,  immunoblotting with anti-VSV antibody identified two species 
of wild-type PDE4D5 migrating at ~100 and 125 kDa corresponding to 
unmodified PDE4D5 and SUMOylated PDE4D5 respectively (upper panel). 
However, the PDE4D5 K323R mutant migrated as a single species of 
~100kDa. Co-expression of PIASy E3 ligase was confirmed by probing with 
anti-HA antisera (lower panel). In a separate experiment, probing for SUMO-1 
using an antibody against SUMO-1 identified a single band of ~125 kDa in the 
lysates expressing wild type PDE4D5 but not the K323R mutant (figure 3.2 a 
2).  
 
Since the lysine of PDE4D5 which undergoes SUMO modification is located 
within a region of the catalytic domain of PDE4D which is moderately 
conserved between the PDE4 subfamilies, sequence alignment of each PDE4 
subfamilies was performed which revealed the SUMO consensus site to be 
present in only the PDE4A and 4D sub-families but not the PDE4B and 
PDE4C subfamilies (Figure 3.2 b).To test the ability of other PDE4 sub-
families to serve as SUMOylation substrates plasmids expressing PDE4 
isoforms from the other three sub-families namely, PDE4A4, PDE4B1 and 
PDE4C2 were co-expressed with or without PIASy E3 ligase in HEK293 cells. 
Immunodetection of transfected lysates showed, as predicted, PDE4A4 
migrated as two species when co-transfected with PIASy E3 ligase with the 
higher molecular weight band corresponding to SUMOylated PDE4A4 (Figure 
3.2 C 1).  In contrast, the migration of immunodetected PDE4B1 and PDE4C2 
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isoforms was unaltered by PIASy co-expression (Figure 3.2 C 2, 3) indicative 
of their inability to serve as SUMOylation substrates.  
 
3.2.2 Interaction of UBC9 with PDE4D5 
 
Work from our group has indicated that PDE4D5 interacts with UBC9 SUMO 
conjugating enzyme E2 (unpublished data). To identify putative sites of 
interaction, a peptide array strategy was used. Indeed our group has exploited 
this technique to identify interaction sites that define the interaction of the 
PDE4D5 isoform with the signalling scaffold proteins,  arrestin and RACK1 
(Bolger et al., 2006; Baillie et al., 2007). PDE4D5 peptides (25-mers) 
sequentially shifted by 5 amino acids across the entire sequence of PDE4D5, 
were immobilized on cellulose membranes. This was then probed with GST-
UBC9, a recombinant fusion protein of UBC9 with Glutathione-S-transferase 
and expressed in E. coli prior to purification for use as a probe. Positive 
interactions were evident as dark spots on the PDE4D5 array. The probe 
identified an interaction site within the C-terminal portion of the PDE4D5 
catalytic domain. This site is called FQF ERK docking site (Mackenzie et al; 
2000) and is present in the catalytic region that maps to amino acids 661-685 
(Spot 133, figure 3.3 a). Each amino acid of the interaction peptide was then 
sequentially mutated to alanine to identify key residues for interaction. On the 
alanine scanning substitution array mutation of either phenylalanine residue 
within the sequence “F670A/Q671/F672A” severely ablated the interaction of 
UBC9 with PDE4D5 (Figure 3.3 a). To further support of these findings, a 
peptide with N-terminal stearoyl group representing the PDE4D5 25-mer 
(Spot 133, figure 3.3a) shown to interact with UBC9 was generated in an 
effort to disrupt this interaction in vivo. Stearated peptides have been shown 
to enter cells and specific species have been used to disrupt protein-protein 
complexes by competing for binding partners (Hundsrucker et al; 2006, Baillie 
et al; 2007, Murdoch et al; 2007). HEK293 cells transiently expressing 
PDE4D5-VSV and UBC9 were treated with a non-related control stearated 
peptide or the PDE4D5 peptide containing “FQF” motif for 3 hours. PDE4D5-
VSV was immunoprecipitated from lysates using VSV-conjugated agarose 
beads and co-precipitating UBC9 was detected using anti-UBC9 antisera. 
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PDE4D5 interaction with UBC9 in cells treated with the control peptide was 
unaltered from non-treated cells. However, in the cells treated with PDE4D5 
“FQF” containing peptide, interaction of UBC9 with PDE4D5 was then 
abolished (Figure 3.3 b).  
 
3.2.3 Interaction of PIASy SUMO E3 ligase with PDE4D5 
 
Having determined an interaction of PDE4D5 with UBC9, interaction of PIASy 
E3 ligase with PDE4D5 was also studied. HEK293 cells transiently expressing 
wild type PDE4D5-VSV and PIASy-HA were harvested and the complexes 
were immunoprecipitated using VSV- and HA-conjugated agarose 
respectively. Control immunoprecipitation experiments were performed with 
Protein G-sepharose. Non-SUMOylated PDE4D5-VSV species showed 
interaction with immunoprecipitated PIASy (Figure 3.4 a1). In order to 
determine if PIASy interacts within the same region as UBC9, an 
“F670A/Q671/F672A” mutant of PDE4D5 was used. The F670A/Q671/F672A 
mutant of PDE4D5, which is unable to interact with UBC9, was still able to co-
precipitate with PIASy E3 ligase. However, the PDE4D5-VSV 
“F670A/Q671/F672A” mutant migrated as a single band indicative the 
PDE4D5 was not SUMOylated (Figure 3.4 a2). Furthermore, the PDE4D5 
mutant K323R, which is not a SUMOylation substrate, was also able to co-
precipitate with PIASy (Figure 3.4 a3).  
 
To further characterise the interaction of PDE4D5 with PIASy, purified GST-
fusion proteins of PDE4D5 and its individual domains (UCR1, UCR2 and 
catalytic regions) were used in pull-down assays to test their ability to interact 
with PIASy-HA from transfected HEK293 cell lysates. The purified PDE4D 
GST fusion proteins were immobilised on glutathione sepharose beads and 
then incubated with PIASy-HA lysates for 2 hours. The complexes 
immobilised were then analysed for pull-down of PIASy. PIASy was shown to 
interact with only full-length PDE4D5 and not with any of the individual 
PDE4D domains of PDE4D5 (Figure 3.4 b). Expression and pull-down of the 
GST fusion proteins was visualized by Ponceau S staining of the membrane 
(Figure 3.4 b) 
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To study this interaction in greater detail, a scanning peptide array analysis 
was used. A peptide array spanning the full length PDE4D5 was incubated 
with PIASy-HA purified from an in vitro protein expression system as 
described in sections 2.4.3 and 2.4.4 and probed with a monoclonal anti-HA 
antibody. PIASy showed interaction with spots B8-10 and G2-G5, which 
correspond to PDE4D5 residues 111-140, which lie within the UCR1 region, 
and residues 486-530 within the catalytic domain (Figure 3.4 C2).  
 
3.2.4 Affect of signalling pathways on SUMOylation of PDE4D5 
 
In an attempt to determine the stimulus for SUMOylation of PDE4D5, HEK293 
cells expressing PDE4D5-VSV and PIASy-HA were subjected to various 
treatments as indicated that would modulate various cellular signalling 
cascades including cAMP signalling (forskolin/IBMX, EPAC, Rolipram), 
oxidative stress pathway (H2O2)and ERK signalling (EGF, PMA, Anisomycin). 
SUMOylated PDE4D5 was immunoprecipitated using the SUMO-1 antibody 
and immunodetected with VSV antisera. SUMOylation of PDE4D5 did not 
appear to be affected by any of these stimuli (Figure 3.5). 
 
3.2.5 Affect of SUMOylation on Sub-cellular localisation of PDE4D5 
 
SUMO modification of various substrate proteins is shown to alter their sub-
cellular localisation (Wies, 2003 and Zhao 2007). Nuclear extraction analysis 
was used to elucidate the effect of SUMOylation on sub-cellular localisation of 
PDE4D5. HEK293 cells transiently expressing PDE4D5 VSV with and without 
PIASy were treated with hypotonic buffer and extraction buffer to separate 
cytoplasmic and nuclear fractions respectively. Lysates were then analyzed 
by SDS-PAGE and immunoblotted for PDE4D5-VSV. SUMOylated and 
unmodified forms of PDE4D5 localised exclusively to cytoplasmic fractions 
and not to nuclear fractions of the cell (Figure 3.6). Lysates were re-probed for 
C-Jun, a nuclear protein, and p70S6 Kinase, a cytoplasmic protein as positive 
controls. To further evaluate the role of SUMOylation in determining sub-
cellular localisation, fraction studies were carried out by differential 
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centrifugation. HEK293 cells expressing PDE4D5 before and after 
SUMOylation were subjected to sub-cellular fraction as described in section 
2.9. The fractions were analysed by SDS-PAGE and immunoblotting (figure 
3.6).  
 
3.2.6 Affect of SUMOylation on PDE4 activity 
 
Various interacting partners have been shown to change the activity and 
rolipram sensitivity of PDE4 isoforms (Houslay and Adams; 2003). A PDE 
assay was performed to determine the potential role of SUMOylation in 
regulating PDE4 activity. Purified GST-PDE4D5 was in vitro SUMOylated as 
described in section 2.16. The SUMOylated pool of GST-PDE4D5 was 
selectively isolated upon incubation with SUMO-1 antibody complexed with 
Protein G-sepharose beads. The precipitates were then used for PDE assays 
as described in section 2.13.  SUMOylation did not affect the PDE4 activity in 
comparison to nonSUMOylated PDE4D5. A similar assay was performed with 
GST alone and GST incubated with SUMO ligases as controls (Figure 3.7 a). 
 
PKA phosphorylation is known to increase PDE4 activity by activating the 
enzyme (Sette and Conti; 1996, Hoffmann et al; 1998, Mackenzie et al, 2002, 
Ekholm et al; 1997). In order to evaluate the role of SUMOylation in regulating 
the PKA-mediated activation of PDE4D5, SUMOylated and un-SUMOylated 
PDE4D5-GST was in vitro PKA phosphorylated as described in 2.14.1. 
Samples then immobilised on glutathione sepharose were washed and 
subjected to PDE assay as described in 2.13. PKA phosphorylated PDE4D5 
showed a 2.5-fold increase in PDE activity compared to non-phosphorylated 
PDE4D5 whereas PKA phosphorylated SUMO PDE4D5 showed a five-fold 
increase in activity compared to its non-phosphorylated form (Figure 3.7 b). In 
similar experiments looking at the effects of ERK2 phosphorylation, un-
SUMOylated PDE4D5 showed a decrease in activity by ~60% whereas ERK 
phosphorylation did not have any effect on SUMOylated PDE4D5 activity 
(Figure 3.7 c) with the PDE activity the same as the non-GRK phosphorylated 
PDE4D5-SUMO protein. 
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3.2.7 Affect of SUMOylation on rolipram sensitivity of PDE4D5 
 
Interaction of SRC tyrosyl kinases through its SH3 domains is known to affect 
the rolipram sensitivity of PDE4 isoforms (McPhee et al, 1999). A rolipram 
dose response curve of in vitro SUMOylated and nonSUMOylated PDE4D5 
was therefore performed to determine the effect of SUMOylation on rolipram 
sensitivity. PDE4D5 had an IC50 of 3.8 +/- 0.2uM for rolipram whereas 
SUMOylated PDE4D5 had an IC50 of 0.45 +/- 0.03uM, thus showing more 
sensitivity to rolipram. As anticipated, a mixed population of nonSUMOylated 
PDE4D5 and SUMOylated PDE4D5 exhibited an IC50 of 1.5 +/- 0.01uM for 
rolipram, a value intermediary with the two previous observations (figure 3.8 
top panel). A further dose response assay was performed with the K323R 
SUMO mutant of PDE4D5, which similar to findings with the nonSUMOylated 
wild-type form had an IC50 of 3.9 +/- 0.027uM for rolipram in vitro (Figure 3.8 
bottom panel).  
 
3.2.8 Affect of SUMOylation and PKA phosphorylation on rolipram sensitivity 
of PDE4D5 
 
Since SUMOylation was found to augment the increase in activity of PKA 
phosphorylated PDE4D5, whilst not having a direct effect itself on activity, a 
dose response assay for rolipram was carried out to examine the conjoint 
effects of PKA phosphorylation and SUMOylation on rolipram sensitivity of 
PDE4D5. PKA-phosphorylated PDE4D5 was shown to have an IC50 of 0.5 +/-
0.01uM whereas the non-phosphorylated PDE4D5 exhibited an IC50 of 3.8 +/- 
0.2uM. The PKA phosphorylated and SUMOylated PDE4D5 form had an IC50 
of 0.15 +/-0.009uM compared to 0.47 +/- 0.03uM for the non-PKA 
phosphorylated SUMOylated PDE4D5 protein (figure 3.9).  
 
 
 
3.2.9 Affect of SUMOylation and PKA phosphorylation on rolipram sensitivity 
of PDE4D5 
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Mackenzie et al, 2000 showed that ERK2 phosphorylation has an inhibitory 
effect on PDE4D5 activity. To analyse the effect of SUMOylation on ERK-
mediated inhibition of PDE4D5 activity a PDE assay was performed as shown 
in figure 3.7. To investigate the subsequent role of SUMOylation and ERK 
inhibition on rolipram sensitivity, a dose response curve was performed on 
SUMOylated and non-SUMOylated PDE4D5 proteins after in vitro ERK 
phosphorylation as described in 2.14.2.  Non-SUMOylated PDE4D5 was 
totally inhibited by ERK phosphorylation. In contrast to this, ERK 
phosphorylation of SUMOylated PDE4D5 did not alter its rolipram sensitivity 
as compared to non-phosphorylated, SUMOylated PDE4D5 (figure 3.10). 
 
3.2.10 Affect of SUMOylation and RACK1 binding on rolipram sensitivity of 
PDE4D5  
 
RACK1 is an identified binding partner of PDE4D5 and is shown to change 
the sensitivity of PDE4D5 for rolipram by 3-4 fold (Yarwood et al; 1999). Given 
these findings, a dose response curve was performed to ascertain the effect 
of RACK1 binding on the rolipram sensitivity of SUMOylated and non-
SUMOylated PDE4D5 in vitro. As the only fusion protein we have for RACK1 
is a GST species, here I investigated the interaction of RACK1-GST with 
PDE4D5-MBP, instead of PDE4D5-GST. Purified RACK1-GST was incubated 
with immobilised SUMOylated and non-SUMOylated PDE4D5-MBP 
recombinant proteins and assayed for PDE activity. RACK1-bound PDE4D5 
showed a 1.5 fold decrease in rolipram sensitivity with a shift in IC50 from 3.8 
+/- 0.2uM (wild type) to 5.6 +/- 0.03uM. Similarly, the IC50 of rolipram for 
RACK1-bound, SUMOylated PDE4D5 increased from 0.45 +/- 0.03uM to 1.2 
+/- 0.009uM. A control experiment was performed concomitantly in which 
GST-RACK1 was substituted with GST alone. GST alone did not affect the 
rolipram sensitivity of either SUMOylated or non-SUMOylated species of 
PDE4D5 (Figure 3.11).  
 
3.2.11 Affect of SUMOylation on affinity of PDE4 isoforms for β-arrestin 
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All PDE4 isoforms are known to bind to β-arrestin at a site within the catalytic 
region (Bolger et al; 2003), an interaction which is critical for the recruitment of 
PDE4 isoforms to the β2-AR and mediating receptor desensitisation (Perry et 
al; 2002). As SUMOylation of proteins is known to change the affinity of 
proteins for their interacting partners (Zhao, 2007), the role of SUMOylation in 
regulating the affinity of PDE4 isoforms for their interacting partners was 
assessed using in vitro pull-down assays. Purified MBP- PDE4A4 and 4B1 
were incubated with β-arrestin-GST before and after SUMOylation. The 
complexes immobilised on amylose resin were washed and analysed by SDS-
PAGE and subsequent immuno-detection for bound β-arrestin was carried 
using a polyclonal GST antibody. The amount of β-arrestin bound to 
SUMOylated 4A4 and 4B1 was determined by densitometric analysis using 
Quantity one software. It was shown that the level of immonodetected β-
arrestin bound to SUMOylated PDE4A4 was ~50% more than the β-arrestin 
bound to non-SUMOylated PDE4A4. However, in assays with recombinant 
PDE4B1 no change in affinity for β-arrestin binding was detected upon 
incubation with SUMO ligases (Figure 3.12 b). A control experiment to rule out 
any non-specific interactions was performed by incubating PDE4A4 and 
PDE4B1 with GST alone. Neither PDE4A4 nor PDE4B1 showed any 
interaction with GST alone (Figure 3.12 a).  
 
3.2.12 Affect of SUMOylation on interaction of PDE4D5 with its partners in 
vitro 
 
PDE4 isoforms interact with a plethora of signalling proteins that have 
multifarious functions (Lynch et al 2006). Pull-down assays were performed in 
order to understand the effects of SUMOylation on PDE4D5 interactions with 
partner proteins. Purified GST fusion proteins of PDE4 interacting partners 
including β-arrestin-1; AKAP18 δ, ERK2, UBC9 and RACK1 were incubated 
with PDE4D5-MBP or MBP alone. Complexes immobilised on amylose resin 
were analysed by SDS-PAGE and immunodetected using a GST antibody. All 
the partners showed an interaction with PDE4D5 MBP but not with MBP alone 
(Figure 3.13 I). Purified GST- partner proteins (β-arrestin-1; AKAP18 δ, ERK2, 
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UBC9 and RACK1) were incubated with SUMOylated and non-SUMOylated 
PDE4D5-MBP and also with the K323R PDE4D5-MBP SUMO mutant. It was 
found that all partner proteins examined exhibited an increased association 
for SUMOylated PDE4D5 compared to the non-SUMOylated form with 
association for β-arrestin-1, AKAP18δ, ERK2, RACK1 and UBC9 increased by 
2.5-, 1.5-, 2.5-, 1.5- and 1.5-fold respectively. As anticipated, there was no 
change in partner association upon incubation with the K323R PDE4D5-MBP 
mutant even in the presence of SUMO ligases (Figure 3.13 ii a-e).  
 
3.2.13 Affect of SUMOylation on interaction of PDE4D5 with its partners in 
HEK293 cells 
 
The effect of SUMOylation of PDE4D5 on its interactions with binding partners 
was further assessed in vivo. HEK293 cells were transfected with plasmids 
encoding PDE4D5 partner proteins as described along with PDE4D5-VSV or 
the K323R PDE4D5-VSV SUMO mutant construct. Cells were also 
transfected with or without the PIASy expression vector. PDE4D5-VSV was 
immunoprecipitated using VSV-agarose and probed for individual partners 
proteins as indicated in figure 3.14 (a-e). Blots were then re-probed with a 
VSV monoclonal antibody. The association for SUMOylated PDE4D5 
compared to the non-SUMOylated form for AKAP18δ, β-arrestin 1, ERK2, 
RACK1 and UBC9 was increased 1.5-, 1.5-, 5-, 5-, and 2-fold respectively. No 
change in association was detected in cells expressing the K323R PDE4D5 
mutant with or without PIASy overexpression (Figure 3.14 a-e lanes three and 
four bottom and top panels). Membranes were re-probed for tubulin 
expression as a loading control.  
 
 
 
 
 
3.3 Discussion 
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Post-translational modifications have long been known to regulate the function 
of proteins in distinct ways (Hasselgren, 2007). Modifications like 
myristoylation are known to be involved in membrane targeting (Frame, 2002) 
whereas ubiquitylation is known to recruit proteins for proteasomal 
degradation (Kaiser et al; 2000).  
 
SUMO modification of proteins is a relatively newly identified and poorly 
characterised post-translational modification (Johnson et al; 2004). 
Components of SUMO modification are closely related to the Ubiquitin family 
in structure (Zha, 2007 and Krescher 2006). Of the PDE4 family of enzymes, 
sub-families 4A and 4D, but not 4B and 4C, have a conserved SUMO 
consensus site near their catalytic region (Figure 3.2 b). SUMO plot analysis 
of PDE4D5 sequence (www.abgent.com.cn/doc/sumoplot), using high 
stringency parameters, revealed a SUMOylation site at lysine 323. Previous 
work from our group has shown that PDE4D5 is SUMOylated in vitro. It was 
shown that only E1 and E2 components of the SUMO conjugation pathway 
but not E3 ligases were required for SUMOylation in vitro (Okuma et al; 1999). 
In similar studies in HEK293 cells which were co-transfected with UBC9 and 
PDE4D5, no SUMOylated PDE4D5 species were immunodetected in cell 
lysates. Furthermore, in HEK293 cells overexpressing PDE4D5 and E3 
ligases, PIAS1 and PIAS2, no detectable levels of SUMOylated PDE4D5 
were noted. However, in cells co-transfected with PIASy E3 ligase, 
SUMOylation of PDE4D5 (migrating at ~125KD) that could be readily detected 
by both SUMO-1 and PDE4D5 antibodies (Figure 3.2 a). Immunblot analysis 
revealed that not all the PDE4D5 cellular pool was SUMOylated as shown by 
two distinct PDE4D5 migration bands on the gel. Non-SUMOylated PDE4D5 
migrated at ~100 KD as opposed to SUMOylated PDE4D5 that migrated at 
~125 KD. Consequent analysis of PDE4A4 transfected into HEK293 cells with 
PIASy E3 ligase yielded similar results. SUMOylated PDE4A4 migrated at 
~150KD and the non-SUMOylated species at 125KD (Figure 3.2 c).  
 
PIASy E3 ligase is a complex molecule possessing a Chromatin binding 
domain, SUMO ligase domain and an acidic domain from its N-terminus to 
variable C-terminus in the same order (Sachdev et al; 2001). PIASy is known 
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to conjugate SUMO substrates such as LEF1 with SUMO-2 molecules and 
exhibits a preference for SUMO-2 over SUMO1 (Sachdev et al; 2001). In this 
study, PDE4D5 conjugates with SUMO-1 as confirmed by probing lysates 
transfected with PDE4D5 and PIASy for SUMO-1. However, probing same 
lysates for other SUMO species did not show any SUMOylated forms of 
PDE4D5. Overexpression of SUMO-2 in HEK293 cells in the presence of 
PIASy and PDE4D5 did not result in conjugation of PDE4D5 with SUMO-2 nor 
was PDE4D5 conjugation with SUMO-2 detected in vitro.  The underlying 
preference of PIASy for SUMO-1 in conjugation with PDE4 isoforms is 
unclear. Mutation of the predicted SUMO site, Lys323 to Arg323 ablated 
SUMOylation of PDE4D5 (Figure 3.2 a).  
 
Having confirmed SUMOylation of PDE4 isoforms in vivo, PDE4D5 was 
chosen for further characterisation due to its high expression levels and 
relatively known biochemistry. However, where appropriate, other isoforms 
were are also analysed in this study. To further understand the mechanism of 
SUMOylation of PDE4D5, interaction of the isoform with various components 
of SUMO conjugation pathway was investigated. 
 
Although UBC9 did not directly lead to SUMOylation of PDE4D5 in vivo, it 
interacted with PDE4D5 both in vitro and in vivo (figure 3.3 and 3.13 ii e). 
UBC9 interacts at a multi-functional docking site on PDE4D5. This region is 
the FQF region located near the catalytic region of all PDE4s and is well 
known for it ability to act as a docking site for ERK2 for all isoforms 
(Mackenzie et al 2000). Other PDE4 binding partners such as β-arrestin and 
AKAP18δ are also known to interact with the FQF region (McSorley et al, 
2006 and Bolger et al 2003). Although the FQF region plays an important role 
as a docking site for many PDE4-interacting partners, most partners bind 
PDE4s at multiple sites; for β-arrestin interaction at N-terminal region of 
PDE4D5 as well as the FQF region has been shown (Bolger et al; 2006) 
Alanine mutagenesis of the F670A/Q671/F672A region severely ablated the 
interaction of UBC9 with PDE4D5 in peptide array analysis and incubation 
with a cell permeable disruption peptide comprising the FQF region produced 
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similar effects on PDE4D5:UBC9 interaction in HEK293 cells (Figure 3.3). 
Since UBC9 interacts at FQF region of PDE4D5, which conserved in all PDE4 
isoforms, it could be postulated that UBC9 can potentially interact with 
members from all PDE4 subfamilies. However, the functional outcome of 
UBC9 interaction with the PDE4 subfamilies which cannot be SUMOylated 
remains unclear, as UBC9 is required for recognition of the SUMO consensus 
motif in substrates of SUMO conjugation pathway (Johnson and Blobel, 
1997). The roles of UBC9 in functions other than SUMOylation have not been 
determined. 
 
PDE4D5 was shown to interact with PIASy E3 ligase both in vitro and in vivo 
(Figure 3.4). E3 SUMO ligases exert functions that are independent of their 
ligase activity. For example, Pc2 is an E3 ligase that is known to regulate 
histone methylation (Kagey et al; 2003). Similarly, the PIAS class of E3 
ligases are inhibitors of transcription factors STATs (Jackson 2001, Chung et 
al; 2003 and Chun et al; 2003). PIASy interaction with PDE4D5 in HEK293 
cells led to SUMOylation of the isoform. In order to confirm the role of UBC9 
in PIASy-mediated SUMOylation of PDE4D5, an F670A/Q671/F672A mutant 
of PDE4D5 was co-transfected with PIASy-HA into HEK293 cells. The 
F670A/Q671/F672A mutant immunoprecipitated with PIASy but PIASy did not 
SUMOylate the F670A/Q671/F672A mutant (Figure 3.4 a2). It could therefore 
be suggested that since UBC9 cannot be recruited to the FQF mutant, PIASy 
is unable SUMOylate the isoforms. In support of this; previous studies have 
shown that UBC9 is critical in identifying the SUMO consensus site on the 
substrate (Okuma et al, 1999, Johnson and Blobel, 1997).  
 
Experiments showed that PIASy was able to interact with the K323R PDE4D5 
mutant although it did not SUMOylate PDE4D5 due to the loss of lysine 
residue within the SUMO consensus site. These results also confirmed the 
prediction that only one consensus site for SUMOylation in PDE4 isoforms is 
present (Figure 3.4 a3). Partial pull-down assays were used to identify the 
binding regions of PIASy on PDE4D5. PIASy from HEK293 cell lysates failed 
to interact with purified GST fusion proteins of the UCR1, UCR2 and catalytic 
regions of PDE4D. PIASy only interacted with purified full length GST-
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PDE4D5 (Figure 3.4 b). Further investigation of the interaction sites using 
scanning peptide array analysis identified two potential binding regions for 
PIASy on PDE4D5 (Figure 3.4 c). Region 1 included amino acids 111-140, 
which correspond to beginning of UCR1 region of PDE4D5. Region 2 included 
amino acids 486-530 that correspond to catalytic region of PDE4D5 (Figure 
3.4 C). From these results it could be inferred that PIASy requires binding to 
more than one region on PDE4D5 for interaction and subsequent 
SUMOylation of the isoform in vivo.  
 
Cell conditions like oxidative stress are known to activate certain post-
translational modifications including phosphorylation of PDE4 isoforms (Hill et 
al; 2006). Similarly, various stress conditions such as heat shock, oxidative 
stress and ethanol are known to upregulate SUMOylation of target proteins 
(Kurepa et al; 2003). Furthermore, ERK phosphorylation is known to modulate 
SUMOylation of transcription factors including Elk-1 (Yang et al, 2003). On the 
basis of these observations, various signalling pathways which modulate 
PDE4 activity were examined to determine their effect on SUMOylation of 
PDE4D5. SUMOylation of PDE4D5 in HEK293 cells was unaltered by 
activation of ERK, elevation of cAMP, or oxidative stress (Figure 3.5). It may 
be that SUMOylation of PDE4D5 in this cellular environment is regulated by 
factors that are independent of the pathways studied in this investigation.  
SUMOylation sites of certain substrates also act as sites for ubiquitylation as 
is reported for IΚBα (Hay et al; 1999). In some instances SUMOylation is 
known to protect the substrate from being ubiquitylated and consequently 
targeted for proteasomal-degradation as has been shown for smad4 (Lin et al; 
2003). Research from our group has shown that PDE4D5 is ubiquitylated 
within its N-terminus and that SUMOylation has no affect on ubiquitylation of 
PDE4D5 (unpublished findings).   
 
SUMOylation is known to regulate or alter the sub-cellular localisation of 
substrates and most of the known SUMO substrates are nuclear proteins 
(Zhao, 2007 and Rodriguez et al; 2001). Analyzing PDE4D5 sequence 
reveals that the isoform does not have any nuclear localisation sequence. 
However, to confirm the role of SUMOylation and subsequent modulation of 
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PDE4D5 structure and function on sub-cellular localisation, nuclear 
translocation studies were carried out. Nuclear extracts were prepared and 
probed for the presence of PDE4D5. The purity of the subcellular fractions 
were confirmed using nuclear protein C-jun and cytosolic p70S6 Kinase as 
controls. In resting cells transiently expressing PDE4D5, the isoform was 
found to be exclusively localised to cytoplasmic fractions and excluded from 
the nucleus in both its non-SUMOylated and SUMOylated states (Figure 3.6). 
However, it has yet to be determined if modulators of cellular signalling would 
induce redistribution of SUMOylated PDE4D5 with cell. Furthermore, the 
possible role of SUMOylation in altering the localisation of PDE4D5 to various 
subcellular organelles including golgi and endoplasmic reticulum is yet to be 
determined. This would involve extensive microscopic analysis using 
organelle markers. 
  
PDE activity is critical in regulating the cAMP levels in various compartments 
of cell. PKA and ERK phosphorylation are known to activate and inhibit the 
cellular PDE4 activity respectively (Mackenzie et al, 2000, Baillie et al 2001, 
Baillie et al; 2000, Sette and Conti, 1996 and Ekholm et al; 1997). It was 
therefore of interest to examine the effect of SUMOylation on PDE4 activity 
before and after PKA/ERK phosphorylation of the enzyme (Figure 3.7). 
SUMOylation did not affect non-PKA phosphorylated PDE4 activity. However, 
SUMOylation had an additive effect on PKA phosphorylation. Non-
SUMOylated PDE4D5 showed a 2-fold increase in its activity after PKA 
phosphorylation whereas PKA phosphorylation of SUMOylated PDE4D5 
exhibited a 4-fold increase in its activity. In contrast to this, ERK 
phosphorylation of non-SUMOylated PDE4D5 led to a decrease in activity by 
75% whilst the activity of SUMOylated PDE4D5 was, rather remarkably, 
unaffected by ERK phosphorylation (Figure 3.7).  
 
Upstream conserved regions (UCR) 1 and 2 as the name indicates are 
regulatory regions of PDE4 isoforms and associate with each other forming a 
regulatory module that interacts with catalytic region thereby regulating the 
catalytic activity of the PDE4 isoforms (Beard et al; 2000) . It is proposed that 
PKA phosphorylation at UCR1 region of PDE4 isoforms causes a 
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conformational change that leads to the disruption of binding between UCR1 
and UCR2 region which in turn activates the enzyme activity (Richter and 
Conti 2002).  ERK phosphorylation within the catalytic region of PDE4 long-
isoforms is thought to promote the interaction of UCR1 and UCR2 regions and 
stabilise the isoform in a conformation that leads to inhibition of the PDE4 
enzymes (Mackenzie et al; 2000). It is possible that SUMOylation stabilises 
the conformational changes initiated by PKA phosphorylation in PDE4D5 thus 
leading to elevated catalytic activity of the isoform. At the same time these 
conformational changes induced and or stabilised by SUMOylation of 
PDE4D5 may have an antagonistic effect on the conformational changes 
initiated by ERK phosphorylation thus keeping the isoform catalytically active. 
Considering the data so far, it could be postulated that since only a small 
fraction of the total intracellular pool of PDE4D5 is SUMOylated, SUMOylated 
PDE4D5 might contribute to differential regulation of the cAMP levels within 
the sub-cellular regions to which it is localised due to its inability to be 
inhibited in response to ERK signalling. SUMOylation of PDE4 enzymes may 
therefore serve to tailor cAMP signalling within distinct intracellular 
compartments. 
 
To further elucidate the role of SUMOylation on affecting PDE4 catalytic 
activity, rolipram dose-response curves were carried out to study the kinetics 
of inhibition. Rolipram is a competitive inhibitor specific for PDE4 isoforms. 
Non-SUMOylated PDE4D5 elicited a 50% inhibition (IC50) in its activity in 
response to 3.8+/-0.2 µM rolipram whereas purified SUMOylated PDE4D5 
had an IC50 of 0.45 +/- 0.03µM. When an equimolar amount of SUMOylated 
and non-SUMOylated PDE4D5 were used the mixed population exhibited an 
IC50 of 1.5 +/- 0.01 µM whereas the K323R SUMO-null PDE4D5 mutant had 
an IC50 of 3.9 +/- 0.027 uM, a concentration similar to that of non-SUMOylated 
PDE4D5 suggesting that the change in rolipram sensitivity is a direct result of 
SUMOylation (Figure 3.8). PDE4 isoforms are known to exist in two different 
affinity states for rolipram, HARBS (High affinity rolipram binding state) and 
LARBS (Low affinity rolipram binding state) (Rocque et al; 1997). HARBS is 
promoted by PKA phosphorylation and the binding of interacting partner 
proteins including SRC family tyrosyl kinase LYN (Sette and Conti, 1996 and 
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McPhee et al, 1999). Given the observed effect of SUMOylation on rolipram 
sensitivity of PDE4D5, it could be argued that SUMOylation, like PKA 
phosphorylation, promotes the HARBS conformation in PDE4D5 thereby 
increasing its sensitivity to rolipram. This is evident from the unaltered 
rolipram sensitivity of PDE4D5 SUMO-null mutant as compared to the wild-
type. Furthermore, a mixed population of PDE4D5 and SUMOylated-PDE4D5 
exhibited a rolipram sensitivity that could be roughly placed between the 
values of the non-SUMOylated and SUMOylated PDE4D5 species.  
 
Having determined the effect of PKA phosphorylation on PDE4 activity, the 
effect of the same on rolipram sensitivity of SUMOylated and non-
SUMOylated PDE4D5 was determined. PKA phosphorylation increased the 
rolipram sensitivity of PDE4D5 by 7-fold whilst that of SUMOylated PDE4D5 
was elevated only 3-fold (Figure 3.9).  Increase in rolipram sensitivity after 
PKA phosphorylation is reflective of a switch to the HARBS conformation. It is 
likely most of the SUMOylated PDE4D5 pool exists in a HARBS conformation 
and therefore the effects of PKA phosphorylation on rolipram sensitivity are 
not as significant as those observed in non-SUMOylated PDE4D5. In order to 
evaluate the inhibitory effect of ERK phosphorylation on PDE4D5 activity and 
its rolipram sensitivity, dose response curves were performed with in vitro 
ERK-phosphorylated recombinant PDE4D5. As anticipated, wild type 
PDE4D5 activity was inhibited by ERK and rolipram sensitivity was lost 
whereas SUMOylated PDE4D5 exhibited no change in rolipram sensitivity in 
response to ERK phosphorylation as compared to the non-phosphorylated 
form. It is possible that SUMOylated PDE4D5 is able to counterbalance the 
conformational switches initiated by the ERK phosphorylation within the 
catalytic site thus overriding ERK’s inhibitory effects on PDE4D5 (Figure 
3.10). The SUMO consensus site on PDE4 isoforms is located proximal to the 
catalytic region and the presence of a SUMO molecule near the catalytic 
region may hinder the conformational changes induced by ERK 
phosphorylation. To confirm that the activity of SUMOylated PDE4D5 is non-
responsive to ERK action, in vitro ERK phosphorylated purified fractions of 
both PDE4D5 and SUMOylated PDE4D5 were immuno-blotted using a 
phosphor-serine antibody to show that SUMOylated PDE4D5 is able to 
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undergo ERK phosphorylation (Figure 3.7 c). Similar analysis was performed 
using a phospho-PKA antibody to show that the recombinant proteins are able 
to serve as PKA substrates (Figure 3.7 b). The mechanism by which SUMO 
exerts these changes in structure and function of PDE4D5 is not understood. 
These structural effects would be best studied by X-ray crystallography 
analysis of the SUMOylated and non-SUMOylated PDE4D5 proteins in both 
the absence and presence of rolipram.  
 
RACK1 is a scaffolding protein known to recruit activated PKC to different 
locations in cells. It has been reported that RACK1 selectively interacts with 
PDE4D5 through its unique N-terminal region thus preventing RACK1 binding 
other PDE4 isoforms (Yarwood et al; 1999). As it had also been shown that 
an in vitro PDE4D5-RACK1 complex displayed a decreased affinity for 
rolipram compared to PDE4D5 alone similar experiments were performed to 
determine the effect of RACK1 on rolipram sensitivity of PDE4D5 and 
SUMOylated-PDE4D5. In accord with the findings of Yarwood and co-
workers, a recombinant  MBP fusion of PDE4D5 protein incubated with a 
RACK1-GST fusion protein showed a slight increase in its rolipram  IC50 value 
(5.6µM for the complex compared to 3.8µM for PDE4D5 alone). SUMOylated 
recombinant PDE4D5 incubated with RACK1-GST showed a similar shift in 
IC50 value with an increase from 0.45 µM to 1.2 µM. To rule out any effect of 
the GST moiety, both SUMOylated and non-SUMOylated species of PDE4D5 
were incubated with GST alone. This had no effect on the rolipram sensitivity 
of either PDE4D45 species (Figure 3.11). The effect of RACK1 on rolipram 
sensitivity of PDE4D5 may be due to the conformational changes elicited by 
RACK1 interaction with the N-terminal region of PDE4D5, leading to a slight 
destabilisation of the catalytic region thereby affecting its rolipram sensitivity. 
SUMO-1 is an 11-KD molecule and is conjugated to a region close to catalytic 
domain at the C-terminal region of PDE4D5 whereas 37-KD RACK1 binds at 
the N-terminal region as well as the catalytic region (Bolger et al, 2006). The 
binding of these two molecules at either end of the PDE4D5 protein could 
restrict it and induce a conformation change that is somewhat between the 
conformational states produced by binding of either of the these molecules 
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individually. This “new” conformation may change the rolipram sensitivity of 
the isoform.  
 
SUMOylation of several substrates is known to change their binding affinity for 
their various interacting partners. However the underlying mechanism for this 
phenomenon is not known (Zhao, 2007). The modifications of histone 
acetylation and de-acetylation are processes which have been shown to 
regulate transcription with acetylation promoting and de-acetylation repressing 
transcriptional activity (Motter and Castronovo, 2007). SUMOylation of 
transcription factors including ELK1 and MEF2 inhibits their transcriptional 
activity by altering their affinity for their binding partners. However, ERK 
phosphorylation of ELK-1 and deSUMOylation of MEF2 by SENP3 leads to 
their eventual activation and prevents further SUMOylation (Yang et al; 2003 
and Zhao et al; 2005). In case of p53, Arf targeted to nucleus increases the 
SUMOylation of p53 and its interaction with mdm2, which further promotes 
SUMOylation of p53 and prevents it from being ubiquitylated (Chen and Chen 
2003). In light of these studies, similar experiments were performed to 
evaluate the affinity of PDE4 binding partners for SUMOylated PDE4 isoforms 
compared to non-SUMOylated forms. Beta arrestin 1 interacts with all PDE4 
isoforms at site within their catalytic region (Figure 3.12 a) although it shows a 
preferred binding to PDE4D5 due to an extra interaction site present within 
the unique N-terminal region of isoform (Bolger et al, 2003 and Perry et al; 
2002). For in vitro β-arrestin binding assays, recombinant PDE4D5 was not 
used as its β-arrestin binding is supplemented by this extra binding site. 
Instead, PDE4A4 and PDE4B1 were selected for the competition assays. 
SUMOylated and non-SUMOylated purified MBP-PDE4A4 and PDE4B1 were 
incubated with purified equal amounts of β-arrestin (Figure 3.12 b). As 
discussed earlier, PDE4B1 cannot be SUMOylated due to the lack of 
conserved lysine within the SUMO consensus motif (Figure 3.2) SUMOylated 
PDE4A4 showed an increased binding to β-arrestin compared to the non-
SUMOylated form. However, PDE4B1 did not show any difference in its ability 
to bind β-arrestin before and after incubation with SUMO ligases. This 
observation also eliminates the possiblity of SUMO ligases in mediating any 
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increase in partner association directly. SUMOylated PDE4A4 showed a 50% 
increase in binding to β-arrestin1 compared to non-SUMOylated PDE4A4 and 
PDE4B1 (Figure 3.12). Similar in vitro and in vivo binding assays with PDE4 
binding partners, AKAP18δ, ERK, RACK1 and UBC9, were performed. In all 
instances, the binding partners of PDE4D5 showed varying levels of 
increased association to SUMOylated PDE4D5 compared to the non-
SUMOylated form in both in vitro and in vivo assays whereas association of 
partner proteins to the K323R SUMO mutant of PDE4D5 were unchanged in 
the presence of the SUMO ligases; There were significant differences in the 
association observed for each PDE4D5 partner proteins between in vitro and 
in vivo analyses. The binding affinities determined from in vivo experiments 
may differ from those of in vitro studies as other cellular components are 
known to influence SUMOylation. Factors including the SUMO cycle of PDE4 
isoforms and the cell cycle which is known to be affected by the SUMO 
(Bischof and Dejean; 2007, Gutierrez and Ronai 2007) may contribute to the 
observed disparities. It could also be suggested that the competition between 
binding partners for SUMOylated species of PDE4D5 might also affect the 
partners’ binding affinities for PDE4D5. The functional outcome of such 
increased binding can only be interpreted based on the existing evidence of 
function of their interaction. Increased binding of scaffolding proteins such as 
AKAPs, β-arrestins and RACK1 to SUMOylated PDE4D5 might result in 
sequestration of the isoform to various sub-cellular locations where the 
isoform would play a key role in regulating the cAMP levels in and around 
various protein complexes whose function is under stringent control of local 
cAMP levels. Such functioning of SUMOylated PDE4D5, which cannot be 
inhibited by ERK and is extremely sensitive to PKA phosphorylation, would 
only add more to the complexity of compartmentalised cAMP signalling. 
Furthermore, the ability of only certain PDE4 sub-families to become 
SUMOylated, a modification which would subsequently alter enzyme activity 
would allow a further means for regulating cAMP-associated signalling 
pathways within cells. SUMOylation of PDE4 isoforms may help maintain the 
cAMP levels within various cellular compartments of cells thereby specifically 
regulating the localised functions of various PDE4 associated proteins.  
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In conclusion, SUMOylation is novel post-translational modification of PDE4 
isoforms, a discovery which increases the complexity of compartmentalised 
cAMP signalling. Further investigations are required to identify the pathways 
involved in regulating the SUMOylation of PDE4 isoforms. Also, considering 
the SUMO consensus site is semi-conserved among the PDE4 families, and 
the consequences of SUMOylation on PDE4 structure and function deserve 
further study.  
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Figure 3.2  SUMOylation of PDE4 isoforms in HEK293 cells co-transfected with
PIASy  E3 ligase.
a) Wild type and K323R mutant of PDE4D5 VSV were co-transfected with PIASy-HA
E3 ligase and blotted for 1)PDE4D5  2)SUMO1(top panel) and PIASy HA (bottom
panel) respectively.
b) Sequence alignment near the semi-conserved SUMOylation site of PDE4
subfamilies  A, B, C and D respectively.
c) PDE4A4, 4B1 and 4C2 were co-transfected with PIASy-HA E3 ligase and the
lysates were blotted for 1)PDE4A4 2) PDE4B1 and 3)PDE4C2 respectively. All the
blots were then reprobed for PIASy-E3 ligase with an HA antibody. The results
shown are examples of experiments done from three separate transfections
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Figure 3.3 Interaction of UBC9 SUMO E2  ligase with PDE4D5 in vitro and in vivo.
A) PDE4D5 is shown schematically as unique N-terminal region, Upstream conserved
regions, catalytic domain and C-terminal region. Results show immobilized peptide ‘spots’ of
overlapping 25-mer peptides each shifted along by five amino acids in the entire PDE4D5
sequence probed for interaction with either UBC9 GST or GST and detection by
immunoblotting. Positively interacting peptides generate dark spots, while those that do not
interact leave white (blank) spots. In all other sections of the array, spots were blank with
either probe. Spot numbers relate to peptides in the scanned array and whose sequence is
given as indicated. Arrays probed with purified GST did not yield any positively interacting
spots..
b) PDE4D5peptide arrays were probed for UBC9-GST binding based upon the indicated 25-
mer ‘parent’ PDE4D5 peptide, where the indicated amino acids were sequentially and
individually replaced by alanine. Ct refers to the native peptide and all other spots reflect
alanine substitutions of individual amino acids in the native spot. GST alone did not give any
spots.
c) HEK293 cells were co-transfected with PDE4D5 VSV and UBC9. Cells were subjected to
no treatment, control peptide treatment or FQF peptide treatment for 3hrs in an incubator
and the lysates were used to immunoprecipitate PDE4D5 and the precipitate were blotted for
UBC9 using an UBC antibody (Santa cruz) and VSV. All western blots shown are
representative of the results obtained from three separate experiments. The peptide arrays
interaction data are from experiments done once.
b) Interaction of UBC9 at FQF region of PDE4D5 in HEK293 cells
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Figure 3.4 Interaction of PIASy  SUMO E3 ligase with PDE4D5 in vitro and in vivo
a) HEK 293 cells were co-transfected with wt PDE4D5-VSV, FQF mutant of PDE4D5
VSV, K323R mutant of PDE4D5-VSV and PIASy-HA respectively. Lysates were
used to immunoprecipitate  using HA and VSV tags and Detection of bound proteins
was performed by immunoblotting using monoclonal antibodies for VSV and HA
tags. Protein G sepharose was used as a control.
b) HEK293 cell lysates transiently expressing PIASy-HA were incubated with purified
GST (lane 1) or various truncates of purified GST PDE4D5 (UCR1 region, UCR2
region, catalytic region and full length 4D5). Complexes were immobilised on
glutathione sepharose beads washed and analysed by SDS-PAGE. Detection of
bound proteins was carried by immuno-blotting with monoclonal HA antibody. Later
the membranes were ponceau-S stained to show the presence of GST proteins. Cell
lysates expressing PIASy were loaded on to the gel as a standard.
c) Mapping the binding sites of PIASy interaction on PDE4D5 using peptide array
analysis. PIASy-HA DNA was used to express the protein in vitro TnT ® kit as
described in section 2.4.3 and 2.4.4. PDE4D5 is shown schematically as unique N-
terminal region, UCR1 and UCR2, conserved catalytic region  and sub-family specific
C-terminal region. Results show immobilized peptide ‘spots’ of overlapping 25-mer
peptides each shifted along by five amino acids in the entire PDE4D5 sequence
probed for interaction with purified PIASy and detection by immunoblotting. Positively
interacting peptides generate dark spots, while those that do not interact leave white
(blank) spots. In all other sections of the array, spots were blank with either probe.
Spot numbers relate to peptides in the scanned array and whose sequence with
a.acids in parentheses is given as indicated. Arrays probed with lysates without
PIASy did not yield any positively interacting spots. All western blots shown are
representative of the results obtained from three separate experiments. The peptide
arrays interaction data are from experiments done once.
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Figure 3.5 Effect of PDE4 activity on SUMOylation of PDE4D5
HEK293 cells co-transfected with PDE4D5 VSV and PIASy-HA were  treated as
indicated above and the lysates were then incubated with SUMO1 antibody (Cellular
signalling). The complexes immobilised on to protein G sepharose were washed and
analysed by SDS-PAGE.  Detection of bound proteins was carried out by
immunoblotting using a monoclonal VSV  antibody. All western blots shown are
representative of the results obtained from three separate experiments.
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Figure 3.6  Effect of SUMOylation on sub-cellular localisation and of PDE4D5
a) HEK293 cells co-transfected with PDE4D5-VSV with and without PIASy-HA were
subjected to nuclear extraction as described in section 2.8.3. The extracts were then
normalised for protein by Bradford’s assay and were analysed by SDS-PAGE. Detection of
the proteins was performed by immunoblotting. C-jun and p70 S6 kinase were used as
positive controls for nuclear and cytosolic proteins respectively.
b) HEK293 cells co-transfected with PDE4D5-VSV with and without PIASy-HA were
subjected to sub-cellular fractionation. The extracts were the normalised for protein by
bradford’s assay and were analysed by SDS-PAGE followed by immunoblotting. All western
blots shown are representative of the results obtained from three separate experiments.
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Figure 3.7 The effect of SUMOylation on PDE4 activity
a) Purified GST, GST PDE4D5, SUMOylated GST PDE4D5 and SUMOylated GST were used
to perform PDE4 activity assay with 1µM cAMP.
b) Purified GST PDE4D5 and SUMOylated GST PDE4D5 were in vitro PKA phosphorylated
and the samples immobilised on glutathione sepharose were washed and used for PDE4
activity assay with 1µM cAMP. A fraction of the samples were analyzed on SDS-PAGE and
phosphorylation was detected by immunodetection using a monoclonal phospho PKA
substrate antibody (Upstate).
C) Purified GST PDE4D5 and SUMOylated GST PDE4D5 were in vitro ERK2 phosphorylated
and the samples immobilised on glutathione sepharose were washed and used for PDE4
activity assay with 1µM cAMP. A fraction of the samples were analyzed on SDS-PAGE and
phosphorylation was detected by immunodetection using a conjugated phospho serine
antibody (Abcam). All experiments are representative of the results obtained from three
different experiments Paired t-test statistical analysis of the PDE activity data were undertaken
where p<0.05 indicates significant difference in PDE activity    120
Figure 3.8 The effect of SUMOylation on rolipram sensitivity of PDE4D5
Inhibition of PDE4D5, SUMOylated PDE4D5, and an equimolar mixture of PDE4D5
and SUMOylated PDE4D5 by rolipram. Dose response curves for  inhibition of
purified recombinant PDE4D5 before and after SUMOylation and assayed with 1µM
cAMP for rolipram. These data are given as IC50 values in micro-molar(µM)
concentrations and are mean values +/- Standard deviation from three separate
experiments. Paired t-test statistical analysis of the rolipram data were undertaken
where p<0.05 indicates significant difference in rolipram sensitivity.
IC50:
PDE4D5: 3.8+/-0.2uM
SUMO-PDE4D5: 0.45+/-0.03uM
PDE4D5+SUMO PDE4D5: 1.5 +/-
0.01uM
K323R PDE4D5: 3.9 +/- 0.027uM
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          P<0.0001
***
Figure 3.9 The effect of SUMOylation and PKA phosphorylation on rolipram
sensitivity of PDE4D5
Dose response curves for  inhibition of purified recombinant PDE4D5 and
SUMOylated PDE4D5 before  and after  PKA phosphorylation assayed with 1µM
cAMP for rolipram. These data are given as IC50 values in micro-molar(µM)
concentrations and are mean values +/- Standard deviation from three separate
experiments. Paired t-test statistical analysis of the rolipram data were undertaken
where p<0.05 indicates significant difference in rolipram sensitivity.
a) IC 50:
Wt: 3.8 +/- 0.2uM
Wt-PKA: 0.5 +/-
0.01uM
P < 0.0001
b) IC 50:
SUMO: 0.47 +/-
0.03uM
SUMO-PKA: 0.15+/-
0.009uM
P < 0.0001
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IC 50:
PDE4D5: 3.8 +/-
0.2uM
IC 50:
SUMO PDE4D5:
0.45 +/- 0.03uM
ERK SUMO PDE4D5:
0.45+/-0.01uM
Figure 3.10 The effect of SUMOylation and  ERK phosphorylation on rolipram
sensitivity of  PDE4D5
Dose response curves for  inhibition of purified recombinant PDE4D5 and SUMOylated
PDE4D5 before  and after  ERK2 phosphorylation assayed with 1µM cAMP for rolipram.
These data are given as IC50 values in micro-molar(µM) concentrations and are mean
values +/- Standard deviation from three separate experiments. Paired t-test statistical
analysis of the rolipram data were undertaken where p<0.05 indicates significant difference
in rolipram sensitivity.
a)
IC50:
PDE4D5  MBP+RACK1 GST: 5.6+/-
0.03uM
PDE4D5 MBP+GST: 3.8 +/- 0.19uM
b)
P<0.0001
P<0.0001
IC50:
SUMO PDE4D5  MBP+RACK1 GST:
1.2 +/- 0.009 uM
SUMO PDE4D5 MBP+GST: 0.45 +/-
0.03 uM
Figure 3.11 The effect of RACK1 binding on rolipram sensitivity of SUMOylated and
unSUMOylated PDE4D5
Dose response curves assayed with 1µM cAMP for rolipram inhibition of purified,
recombinant PDE4D5 MBP and SUMOylated PDE4D5-MBP after RACK1GST binding.
Same dose response curves were carried out on PDE4D5-MBP and SUMO-PDE4D5-
MBP mixed with GST alone as control. These data are given as IC50 values in micro-
molar(µM) concentrations and are mean values +/- Standard deviation from three
separate experiments. Paired t-test statistical analysis of the rolipram data were
undertaken where p<0.05 indicates significant difference in rolipram sensitivity.
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Figure 3.12 Effect of SUMOylation on affinity of PDE4 isoforms for arrestin
A) Purified MBP PDE4A4 and PDE4B1 were incubated with GST βarrestin 1 or GST alone.
Complexes immobilised on amylose resin were washed and analysed by SDS-PAGE.
Detection of bound proteins was carried by immuno blotting using a polyclonal antibody
against beta arrestin 1.
B)    Purified  MBP PDE4A4 and PDE4B1 were SUMOylated in vitro and incubated with GST
βarrestin 1 or GST alone. Complexes immobilised on amylose resin were washed and
analysed by SDS-PAGE. Detection of bound proteins was carried by immuno blotting
using a polyclonal antibody against beta arrestin 1. The amount of arrestin bound to each
of the sample was was analysed by densitometry using Quantityone® software. These
results shown were typical of experiments done on three different occasions. Paired t-test
statistical analysis of the densitometry data were undertaken where p<0.05 indicates
significant difference in beta arrestin binding.
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Figure 3.13 The effect of SUMOylation on interaction of PDE4D5 with its partners in
vitro
i) Purified MBP and PDE4D5 were incubated with purified GST and GST fusion proteins of
indicated partner proteins respectively. Complexes were immobilised on amylose resin,
washed and analysed by SDS-PAGE. Detection of bound proteins was carried out by
immunoblotting using a monoclonal GST and MBP antibodies.
ii) Equimolar amounts of MBP fusion proteins of SUMOylated and non-SUMOylated
PDE4D5 and K323R SUMO mutant of PDE4D5 were incubated with purified GST fusion
proteins of indicated proteins. Complexes were immobilised on amylose resin, washed and
analysed by SDS-PAGE. Detection of bound proteins was carried out by immunoblotting
using a monoclonal GST and MBP antibodies. Quantification of bound proteins were
carried out by densitometric analysis using Quantityone software ®. The results shown are
examples of experiments done from three separate pull down assays performed by using
purified proteins obtained from a single successful expression experiment undertaken for
all the proteins in E.coli. Paired t-test statistical analysis of the densitometry data were
undertaken where p<0.05 indicates significant difference in interacting partner binding as
indicated.
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Figure 3.14 The effect of SUMOylation on interaction of PDE4D5 with its partners in
HEK293 cells
HEK 293 cells were triple transfected with PDE4D5 VSV or K323R mutant of PDE4D5 VSV
with PDE4D5 interacting partners indicated above and with or without PIASy respectively.
Bound complexes were immunoprecipitated by VSV agarose, washed and analyzed by SDS-
PAGE. Detection of bound complexes was performed by antibody to the respective partner
protein. Non-specific IgG  was used as a control and tubulin was immunoblotted as a loading
control. Quantification of bound proteins was carried out by densitometric analysis using
Quantityone software®. The results shown are examples of experiments done from three
separate transfections and immunoprecipitation assays.  Paired t-test statistical analysis of
the densitometry data were undertaken where p<0.05 indicates significant difference in
interacting partner binding as indicated.
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Chapter 4 Rolipram induced foci formation of PDE4A4 
 
4.1 Introduction 
 
4.1.1 Altered localisation of proteins is regulated by multiple factors  
 
The localisation of a protein and its function are often inter-dependent. 
Changes in a protein’s sub-cellular localisation are affected by various factors 
including post-translational modifications, alterations in 
expression/degradation rates and sequestration into complex aggregates. 
Protein localisation may also alter between various states of disease and 
health (Chu et al, 2007). For instance, Elk-1 transcription factor is a key 
component of ERK-MAPKinase pathway (Iwata et al; 2001). Elk-1 along with 
alpha-synuclein is known to form cytoplasmic inclusion bodies where it is 
known to cause MAPKinase attenuation in glial cells in Parkinson’s disease 
and multiple system atrophy (Chu et al, 2007 and Iwata et al; 2001).  Similarly, 
importin α1 is involved in transport of proteins across the nuclear membrane 
into nucleus. In conditions like Alzheimer’s disease, the function of importin α1 
is disrupted and the protein is shown to localise to aggregates called Hirano 
bodies which are also seen in conditions associated with oxidative stress 
mediated injury (Chu et al; 2007 and Lee et al, 2006).   
 
4.1.2 PDE4A4 redistributes into foci 
 
It has been shown that the PDE4 isoform, PDE4A4 undergoes redistribution 
when subjected to chronic rolipram treatment (Terry et al; 2003). This 
redistribution is specific for PDE4A4 and its rat ortholog PDE4A5. It was 
demonstrated that the process occurs over 16 hours and is dependent upon 
de novo protein synthesis as inhibition of protein synthesis by cycloheximide 
or puromycin prevents redistribution of the isoform  
 
Rolipram, as well as a few other PDE4-specific inhibitors such as RO20-1724 
and RS25344, induce a profound redistribution of the PDE4A4 isoform. This 
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occurs in a dose-dependent, reversible manner and leads to the formation of 
accretion foci within the cell (Figure 4.1). Foci formation confers memory in 
that, cells having been pre-exposed to rolipram form foci, which are then 
dispersed upon the removal of rolipram, re-form foci upon further rolipram 
challenge at a faster rate than naïve cells being exposed to rolipram for the 
first time. This is likely due to rolipram-induced initiation of de novo synthesis 
of protein(s) required for foci formation (Terry et al, 2003). 
 
Accretion foci formation is PDE4 isoform-specific thus suggesting a 
contribution of the N-terminal regions of human PDE4A4 rat PDE4A5 in foci 
formation. In support of this, foci formation is not seen with other long 
isoforms of PDE4A subfamily such as PDE4A10 and PDE4A11 (Wallace et al; 
2005). Foci formation has not been demonstrated by isoforms of the PDE4B, 
PDE4C and PDE4D subfamilies. However, it has not been investigated 
whether a chimeric PDE4B, 4C or 4D isoform expressing the unique N-
terminal region of PDE4A4 would form foci in response to prolonged rolipram 
treatment. Foci formation is known to be blocked by PDE4 inhibitors such as 
Ariflo® which inhibit the foci formation by displacing rolipram from the catalytic 
site.  
 
4.1.3 Molecular mechanisms of foci formation and inside-out signalling 
 
Since foci formation is only shown by PDE4A4 and PDE4A5, It was proposed 
that the isoform specific N-terminal region along with catalytic region mediates 
conformational changes upon rolipram binding thus leading to foci formation 
(Terry et al; 2003). These changes along with other factors like protein 
synthesis are collectively called ‘inside-out’ signalling as foci formation is a 
cAMP-independent action and is thought to be triggered by an altered 
conformation of PDE4A4 (Figure 4.1e). This model proposes that when 
rolipram binds the catalytic region, conformational changes are induced which 
are exposed to the surface of the PDE4 molecule (Appendix II for image). 
Knowledge of the 3-D structure of the catalytic unit has led to a model in 
which a conformational change emanating from the catalytic pocket is relayed 
through the loop connecting helix-7 with helix-8 to the surface of the catalytic 
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unit via interactions with the N- and C-termini of helix 10 and helix-11. Two 
residues, His505 and His506, of loop 7/8 are thought to interact with Val475 of 
helix-10. These residues play a crucial role in foci formation as mutation at 
any of these sites leads to disruption in foci formation. The 7/8-loop, along 
with helix-10 and helix-11, forms a groove-like structure that could potentially 
serve as a binding pocket for other proteins or PDE4A4’s N-terminal region. 
These rolipram-induced conformational changes, may subsequently allow for 
PDE4A4 partner protein(s), or PDE4A4 itself to interact thus triggering 
redistribution of the isoform into foci.  
 
4.1.4 Foci formation and signalling pathways 
 
The aim of this investigation was to identify the signalling pathways mediating 
foci formation, maintenance and dispersal. It was also of interest to determine 
if PDE4A4 interacting proteins are components of foci.  
 
4.2 Results  
 
4.2.1 Formation of rolipram-induced foci of PDE4A4 
 
CHO cells stably expressing a GFP fusion of PDE4A4 were analysed by 
confocal microscopy following incubation with rolipram or DMSO for 10-16hrs. 
Foci could be seen as tiny green aggregates in cells treated with rolipram. 
Cells treated with DMSO showed no foci (Figure 4.1). The amount of foci 
formation was quantified by a fluorescence based plate reader assay as 
described previously (Terry et al; 2003). A similar experiment was carried out 
with CHO cells transiently expressing GFP alone. Rolipram treatment did not 
lead to any aggregation of GFP in CHO cells (Figure 4.1d).  
 
4.2.2 The effect of cAMP signalling on foci formation 
 
Terry and co-workers (Terry et al; 2003) showed that foci formation was 
independent of PKA action and that cAMP had inhibitory effect on foci 
formation by displacing rolipram from the active site. In order to identify the 
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component(s) of cAMP signalling through which these effects are mediated, 
cells were treated with various cAMP effectors. Elevation of intracellular cAMP 
upon challenge with forskolin alone or forskolin plus the non-selective PDE 
inhibitor, IBMX, in the presence or absence of PKA inhibitor, H89, inhibited 
foci formation. However, augmentation of cAMP levels through activation of 
the Gs-coupled β2-AR with isoprenaline treatment had no effect on foci 
formation. Similarly, treatment with EPAC agonist (8-CPT-2’-O-Me-cAMP) did 
not alter foci formation (figure 4.2). 
 
4.2.3 The effect of MAP kinase pathway on foci formation 
 
Previous work has shown that ERK MAP kinases are able to regulate PDE4 
activity by phosphorylating isoforms from the PDE4B/C/D sub-families, which 
possess a KIM domain, a proline-directed serine consensus and FQF domain 
in the same order (Mackenzie et al, 2000). Isoforms of the PDE4A subfamily 
have KIM and FQF domains but cannot be phosphorylated and regulated by 
ERK due to the presence of an arginine residue in the proline-directed serine 
consensus making the sequence R-x-Ser-P instead of P-x-Ser-P (Baillie et al; 
2000, Baillie et al; 2001, Hoffmann et al 1999 Mackenzie et al; 2000).  
 
To assess any potential role of ERK and other MAP kinases in regulating the 
foci formation of PDE4A4-GFP, various inhibitors and activators of MAP 
kinases were evaluated. Cells were incubated with MEK inhibitors (UO126 
and PD98059), p38 MAP kinase activator, anisomycin, p38 MAP kinase 
inhibitor, SB203580, and a JNK inhibitor (Anthra [1, 9-cd] pyrazol-6(2H)-one 
1, 9-pyrazoloanthrone). The compounds were added to cells individually as 
well as in various combinations in the presence or absence of rolipram. 
Inhibition of MEK enhanced foci formation by 50 ± 17 % as determined by the 
fluorescent plate reader assay whereas Activation of p38 MAP kinase 
completely inhibited foci formation. Addition of either the p38 MAP kinase 
inhibitor SB203580 (Davies et al; 2000) or the JNK inhibitor did not have any 
effect on foci formation. Cells treated with both anisomycin and SB203580 
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inhibited foci formation. Similarly, cells treated with anisomycin and JNK 
inhibitor did not form foci (figure 4.3).  
 
4.2.4 The effect of MAP kinase pathway on foci formation 
 
In order to investigate the role of PKC and calcium signalling in foci formation 
of PDE4A4-GFP, cells were challenged with various PKC inhibitors and 
calcium modulators. PMA, a PKC activator, did not affect foci formation nor 
did EGCG (Epigallocathecingallate) Rottlerin, a PKCδ inhibitor, completely 
inhibited foci formation. PMA treatment reversed the effects of rottlerin on foci 
formation and led to 80% ± 10.1% increase in foci formation compared to 
incubation with rottlerin alone. PKC inhibitors, RO320432 (PKCα,β1,ε) and 
GO6983 (PKCα,β,γ,δ) elicited a 70-90% enhancement in the fluorescence 
immobilised in PDE4A4-GFP accretion foci as compared to treatment with 
rolipram alone (Figure 4.4a).  
 
To further ascertain the role of PKC-calcium signalling, various calcium 
modulators such as thapsigargin and ionomycin were used. Both compounds 
completely inhibited foci formation as evident by a 98% decrease in immobile 
GFP. Inhibiting CaMKII with KN62 had no effect, nor did inhibition of 
calcineurin with cyclosporin A (Figure 4.4b), whilst inhibition of calmodulin with 
W-7 and ophiobolin-A treatments led to cell loss/death.  
 
4.2.5 PI3 kinase inhibition enhances foci formation 
 
To assess the possible role of PI3 kinase signalling in foci formation, cells 
were incubated with PI3-K inhibitor wortmannin. This increased the 
percentage of immobile GFP in accretion foci to 175% ± 15.5 % (Figure 4.5). 
Furthermore, PI3-K-specific inhibitor LY294002 also increased the percentage 
immobile GFP by a similar extent (196% ± 19.2, 5). However, inhibiting the 
downstream effectors of PI3 kinase, p70S6K and GSK3β, with rapamycin and 
GSK3β Inhibitor respectively, had no effect on rolipram-induced foci formation.  
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4.2.6 The effect of tyrosine kinases on foci formation 
 
Inhibition of cellular tyrosine kinase activity using Genistein ablated foci 
formation (Figure 4.6). To identify the role of individual tyrosine kinase families 
in foci formation, cells were challenged with Src tyrosyl kinase inhibitors, 
SU66656 and PD163893. Blockade of SRC tyrosyl kinase signalling elicited 
no effect on foci formation. However, inhibition of the PDGF receptor tyrosine 
kinase inhibited rolipram-induced foci formation (figure 4.6). 
 
4.2.7 Role of cdk5 in foci formation  
 
To evaluate the role of cdk5 on foci formation, cells stably expressing 
PDE4A4-GFP were treated with Roscovitine. At a concentration of 10µM, 
Roscovitine inhibited foci formation but did not have any effect at 1uM 
concentration.  
 
4.2.8 The role of thalidomide in foci formation 
 
PDE4 isoforms, of the PDE4A and PDE4B subfamilies are known to be 
involved in regulating the functioning of immune cells. PDE4 inhibition blocked 
antigen-stimulated T-cell proliferation and bacterial lipopolysaccharide (LPS)-
stimulated tumour necrosis factor alpha (TNFalpha) release from peripheral 
blood monocytes (Manning et al; 1999). The ability of thalidomide to inhibit 
TNF production and acts as an immunomodulator in conditions including 
Erythema nudosum leprosum is well established (Melchert and list; 2007, 
Okafor et al. 2003). Considering the possible link between thalidomide and 
PDE4 signalling, the role of thalidomide in affecting foci formation of 
PDE4A4GFP was examined. It was found that thalidomide was able to inhibit 
foci formation at a concentration of 400µM±3.6uM.  
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4.2.9 PDE4 oligomerisation and foci formation 
 
It has been suggested that PDE4 isoforms may oligomerise by interactions 
involving their UCR1 and UCR2 domains (Richter et al; 2002). In order to 
determine if PDE4A4 is able to oligomerise, CHO cells stably expressing 
PDE4A4-GFP were transfected with a V5-tagged PDE4A4. Post-transfection, 
cells were treated with and without rolipram for 16hours to allow foci formation. 
GFP- and V5- immunoprecipitates were blotted for both with both GFP and V5 
antisera (Figure 4.9). Similar experiments were carried out with VSV- and 
Flag-tagged forms of PDE4D3 in transfected CHO cells treated with or without 
rolipram. PDE4A4 oligomerisation was not detected (Figure 4.9b) under these 
conditions used. However, PDE4D3 oligomerisation was detected (Figure 
4.9a).  
 
4.2.10 Role of protein turnover on foci formation 
 
As reported previously, protein synthesis is required for foci formation (Terry 
et al: 2003). Assays were therefore carried out in an effort to better 
understand the roles of protein synthesis and degradation on foci formation. 
CHO cells expressing PDE4A4-GFP treated with rolipram were also treated 
with either cycloheximide (CHX) or puromycin to inhibit protein synthesis or 
with MG132 to inhibit proteasomal degradation of proteins. Cells were also 
treated with MG132 and CHX at the same time in order to inhibit protein 
turnover. In all instances, foci formation was blocked (Figure 4.10).  
 
4.2.11 Role of protein turnover on stability of preformed foci 
 
To evaluate the role of protein turnover on the stability and dispersal of 
preformed foci, cells expressing PDE4A4-GFP were pre-treated with rolipram 
for 16hours, followed by treatment with CHX, MG132, or both in the presence 
of rolipram over time. Cells treated with rolipram alone were used as a 
positive control and untreated cells as a negative control. Inhibition of protein 
synthesis by CHX started to disperse rolipram-induced foci within 30 minutes 
of its addition to the cells and completely dispersed foci after 5 hours. 
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Inhibition of proteasomal protein degradation with MG132 yielded similar 
effects on foci dispersal. The rate of foci dispersal did not change when both 
protein synthesis and degradation were inhibited simultaneously (figure 4.11). 
The half life (t1/2) of foci dispersal after inhibition of protein turn over was 
approximately 75 minutes. 
 
4.2.12 The role of MAP kinases in dispersal of preformed foci of PDE4A4 
 
Having evaluated any potential role of various MAP kinases in formation of 
foci, the effects of MAP kinases on dispersal and stabilisation of foci were 
examined. Cells pre-treated with rolipram were challenged with anisomycin or 
anisomycin/MG132/cyloheximide in the continued presence of rolipram 
(Figure 4.12). Similar treatments were carried out with UO126, which is a 
MEK inhibitor. Cells treated with anisomycin with and without 
cycloheximide+MG132 dispersed foci completely within 30minutes after the 
addition of the drug. In a similar experiment, cells treated with UO126, 
incubation with UO126 alone initially led to an increase in foci formation within 
30 minutes of drug exposure by 60% ± 0.06%. After 150 mins, foci levels had 
returned to levels prior to UO126 addition and within 300 min foci were 
completely dispersed. In cells treated with UO126 in the presence of both 
cycloheximide and MG132, foci dispersal was observed as early as 30 mins 
after UO126 addition and all foci had dispersed by 300 mins (Figure 4.12). 
The t1/2 of foci dispersal in the presence of UO126 and rolipram was 240 mins 
while in cells pre-treated with CHX and MG132 this was dramatically reduced 
to 90 minutes.  
 
4.2.13 The role of calcium and PKC signalling on stability and dispersal of foci 
 
In order to evaluate the effects of calcium and PKC signalling in stabilising 
pre-formed foci and foci dispersal, cells pre-exposed to rolipram for 16 hr 
were treated with thapsigargin which elevates intracellular calcium levels by 
triggering Ca2+ release from intracellular stores from endoplasmic reticulum 
(Won and Orth, 1995). Thapsigargin was added to the cells in the presence or 
absence of MG132 and CHX. Similar treatments were carried out with rottlerin 
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and RO320432, which is a PKC inhibitor. Thapsigargin initially dispersed the 
foci at a slightly slower rate than rottlerin and RO320432 treatments, both of 
which dispersed all foci within 30 mins. However, all the three compounds 
dispersed foci within 30 mins in cells treated with MG132 and CHX. The t1/2 for 
foci dispersal by thapsigargin in the presence of rolipram was approximately 
45 mins. An accurate measure of the t1/2 of foci dispersal in the presence of 
thapsigargin, rolipram, CHX and MG132 could not be made using the time 
points analysed. A shorter time course with measurements taken at earlier 
time points would be required to evaluate this. 
 
4.2.14 The role of tyrosine kinases in foci dispersal 
 
To evaluate the role of tyrosine kinase action in dispersal of pre-formed foci, 
genistein was added to cells in the presence or absence of MG132 and CHX. 
Genistein treatment alone, as well as in the presence of MG132 and CHX, 
quickly dispersed pre-formed foci within 30 mins (Figure 4.14). The t1/2 of foci 
dispersal upon tyrosine kinase inhibition could not be determined from the 
existing data and would require measurements over a shorter time course.  
 
4.2.15 The role of PI3 kinases in maintenance of foci 
 
The PI3 kinase inhibitor, LY294002 dispersed pre-formed foci in cells within 
30 mins of inhibitor treatment, both in the presence and absence of MG132 
and CHX (Figure 4.15).  
 
4.2.16 Co-localisation studies 
 
To identify components and localisation of foci, co-localisation studies were 
carried using confocal microscopy to examine the localisation of foci with 
intracellular compartments and various known PDE4 interacting proteins. 
Table 4.1 lists some of the proteins and treatments that were performed. 
Proteins that showed minimum interaction or co-localisation with foci were 
represented by (+) and those with the strongest interaction/co-localisation with 
foci by (+++). Foci were not found to localise to any of the cellular organelles 
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examined including mitochondria, Golgi apparatus or lysosomes. CHO cells 
treated with rolipram for 16hrs showed an up regulation of PYK2. Endosomal 
proteins like Rab9 and Rab11, Ubiquitin ligases like mdm2 and cbl, various 
PKCs and cytoskeletal proteins like actin, tubulin and vimentin were also 
stained in CHO cells stably expressing PDE4A4-GFP and treated with 
rolipram for induction of foci.  (See appendix II for images).  
 
4.3 Discussion 
 
The conformational changes and folding of a protein almost always dictate the 
ability of a protein to function properly. Mis-folding of a protein might lead to 
aggregate formation that may eventually lead to refolding to its native 
functional conformation state or to its degradation (Chu et al, 2007 and 
Murphy et al, 2007). Proteins aggregates also occur in disease states such as 
Huntington’s disease, which is characterised by poly-glutamine aggregates 
(Nagaoka et al; 2004). 
 
Previous work has shown that wild-type PDE4A4 as well as PDE4A4 
chimeras with various epitope tags undergo reversible redistribution into 
accretion foci upon chronic rolipram treatment (Terry et al; 2003). This 
redistribution is isoform-specific as only PDE4A4 and rat PDE4A5, which 
share the same N-terminal sequence, form foci and not any other isoforms 
from other PDE4 sub-family. In order to establish the signalling components in 
promoting and maintaining rolipram-induced foci, CHO cells stably expressing 
a PDE4A4-GFP chimera were subjected to treatments with various inhibitors 
and activators of signalling pathways.  
 
PDE4 isoforms play a pivotal role in controlling cAMP levels within cells. It is 
widely appreciated that PKA phosphorylation activates these isoforms thus 
making them key regulators of the cAMP signalling cascade. To determine to 
the role of cAMP in rolipram-induced foci formation, cells were challenged 
with various effectors of this pathway. Challenge with 8-CPT-2’-Me-cAMP 
which activates EPAC, did not affect foci formation or dispersal. To elevate 
cAMP levels, cells were treated with forskolin, to activate adenylate cyclase 
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independently of Gs-proteins, (Seamon and Daly, 1981) and also in concert 
with IBMX to inhibit PDE activity simultaneously, thus maximising cAMP 
production (Turner et al, 1993 and Leemhuis et al; 2002). Under these 
conditions, foci formation was inhibited. Inhibition of PKA activity by H89 
treatment did not affect foci formation suggesting the effects of cAMP on foci 
formation were not mediated through PKA, or at least through a PKA isoform 
which was H89-sensitive.  Increasing cAMP levels via activation of Gs 
signalling of the β2-adrenoceptor with isoproterenol challenge did not affect 
rolipram-induced foci formation thus indicating that foci formation is not driven 
via a Gs-adenylyl cyclase pathway. Taken together, these data show that 
inhibition of foci formation occurs only with agents, which maximise 
intracellular cAMP levels. It is still unclear which cAMP signalling pathways 
inhibiting foci formation. It is possible that cAMP actions are being mediated 
through a PKA isoform which is H89-insensitive or through other effectors 
including ion channels. 
 
Isoforms of the PDE4A subfamily are not phosphorylated by ERK due to the 
substitution of an arginine for a proline in the proline directed serine 
consensus (Baillie et al; 2000, Baillie et al; 2001, Hoffmann et al 1999 
Mackenzie et al; 2000). However, in order to determine any indirect effects of 
ERK, as well as effects of other members of MAP kinases, on foci formation, 
various inhibitors were tested. Inhibition of MEK using UO126 and PD98059 
did not affect foci formation. Activation of p38 MAP kinase by anisomycin 
(Hazzalin et al; 2002) ablated foci formation. To test the specificity of 
anisomycin treatment on foci formation, SB203580, a p38 MAP kinase 
inhibitor, (Davies et al; 2000) was used. However, SB203580 did not reverse 
the effects of anisomycin. As anisomycin is also known to activate JNK (c-Jun 
N-terminal kinase) along with p38 MAP kinase (Sampieri et al; 2007), a JNK 
inhibitor (Anthra [1,9-cd] pyrazol-6 (2H)-one1, 9-pyrazoloanthrone) was also 
used to study if the effects of anisomycin were being mediated through a JNK 
pathway. However, JNK inhibition failed to reverse the effects of anisomycin 
treatment (Figure 4.3). The role of downstream targets of p38 MAPK was 
therefore studied to determine their influence on PDE4A4-GFP foci formation. 
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Rottlerin was used to inhibit both MAPKAPK2 and PKCδ  (Blanquet et al, 
2003). Rottlerin treatment abolished PDE4A4-GFP foci formation. Signalling 
crosstalk between the PKC and MAPK pathways is well documented 
(Blanquet et al, 2003). Considering the potential role for MAPK action in 
PDE4A4-GFP foci formation and its ablation by rottlerin, the possible 
involvement of PKCδ in this process was investigated using PMA (Powell et al; 
2003). PMA did not trigger PDE4A4-GFP foci formation alone, nor did PMA 
affect rolipram-induction of foci. However, most strikingly, PMA reversed the 
inhibitory effect of rottlerin on foci formation, restoring the percentage 
immobile GFP to ~80% (figure 4.4). This indicated the possible involvement of 
PKC signalling, possibly PKCδ, in foci formation. PKC inhibitor RO320432 
which inhibits isoforms PKCα, β1,ε (Birchall et al; 1994) and GO6983 which 
inhibits PKCα,β,γ, δ isoforms (Wang et al; 2004) elicited a 70-90% 
enhancement in the fluorescence immobilised in PDE4A4-GFP accretion foci 
when compared to treatment with rolipram alone (Figure 4.4a). These data 
suggest that signalling of these PKC isoforms has a restraining influence on 
foci formation.  
 
PKC isoforms can be divided into three classes; conventional, novel and 
atypical. Conventional isoforms includeα, β1, β2 andγ; ε, η, θ, µ are novel 
forms and ζ, λ are atypical forms (Mackay and Twelves, 2007). Conventional 
and novel forms are regulated by diacylglycerol and phosphatidylserine while 
atypical isoforms are regulated by phosphatidylserine only. Activation of 
conventional PKC forms is calcium dependent whereas signalling of PKC 
isoforms of the other two groups is calcium independent (Mackay and 
Twelves, 2007). To investigate the involvement of the calcium-dependent 
PKC isoforms in foci formation, intracellular calcium modulators including 
thapsigargin and ionomycin were used. Thapsigargin elevates intracellular 
calcium levels by inhibiting calcium/ATPase-mediated reuptake of calcium into 
endoplasmic reticulum (Won and Orth, 1995) whereas ionomycin mobilises 
calcium across the cell membrane (Aagaard-tillery and Jelinek, 1995).  
Raising intracellular calcium with these agents blocked rolipram-induced of 
PDE4A4-GFP foci formation (Figure 4.4b) suggesting that Ca2+ ions exert an 
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inhibitory influence on foci formation. These data are also further suggestive 
of a role of a Ca2+-dependent PKC isoform in foci formation. To identify the 
downstream targets responsible for the effect of calcium on foci formation, 
various inhibitors of calcium signalling were tested. Inhibiting CaMKII with 
KN62 (Minami et al; 1994) had no effect, nor did inhibition of calcineurin with 
cyclosporin A (Figure 4.4b), while inhibition of Calmodulin with W-7 (Caulfield 
et al; 1991) and ophiobolin-A led to cell loss/death.  It is possible that 
Ca2+/PKC activates other, as yet unkown, downstream targets or that 
Ca2+/PKC inhibits foci formation directly. 
 
Earlier studies showed that challenging 3T3-F442 fibroblasts with growth 
hormone activates PDE4A5, the mouse orthologue of human PDE4A4, 
through a PI3 kinase and p70S6 kinase pathway (Mackenzie et al 1998). As 
inositol phosphates and PI3 kinase signalling are critical in regulating 
intracellular calcium levels (Balla et al, 2006), various PI3-K inhibitors were 
assessed in their abilities to mediate PDE4A4-GFP foci formation. Blockade 
of PI3-K with wortmannin increased the percentage immobile GFP in 
accretion foci to 175% ± 8.32 %, indicating an inhibitory input for PI3-K 
(Figure 4). However, wortmannin has also been shown to function as an 
inhibitor of MAPK. To address this, the same experiment was performed with 
the PI3-K-specific inhibitor LY294002 (Baumann and West, 1998), which also 
increased the percentage immobile GFP further to a similar extent. However 
inhibiting PI3-K downstream targets, p70S6K, with rapamycin (Powell et al; 
2003) and GSK3β with GSK3β Inhibitor, (Calbiochem, UK) had no effect on 
rolipram-induced foci formation (Figure 4.5). It is therefore likely the effects of 
PI3-K signalling on foci formation are mediated through other downstream 
effectors. 
 
It is known that PDE4A5/PDE4A4 interact with the SH3 domains of Src, lyn 
and fyn kinases (Beard et al, 1999 and Beard et al, 2002). Hence the role of 
tyrosine kinases in foci formation was determined using general tyrosine 
kinase inhibitor, genistein (Constantinou and Huberman; 1995). Interestingly, 
genistein ablated rolipram-induced foci formation implicating tyrosines kinase 
activity in foci formation. However, the Src family inhibitors PD168393 and 
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Su6656 (Fry et al; 1998, Bowman et al; 2001) had no effect on rolipram-
induced foci formation. Inhibitors for JAK2 (AG490) and IR (HNMPA-(AM) 3) 
led to cell loss/death. Inhibition of the tyrosine kinase receptors VEGF-R 
(oxindole) and EGF-R (PD168393) had no effect on foci formation. However, 
the PDGF-R inhibitor AG17 blocked foci formation (Figure 4.6), indicating that 
this receptor kinase may promote rolipram induction of PDE4A4-GFP foci.  
 
Cyclin-dependent kinase 5 is activated by p35/p39 and is known to regulate 
the MEK-ERK pathway and calcium signalling of CAMKII and the Ca2+-
sensitive adenylate cyclase isoform IX (Pareek and Kulkarni, 2006). The role 
of cdk5 signalling in foci formation was examined using its inhibitor roscovitine. 
Cells treated with 1µM roscovitine (Cdk5 IC50 -0.2uM) elicited no effect on foci 
formation. However, at a concentration of 10µM, foci formation was inhibited 
by 40% (Figure 4.7). At this higher concentration, roscovitine can also inhibit 
Cdk1, Cdk2 and ERK1/2 (Dangi and Shapiro, 2005). It is probable, therefore, 
that the inhibitory effect of roscovitine on foci formation is mediated via a 
target other than Cdk5 which can be explained on the basis that cdk5 is a 
brain-specific kinase so it wouldn’t be expressed in CHO cells (Wei and 
Tomizawa, 2007); hence the only effects of roscovitine at higher 
concentrations were seen when it can inhibit other cdks and erk. The 
presence of cdk5 in CHO cells can also be confirmed by immunoblotting the 
CHO cell lysates for the kinase.  
 
PDE4A4 activity has been shown to be of importance in initiation of the 
immune response by T-cells (Manning et al; 1999). Thalidomide® has been 
reported to have immunomodulatory properties as it is known to have a 
variety of effects including decreasing the production of monocyte derived 
TNF-alpha, and regulates the T-helper cell response by regulating the 
production of IL-4, 5 and IFN-γ in vitro (Melchert and List, 2007, Okafor, M.C, 
2003). In order to investigate a potential link between foci formation and 
PDE4A4’s immunoregulatory properties, cells were challenged with 
thalidomide to examine its effects on foci formation (Figure 4.8). At a 
concentration of 400µM, thalidomide completely inhibited foci formation of 
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PDE4A4-GFP (IC50: 150µM). Thalidomide action is proposed to be mediated 
a through Wnt signalling pathway. Gsk3 is known to be a component of 
Bmp/DKK1/Wnt signalling and inhibition of any of the three components 
reverses the effects of Thalidomide treatment (Knobloch et al; 2007). It should 
be noted that although Thalidomide inhibited foci formation, inhibition of GSK3 
had no effect. However, the role of GSK3 inhibition in reversing the 
Thalidomide-induced effects on foci formation is yet to be determined. It is 
possible that the effect of Thalidomide treatment on PDE4A4 foci formation is 
mediated through other components of the Wnt signalling pathway. 
 
In some instances protein aggregates are due to oligomerisation of misfolded 
proteins. For instance chicken Hsp25 is known to form inclusion bodies when 
over expressed in HeLa cells (Katoh et al; 2004). It has been suggested that 
PDE4 isoforms oligomerise by a process that involves their UCR1 and UCR2 
domains (Richter al, 2004, Richter and Conti, 2002). In order to evaluate 
whether PDE4A can form dimers in these cells, CHO cells stably expressing 
PDE4A4-GFP were transfected with a V5 epitope-tagged form of PDE4A4. In 
parallel, oligomerisation experiments were carried out with differentially 
epitope-tagged forms of PDE4D3 (FLAG and VSV tags). PDE4A4 did not 
show oligomerisation/dimerisation prior to, and after rolipram treatment in co-
immunoprecipitation experiments. However, PDE4D3 oligomerisation was 
evident in co-immunoprecipitation assays (Figure 4.9). The lack of observed 
oligomerisation of PDE4A4 is curious.  However, there are a number of 
possible explanations to support these findings. Although PDE4A4 is able to 
form foci, the isoform may require other extraneous stabilising factors, which 
are lost upon cell disruption, i.e. a dynamic process stabilises foci and upon 
cell lysis, foci disaggregate. It is also possible that the tagged PDE4A4 is 
excluded from binding the GFP-tagged species. Immunocytochemical 
analyses and FRET/BRET would of interest to examine whether the 
differentially tagged forms of PDE4A4 co-localise, and potentially dimerise in 
foci in live cells. 
 
Terry and coworkers have shown that protein synthesis is required for foci 
formation (Terry et al; 2003). To further characterise the role of protein 
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turnover in PDE4A4 foci formation, cycloheximide (CHX) and MG132 were 
used to inhibit protein synthesis and proteasomal degradation of proteins 
respectively (Christner et al; 1999, Steinhilb et al; 2001). Both CHX and 
MG132 ablated foci formation (Figure 4.10). Furthermore, when both protein 
synthesis and degradation were inhibited simultaneously, foci formation was 
totally blocked suggesting that protein turnover is crucial for foci formation. 
Similar results were obtained when puromycin was used to inhibit protein 
synthesis (Chow et al; 1995). To further investigate the role of protein turnover 
in continued presence of foci, a time course was carried out of cycloheximide 
and MG132 treatments. Cells pre-treated with rolipram were incubated with 
cycloheximide, MG132 or both over a time course of 5 hours in the continued 
presence of rolipram. In all the cases, foci started to disperse within first 30 
mins of treatment with the t1/2 for dispersal approximately 75 mins. After 5 
hours the total immobile GFP levels was virtually zero (Figure 4.11). This data 
indicated that protein turnover is crucial both for formation and maintenance of 
foci.  
  
As protein turnover had shown to be of significance in foci formation and 
stability, compounds activating/inhibiting various signalling pathways were 
tested in conjunction with CHX and MG132 treatments. The principle behind 
this investigation was to identify and distinguish between signalling pathways 
regulating foci formation from those influencing the stability of the pre-formed 
foci during inhibition of protein turnover. Any compounds that enhance foci 
dispersal presumably do so by a mechanism independent of the effects of 
protein turnover on foci stability.  Activation of p38 MAPK with anisomycin in 
the continued presence of rolipram, after a 16 hr pre-treatment with rolipram, 
dispersed the foci within 30 mins. Addition of CHX and MG132 did not alter 
the effects of anisomycin on foci dispersal. However, inhibition of MEK with 
UO126 delayed the dispersal of pre-formed foci for 4 hrs although all foci 
eventually dispersed by the 5 hr timepoint. However, UO126 enhanced the 
dispersal of foci induced by MG132 and CHX. The t1/2 for foci dispersal by 
MEK inhibitor UO126 in the presence of CHX and MG132 was ~120 mins 
while in cells treated with UO126 and rolipram only, the t1/2 was ~240 mins 
suggesting that UO126-induced dispersal of foci occurs via a mechanism 
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which is enhanced by protein turnover (Figure 4.12). Similarly, raising 
intracellular calcium levels using thapsigargin induced foci dispersal with a t1/2 
of ~45 mins, which was shortened to ~ 30 in the presences of MG132 and 
CHX. Rottlerin and RO320432 treatments also dispersed foci within 30 mins 
of agonist exposure. The presence of MG132 and CHX enhanced the 
dispersal in both cases (Figure 4.13). Similar effects were noted with inhibitors 
of tyrosine kinases and PI3 kinases using genistein and Ly294002 
respectively where both inhibitors dispersed preformed foci within 30 minutes 
and the presence of CHX and MG132 did not affect the rate of foci dispersal. 
As foci dispersal with these compounds was rapid, a shorter time course of 
treatments would be required to accurately determine the rates of foci 
dispersal with these agents. However, these data do suggest that the stability 
of foci is dependent upon phosphorylation events mediated by tyrosine kinase 
and/or PI3-K signalling.  
 
A potential role for PDE4A4 ubiquitination in the turnover of PDE4A4 was 
assessed using confocal microscopy and pulse-chase experiments. However, 
in accord to work from our lab (unpublished data) neither ubiquitination nor 
turnover of PDE4A4 was detected in pulse chase experiments. This was 
confirmed by immunocytochemical analysis (Appendix II for images).  
 
In order to identify components of foci, co-localisation studies were carried out 
by confocal microscopy. The proteins studied and the treatments used in the 
process are listed in Table 4.1 (Please refer to Appendix II for images).  
 
Proteins such as ubiquitin did not co-localise with foci. Similarly, no 
localisation of foci was observed with sub-cellular organelles including 
lysosomes and mitochondria. The role of SUMOylation in foci formation was 
also assessed. CHO cells stably expressing PDE4A-GFP were immuno-
stained for SUMO modification. However, SUMOylation did not affect foci 
formation and SUMO did not co-localise with foci.  
 
The inhibitor/activator studies implicated multiple signalling pathways in foci 
formation/dispersal with the potential for cross-talk between pathways, a 
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model of which is depicted in the figure 4.16. Foci formation appears to be 
independent of a cAMP/EPAC, and possibly a cAMP/PKA, pathway as shown 
from figure 4.2. However, elevated cAMP levels were able it inhibit foci 
formation and induce dispersal of pre-formed foci (Figure 4.2 and Terry et al. 
2003). Inhibition of PI3 kinase signalling increased foci formation (fig 4.5). 
However, whether the effects of PI3 kinase action are direct or mediated by its 
downstream targets or via cross talk with other signalling pathways is yet 
unknown. The PI3 kinase pathway can activate PKC isoforms including PKC 
θ (Theta), ζ (Zeta), δ (Delta) and ε (Epsilon) upon insulin signalling (Sampson 
and cooper, 2006, Campbell et al; 2004, Hirai and Chida; 2003). Inhibition of 
PKC-ε (Epsilon) by RO320432 enhanced foci formation. RO320432, however, 
is not a PKC-ε specific inhibitor and can inhibit other PKC isoforms such as β1 
and α. Hence the effects of other PKC isoforms cannot be ruled out. Similarly, 
PKC θ is also activated by PI3 kinases and its effects on foci are still unknown 
as there are no specific inhibitor compounds available to assess its effects. 
Inhibition of PKC-δ by rottlerin ablated foci formation suggesting a role of 
PKC-δ in foci formation. However, the pathway through which PKC-δ inhibitor 
rottlerin inhibits foci, as well as the mechanisms of PKC-δ regulation, has yet 
to be determined. PKCs might act directly or influence other pathways to 
regulate foci formation. It is possible that PKC signalling cross-talks with the 
MAP kinase pathway. MAP kinase pathway is a canonical pathway that is 
activated by various growth factors and controls cell growth and division 
(Pimienta and Pascual; 2006). Cross-talk between MAP kinase signalling and 
pathways including PKC signalling (Rozengurt; 2007, Baillie et al 2001), PI3 
kinase signalling (Kim et al; 2007, Xu and Yu, 2007) and cAMP signalling is 
well documented (Baillie et al; 2001, Pyne et al; 1997, Pyne et al; 1994). It 
would be of interest to assess the MAP kinase activity in response to inhibition 
or activation of PI3 kinase signalling in the PDE4A4-GFP cell line to determine 
if there is cross-talk between these pathways. Unpublished work from our 
group indicates PDE4A4 can be phosphorylated within its N-terminus by 
MAKAP kinase-2 after stimulation of the PDE4A4-GFP cells with anysomycin, 
a p38 MAP kinase activator. It was therefore of relevance to examine the 
effects of anisomycin on foci formation. Inhibition and activation of MAP 
kinase signalling had conflicting effects on foci formation. Activation of p38 
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MAPK led to scattering of foci whereas MEK inhibition enhanced foci 
formation (Figure 4.3). It has yet to be assessed whether these differential 
effects of MAP-K signalling are directly influencing foci formation or if their 
actions are being mediated through other downstream signalling complexes. It 
would be of interest to establish whether mutation of PDE4A4’s MAPKAP 
kinase-2 phosphorylation site altered the effects of anisomycin/MEK inhibition 
on foci formation.  
           PI3 kinase has also been reported to influence cAMP levels in the cells 
through its downstream effector Akt (Hans et al; 2006). Hans and co-workers 
(Hans et al; 2006) have shown that Akt phosphorylates PDE3A which leads to 
activation of the isoform. PDE3A is a cAMP-specific PDE (Beavo; 1995). 
Since cAMP has an inhibitory effect on foci, it could be suggested that PI3 
kinase-Akt-PDE3A pathway might affect foci formation by modulating cAMP 
levels.   
Thalidomide® is an anti-inflammatory agent and is known to have teratogenic 
properties (Okafor; 2003) Thalidomide inhibited foci formation. However, the 
mechanism for this action is unknown and requires further investigation. 
Thalidomide® is known to affect various pathways including Wnt signalling 
(Knobloch, 2007), PI3 kinase/Akt pathway (Gockel et al; 2004) and signalling 
of some PKC isoforms including PKC-θ (Payvandi et al; 2005). It is probable 
that the effects of thalidomide on foci formation are transduced via one or 
more of these pathways.  
The involvement of multitude of signalling pathways renders understanding 
foci formation rather complex as it hinders identifying the signalling pathway 
involved in the process. Furthermore, the lability of foci in cell lysates 
complicates the identification of components by proteomic analyses, where 
preliminary studies were not of sufficient quality to be useful. In conclusion, 
foci formation of PDE4A4 is a very unique phenomenon not noticed with any 
other PDE4 isoforms. The ability of PDE4A4 to form foci reversibly only in the 
presence of rolipram and its analogues is a very novel finding. Also, the ability 
of only those PDE4 inhibitors that cause emesis to form foci and not the non-
emetic ones suggest that PDE4A4 foci formation might be a key to 
understanding the mechanism of the side-effects caused by PDE4 inhibitor 
usage as therapeutics. Although Terry and coworkers (Terry et al 2003) have 
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identified PDE4 domains that could potentially lead to foci formation, 
extensive truncation mutational analyses is needed to identify the signalling 
complexes and components involved in the process.  
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Figure 4.2 The effect of cAMP signalling components on rolipram induced foci 
formation of PDE4A4 
 
CHO cells stably expressing PDE4A4-GFP were plated 1×105 per well in a cell culture 
treated 96-well plate for a quantitative plate reader assay. The following day, cells were 
then treated with inhibitors as indicated above for 16hrs. Post-treatment, total GFP was 
measured from live cells in Packard Bell Fusion® plate reader. Cells were then subjcted to 
extraction of mobile GFP using an extraction buffer for 10 minutes at room temperature. 
Cells were then fixed in 4% formaldehyde buffer and Hoescht33258 for further 10 minutes 
followed by three washes in PBS. Once the extraction, fixation and Hoescht staining were 
finished, immobile GFP was measured in the plate reader and corrected for cell number 
using Hoescht signal. All the data was background corrected. Untreated cells were used 
as negative control and rolipram alone treated cells as positive control. All the results are 
represented as a percentage of rolipram induced foci. All the data shown are 
representative of results obtained from three separate experiments. Paired t-test statistical 
analysis of the quantified immobile GFP data were undertaken, where p<0.05 indicates a 
statistically significant difference level of inhibition.  
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The effect of Ro320432 on stability of preformed foci of PDE4A4
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 The effect of Ly294002 on stability of preformed foci of PDE4A4
0
20
40
60
80
100
120
30
mi
n
60
mi
n
90
mi
n
12
0m
in
15
0m
in
18
0m
in
21
0m
in
24
0m
in
27
0m
in
30
0m
in
%
 r
ol
ip
ra
m
 i
nd
uc
e
d
 f
oc
i
Rolipram (continued)
No treatment
Ly294002 +Rolipram
Ly294002+Rolipram+MG132+CHX
 170 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 171 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody/probe/Treatment                                           Target                Interaction with foci 
MG132   proteasome inhibitor Inhibits foci formation 
Brefeldin A   protein transport inhibitor  No effect 
Leptomycin B   nuclear export inhibitor No effect 
Ubiquitin ubiquitinated proteins + 
P27kip1 ubiquitinated Cdk inhibitor + 
TGM-76 golgi  + 
GM130 golgi  + 
Rab9 endosome + 
Rab11 endosome + 
Lysotracker lysosomes + 
!-adaptin Golgi protein targeting + 
Actin    actin filaments + 
Tubulin  microtubules + 
Vimentin   intermediate filaments + 
MitoTracker  mitochondria + 
PKC"   PKC"  + 
PKC#    PKC#  + 
PKC$    PKC$  + 
PKC%    PKC%  + 
PKC!    PKC!  + 
PIP3    PIP3 + 
Phospho-tyrosine tyrosine phosphorylated proteins  + 
Pyk2 Pyk2  none detected 
Phospho-Pyk2 phosphorylated Pyk2    upregulated in rolipram treated cells 
Cdk5    Cdk5 None detected 
DISC1    DISC1 None detected 
Mdm2 E3 ubiquitin ligase + 
cbl E3 ubiquitin ligase + 
Calpastatin  Endogenous Protease inhibitor + 
+      Represents minimum or no interaction. 
++    Represents moderate interaction 
+++ Represents high strong interaction 
Figure 4.16 A schematic model of depict the effects of various s ignalling pathways on 
PDE4A4GFP - Foci formation. 
Activation 
inhibition
Foci 
PI3 kinase
PKC _
Tyrosine kinases
PKC _
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Chapter 5   RhoGAPs, Arrestins and PDE4 isoforms 
 
5.1 Introduction 
 
5.1.1 Rho Signalling  
 
Guanine nucleotide-binding proteins (GNBP) regulate a plethora of vital 
cellular processes including cytoskeletal reorganisation, cell adhesion and cell 
cycle progression (Lundquist; 2006, Bishop and Hall; 2000, Jaffe and Hall, 
2005, Luo, 2000). Small GTPases of the Ras superfamily are the most 
studied GNBPs with the monomeric 20-30 KDa Rho GTPases being the best 
characterised among the GTPases of the Ras super family (Bishop and Hall; 
2000).  
 
It is now well appreciated that Rho GTPases are involved in actin-dynamics 
(Aspenstrom, 2004 and Luo, 2000). However, Rho-GTPases have also been 
shown to interact with a wide range of effector proteins, modulating their 
activity and thus participating in various signalling pathways (Jaffe and Hall; 
2005).  Rho GTPases interact with their effectors through a so-called “switch 
region” that is also necessary for their GTPase activity. Point mutations within 
this region have been shown to ablate the interaction of Rho GTPases, such 
as cdc42, Rho and Rac, with most of their effectors (Joneson et al; 1996 and 
Lamarche et al; 1996).  
 
The functioning of GNBPs is activated by the binding of GTP and is 
terminated by the hydrolysis of GTP to GDP by its intrinsic GTPase activity. 
The GTP-GDP cycle is regulated by three different classes of proteins. In 
resting cellular conditions GNBPs exist in a complex with guanine dissociation 
inhibitors (GDIs), which stabilise GDP-bound Rho proteins. GEFs are guanine 
exchange factors that facilitate the exchange of GDP to GTP in the catalytic 
region of Rho proteins. The third class of proteins, GAPs, are GTPase 
activating proteins, which interact with and enhance the otherwise slow 
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intrinsic GTPase activity of species such as Rho proteins (Scheffzek and 
Ahmadian; 2005).  
 
5.1.2 RhoGAPs  
 
RhoGAPs act as negative regulators of GNBPs by enhancing the GTPase 
activity of Rho, consequently shifting Rho into an inactive state (Willars; 2006). 
Almost all members of Rho family have been shown to have specific GAPs. 
Rho-GAPs of different subfamilies possess subfamily-specific structural 
domains that play an important role in regulation and targeting of GAPs 
(Bernards and Settleman; 2005).  
 
GAPs play an important role in brain development. The NR2B subunit of the 
NMDA (N-methyl-D-aspartate) receptor has been shown to interact with 
p250GAP, a GAP for Rho-cdc42. This promotes the dephosphorylation of 
NR2B as well as altering its sub-cellular localisation thereby regulating 
synaptic plasticity by reorganising actin in dendritic spines from hippocampal 
slices stimulated with NMDA (Nakazawa et al; 2003). Similarly, p250GAP is 
phosphorylated by src kinase, Fyn, and leads to differentiation of 
oligodendrocytes (Taniguchi et al; 2003). A detailed description of RhoGAPs 
is discussed in section 1.11.1.3.  
 
5.1.3 Role of cAMP signalling components in Rho transduction pathways 
 
A role for cAMP and its signalling components in Rho signalling pathways has 
been suggested by various studies (Appert-collin et al; 2007, Flemming et al; 
2004, Diviani et al; 2004, Diviani et al; 2006, Howe et al; 2004). In particular, 
elevation of PKA has been shown to both activate and inactivate Rho 
signalling pathways (Howe A, 2004). 
 
In REF52 cells, elevation of cAMP levels by rolipram inhibition of PDE4 
activity was found to downregulate integrin-dependent actin adhesion 
microspikes. It was shown that these effects were mediated by PKA 
regulation of the Rho A-ROCK-Myosin pathway (Fleming et al; 2004).  
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α1 adrenergic receptors have been shown to be involved in cardiac 
hypertrophy (O’Connell et al; 2003) which was showed by double knockout of 
α1A/C and α1B adrenoceptors in male mice where the heart size was smaller 
than wild type and the heart function was affected by the knock out of the 
receptors (O’Connell et al; 2003). In further support to this, AKAP-Lbc has 
been shown to possess GEF activity aside from its PKA anchoring function. In 
cardiomyocytes, activation of its GEF activity has been reported to mediate 
through its interaction with heterotrimeric G protein 12 (G12) downstream to α1 
adrenergic receptors, which subsequently promote Rho-A activation, by 
AKAP-LBc. PKA-mediated phosphorylation and recruitment of 14-3-3 protein 
leads to inactivation of the AKAP-GEF.  The GEF activity of AKAP-Lbc has 
been shown to play a significant role in cardiac hypertrophy, which was 
evident by hypertrophic responses of heart cells subjected to lentiviral 
suppression of AKAP-Lbc (Appert-collin et al; 2007, Diviani et al; 2006, Diviani 
et al; 2004). Furthermore, anchored PKA has been shown to have a key role 
in the formation of pseudopodia and chemotactic cell migration by activating 
Rac GTPase through phosphorylation of vasodilator stimulated 
phosphoprotein (VASP) and protein tyrosine phosphatase localised to 
pseudopodia (Howe et al; 2005).  
 
The studies mentioned above indicate the potential of cAMP signalling, PKA 
action and PDE activity in cytoskeletal rearrangement and cell migration. The 
aim of this study is to try and elucidate the role of the cAMP signalling in Rho 
transduction pathways through PDE4 interactions with ARHGAP21/10.  
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Figure 5.1 Schematic representation of Rho signalling cascade. 
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 5.2 Results  
 
5.2.1 Expression and purification of ARHGAP21/10 
 
ARHGAP21, also known as ARHGAP 10 is a novel Rho/Rac/cdc42-like 
GTPase activating protein expressed in chondrosarcoma, breast cancer, 
kidney and brain tumours (Katoh and Katoh; 2004).  
 
A yeast two hybrid analysis by our group, in collaboration with Hybrigenics, 
France, to look for novel binding partners for βarrestin identified ARHGAP21 
as a potential interactor (Please refer to appendix II for list of constructs used 
in yeast two hybrid analyses). Assays were performed to validate these 
findings. However, ARHGAP 21 is a huge 1957 amino acid protein and no as 
yet, a cDNA construct encoding the full-length protein is still to be generated. 
However, specific ARHGAP21 antisera, allowed for pull-down studies of the 
endogenous protein to be performed. Furthermore seven truncates covering 
amino acids 885-1346 (Figure 5.2), which were gifted from Philippe Chavrier’s 
group at the Curie institute, Paris as previously (Dubois et al, 2005) were used 
to assess ARHGAP21: PDE4 interactions. 
 
In order to examine the potential interaction of ARHGAP21 with β-arrestin, 
various GST truncates of ARHGAP21 were expressed as soluble proteins in 
E. coli and purified on glutathione sepharose beads. These purified proteins 
were analysed by SDS-PAGE and expression was visualised by coommassie 
staining. Truncate-1 corresponds to ARHGAP21 residues 885-1096 (75 KD) 
which includes the ARF binding domain of ARHGAP21 (Dubois et al; 2005). 
Truncate 2 comprises amino acids 929-1052 (37KD); truncate 3 includes 
residues 885-1052 (45 KD); truncate 4 is of amino acid region 929-1096 (45 
KD); truncate 5 incorporates amino acids 929-1346 (160 KD); truncate 6, 
which comprises residues 1064-1346, contains both the ARF binding domain 
and RhoGAP domain, and truncate 7, which is 150 KD, includes amino acids 
1042-1346.  A schematic of full-length ARHGAP21 and truncates described 
here are depicted in figure 5.2 along with a coomassie stained gel analysis of 
the same purified GST fusion proteins. 
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5.2.2 Mapping the binding sites of β-arrestin-1 on ARHGAP21 using peptide 
array analysis 
 
A peptide array analysis was used to identify the potential binding sites of β-
arrestins on ARHGAP21. For this analysis a full-length peptide array of 
ARHGAP21 was incubated with a purified recombinant GST fusion protein of 
β-arrestin1 and probed with a GST antibody. GST alone was used as a 
control to determine non-specific interactions (Figure 5.3). This process 
identified a binding site mapped to amino acids 1321-1360 within the RhoGAP 
region of ARHGAP 21. This potential binding site is consistent with the 
residues of the ARHGAP21 fragment identified in yeast-two hybrid analysis 
carried out by Hyrbigenics, France as well as with previously published data 
by (Xiao et al; 2007), where both RhoGAP10 and RanGAP1 were identified as 
potential β-arrestin interaction proteins in a proteomics analysis study of β-
arrestin immunoprecipitates.  
 
5.2.3 β-arrestin 1-GST binding to an ARHGAP21 alanine-scanning 
substitution array 
  
To determine key amino acid residues within the identified β-arrestin 1 binding 
domain of ARHGAP21, an alanine scanning substitution array of the 
ARHGAP21 parent peptides was used. Each amino acid from the parent 
peptide identified within the binding site (figure 5.3) was sequentially mutated 
to alanine while alanine residues in the parent peptide were substituted with 
aspartic acid (Figure 5.4).  
In this study it was found that substitution of Thr1329Ala reduced the 
interaction severely. Similar substitution of Thr1348Ala and Thr1349Ala 
reduced the interaction to a lesser extent. Substitution of Glu1344Ala and 
Glu1345Ala also ablated the interaction. However, a double mutation of 
Glu1344Ala and Glu1345Ala actually served to increase the binding of β-
arrestin to ARHGAP21 compared to individual substitutions of Glu1344Ala 
and Glu1345Ala. Furthermore, substitution of Glu1340Ala, Glu341Ala, 
Glu1344Ala and Glu1345Ala drastically reduced the interaction. Double 
substitutions of Phe1337Ala and Phe1338Ala decreased the binding. 
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Individual single substitutions of Leu1330Ala, Leu1347Ala and Pro1346Ala 
decreased the binding. No effect was seen upon substituting Histidine 
residues at 1334 and 1334 with alanine (Figure 5.4).  
 
5.2.4 A RhoGAP fragment of ARHGAP21 binds to the N-domain of β-arrestin1 
 
To identify the sites of interaction of ARHGAP21 on βarrestin1, a β-arrestin 1 
peptide array was incubated with a purified GST-RhoGAP fragment (amino 
acids 1064-1346) of ARHGAP21 and probed with a GST antibody. GST alone 
was used as control to identify any non-specific interactions (Figure 5.5). 
Probing with the RhoGAP fragment yielded only three positive spots. These 
peptide spots correspond to β-arrestin 1 residues 96-130 which are located 
within the protein’s N-domain (Figure 5.5). Peptide spots of residues 96-125 
showed a stronger interaction than the spot of amino acids 106-130. Probing 
the peptide array with purified ARHGAP21 fragments, which did not include 
the RhoGAP domain did not yield any positive spots.  
 
5.2.5 Binding of ARHGAP21 RhoGAP domain to β-arrestin1 alanine 
substitution scans 
 
To gain further insight into ARHGAP21 binding regions of βarrestin1, an 
alanine substitution-scanning array was generated. The purified RhoGAP 
domain of ARHGAP21 (amino acids 1064-1346) was overlaid on an alanine 
substitution scan of parent peptides (amino acids 96-130) from the previously 
identified binding region (figure 5.6). Substitution of any of the amino acids 
within the stretch from Lys102 to His106 (sequence KLGEH) to alanine 
ablated the binding of ARHGAP21’s RhoGAP domain. Similarly, substitutions 
within the stretch Pro109 to Glu133 (sequence PFTFE) partially reduced the 
binding of the RhoGAP domain of ARHGAP21 (figure 5.6).  
 
 
 
5.2.6 The interaction of β-arrestin1 with ARHGAP21 in pull-down assays 
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Equimolar amounts of various purified GST fusions of ARHGAP21 truncates 
were used in pull-down assays to determine their ability to interact with a 
purified recombinant MBP fusion of β-arrestin 1. As shown in Figure 5.7, 
MBP-β-arrestin1 was able to interact directly with the RhoGAP domain-
containing fragments 5, 6 and 7 (lanes 6-8; bottom panel, figure 5.7) but with 
fragments 1-4 of ARHGAP21 (lanes 2-5, fig 5.7). MBP-β-arrestin1 did not bind 
to GST alone (lane 1, figure 5.7).  
 
5.2.7 Activation of Rho in HEK 293-AT1aR cells.  
 
Rho GTPases are involved in regulation of F-actin dynamics in cells (Jaffe 
and Hall; 2005, Aspenstrom et al; 2004). HEK293 cells expressing the 
angiotensin AT1a receptor have been shown exhibit stress fibre formation in 
response to angiotensin II challenge through a Gαq/11/Rho-mediated pathway 
(Barnes et al; 2005). In order to evaluate the Rho activation profiles in these 
cells, a Rho activity assay was performed. Figure 5.8(a) shows that in resting 
conditions (0 minutes) there is minimal Rho activity. However, in response to 
angiotensin II challenge this activity is increased transiently for up to 10 
minutes after which activity returns to basal levels within 20 minutes of agonist 
exposure. Confocal analysis (Figure 5.8(b) of the HEK293 cell line stably 
expressing the AT1a receptor demonstrates the formation of stress fibres 
upon stimulation with Angiotensin II.  
 
5.2.8 Interaction of β-arrestin 1 with ARHGAP21 in HEK293-At1aR cells 
 
In order to determine whether full length ARHGAP21 interacts with β-arrestin1, 
a co-immunoprecipitation assay was performed. HEK293-AT1aR cells were 
transfected with β-arrestin 1-GFP and then treated with angiotensin II for 10 
minutes in order to activate the Rho signalling. Panel 1 of Figure 5.9 showed 
that β-arrestin 1 interacted with full-length ARHGAP21 in both resting and 
stimulated cells. However, agonist stimulation did not appear to have an effect 
on the interaction. Panel 2 of figure 5.9 shows the expression of ARHAGP21, 
immuno-detected as a ~250 KD species.  
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5.2.9 PDE4D5 interacts with ARHAGP21 in HEK293-AT1aR cells  
 
Βoth β-arrestin 1 and β-arrestin 2 have been shown to interact with PDE4 
isoforms and recruit them to G-protein coupled receptors at the plasma 
membrane in response to agonist challenge (Perry et al; 2002 and Baillie et al; 
2003). β-arrestins can interact with all PDE4 isoforms through a common β-
arrestin binding site located within the catalytic subunit. However, β-arrestin 
shows preference for interaction with the PDE4D5 isoform due the presence 
of an additional binding site within PDE4D5’s unique N-terminal region (Baillie 
et al; 2003).  
 
In order to assess whether PDE4D5 can also be sequestered to the 
ARHGAP21-β-arrestin 1 complex, immunoprecipitation experiments were 
carried out. Endogenous ARHGAP21 was immunoprecipitated from the 
HEK293-AT1aR cells using an ARHGAP21 antibody and precipitates were 
then probed for endogenous PDE4D5 using a PDE4D5 N-terminal-specific 
antibody. Panel 1) of figure 5.10 shows the endogenous PDE4D5 from 
HEK293-AT1aR cells and its pull-down in ARHGAP21 precipitates as 
detected by immunoblotting with the PDE4D5 N-terminal-specific antibody. 
Panel 2) of figure 5.10 shows the immuno-detected ARHGAP21 from the cell 
lysate as well as IP using ARHGAP21 antisera.  
 
5.2.10 PDE4D5 interacts with ARHAGP21 in vitro 
 
Full-length purified PDE4D5-MBP and GST fragments 1 (residues 885-1096) 
and 6 (residues 1064-1346) of ARHGAP21 were used in pull-down assays to 
determine whether PDE4D5 interaction with ARHGAP21 is direct. Panel 2) of 
figure 5.11 shows that purified recombinant PDE4D5-MBP interacted directly 
with the fragments containing ARF binding domain of ARHGAP21 as well as 
the Rho binding domain of ARHGAP21 (figure 5.11). However there are some 
overlapping regions in both fragments. As a control, purified fragments of 
ARHGAP21-GST were also incubated with MBP alone (lanes 4 and 5, figure 
 183 
5.11). A similar control was set up with PDE4D5 MBP and GST alone (lane 3, 
figure 5.11). No interaction was seen in the control lanes.  
 
5.2.11 Effect of PDE4 activity on interaction of ARHGAP21 with PDE4D5 and 
β -arrestin1 
 
For scaffolding proteins such as DISC1, its interaction with PDE4 isoforms 
can be altered by elevating intracellular cAMP levels (Murdoch et al; 2007). It 
was therefore of interest to determine whether the interaction of PDE4D5 with 
the ARHGAP21/β-arrestin1 complex is dynamically regulated by increasing 
cAMP levels, PDE4 activity or Rho activation in cells. ARHGAP21 was 
immunoprecipitated from HEK293-AT1aR cells under basal conditions and 
from cells, which had been treated with cAMP activators Forskolin/IBMX, 
PDE4 inhibitors like Rolipram and Gq/11/Rho activator, Angiotensin II either 
alone or in combination. The lysates and IPs were then immunoblotted for 
PDE4D5 and Arrestin.  Panel 1 of figure 5.12 confirmed that neither elevated 
Rho activity nor cAMP levels had an impact on Arrestin-ARHGAP21-PDE4D5 
complex. Panel 2 of figure 5.12 shows that increased intracellular cAMP 
levels and PDE4 activity do not alter PDE4-ARHGAP21-arrestin interaction. 
Similarly, Rho activation did not alter the dynamics of ARHGAP21-Arrestin-
PDE4D5 complex. Both the blots were stripped with stripping buffer and were 
reblotted for a PKA phosphorylation using PKA phospho substrate antibody 
as an indicator of PKA activation upon elevation of cAMP levels. 
 
 
 
 
 
 
 
 
 
5.3 Discussion  
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RhoGTPases along with their regulators are involved in important cytological 
functions including cytoskeletal rearrangement, cell migration, cytokinesis and 
cell cycle regulation (Jaffe and Hall 2005). The ability to participate and 
regulate in multiple signalling pathways requires co-ordination, with the 
recruitment signalling scaffolds through protein-protein interactions playing an 
important role (Pawson; 2007, Pawson and Warner, 2007).   
 
RhoGTPases have been shown to interact with a wide variety of proteins, 
which they use as their effectors (Bishop and Hall; 2000, Boguski and 
McCormick; 1993). The dynamics of these interactions can be modified by 
conformational changes of the RhoGTPase induced by GDP/GTP binding and 
its intrinsic GTPase activity the activity of which can be regulated by GAFs 
and GAPs (Bishop and Hall 2000).   
 
ARHGAP21 is a novel GTPase activating protein (GAP) for cdc42 (Khato et al; 
2004, Basseres et al; 2002). Using a novel peptide array analysis technique, 
along with co-immunoprecipitation studies, it was shown that interaction of 
ARHGAP21 with β-arrestin1 and PDE4D5 occurs both in vitro and in vivo. 
ARHGAP21 contains a PDZ domain, a pleckstrin homology (PH) domain and 
a RhoGAP domain (Basseres et al; 2002). Recently it has been reported that 
ARHGAP21 region corresponding to amino acids 885-1096 interacts with 
ARF1 (Figure 5.2 for schematic) implicating it in the regulation of F-actin 
dynamics through the Arp2/3 complex (Dubois et al 2005).  All identified 
domains of ARHGAP21 have individual functions. The pleckstrin homology 
domain is known to be involved in translocation of proteins to plasma 
membrane in response to PI3 kinase activity (Bernards and Settleman 2004, 
Bos et al; 2007). The Rho GAP domain is involved in regulating the activity of 
GTPases.  
 
Yeast two-hybrid analysis of β-arrestin 1 performed commercially for our 
group by Hybrigenics, France, as well as a large-scale proteomic study (Xiao 
et al; 2007) have revealed ARHGAP21 as a potential binding partner for β-
arrestin1 and β-arrestin2.  
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Here, a peptide array of full-length ARHGAP21/10 was overlaid with purified 
β-arrestin1-GST (Figure 5.3). β-arrestin 1 strongly interacted with residues of 
the RhoGAP domain (amino acids 1321-1360), supporting the yeast–two-
hybrid analyses,  and further indicating that the RhoGAP domain acts a 
interaction site for β-arrestin 1 (Figure 5.3).   
 
In order to identify the key residues involved in β-arrestin/ARHGAP21 
interaction, an alanine substitution peptide array scan was performed (Figure 
5.4). The alanine substitution scan of the RhoGAP domain (amino acids 1321-
1360) of ARHGAP21 demonstrated a strip of acidic and basic residues 
interspersed with aromatic and hydrophobic residues to be crucial for β-
arrestin interaction. The Glu1328Ala substitution led to a decrease in β-
arrestin binding by around 30% compared to control, whereas individual 
alanine substitutions of T1329 and L1330 reduced the interaction by 80 and 
20% respectively (Figure 5.4 top panel). Individual alanine substitutions of 
Glu1344 and Glu1345 led to an 80% decrease in binding of β-arrestin. 
Combined alanine substitutions at Glu1340, Glu1341, Glu1344 and Glu1345 
decreased the binding of β-arrestin by 60%. Double alanine substitutions at 
Glu1340 and Glu1341 elicited a 50% decrease in binding whereas the double 
alanine substitution at Glu1344 and Glu1345 produced only a 20% decrease 
in binding. A combined alanine substitution at His1333 and His1334 did alter 
binding (Figure 5.4 top panel). Single alanine substitutions at Pro1346, 
Leu1347, Thr1348 and Thr1349 reduced the binding of arrestin by ~ 30% 
respectively (Figure 5.4 bottom panel). Similarly, double alanine substitutions 
at Phe1337 and Phe1338, Thr1348 and Thr1349, Glu1352 and Glu1353 
reduced the binding by ~20%. Multiple alanine substitution of glutamate 
residues at positions 1340, 1341, 1344, 1345, 1352 and 1353 together 
reduced the peptide’s interaction with by β-arrestin only ~20% (Figure 5.4 
bottom panel). Taken together, these data suggest that residues Thr1329, 
Glu1341, Gly1342, Glu1344, and Glu1345 are critical in determining the 
interaction of β-arrestin 1 with RhoGAP domain of ARHGAP21.   
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To further characterise the interaction, in vitro pull-down assays were 
performed using purified GST truncates of ARHGAP10/21 (Figure 5.7). A 
purified MBP fusion of β-arrestin 1 MBP exhibited an interaction with only 
truncates containing the RhoGAP domain (truncates 5, 6 and 7) of 
ARHGAP10/21 in pull-down assays but not with fragments containing 
comprising the ARF binding domain or the PH domain. These data suggested 
that the interaction of β−arrestin with ARHGAP21 is mediated by the RhoGAP 
domain of ARHGAP21/10 and that the interaction is direct (Figure 5.7). 
 
In reciprocal binding studies, in which a full-length peptide array of β−arrestin 
1 was overlaid with purified GST-RhoGAP domain (1064-1346) of 
ARHGAP21, an interaction site within the N-domain of β−arrestin 1 was 
identified (Figure 5.5 top panel). No interaction was observed with GST-
ARHGAP21 fragments 1-4.  
 
To further define the residues of β−arrestin involved in its interaction with 
ARHGAP21, an alanine substitution-scanning array was used. Individual 
mutations of any of residues within the region 102-106 (sequence KLGEH) 
abolished the interaction of β−arrestin with ARHGAP21 (Figure 5.6). Alanine 
substitution of residues Pro109 and Phe110 attenuated the interaction 
severely. A similar effect was observed with substitutions at Phe112 and 
Glu113 (Figure 5.6).  
 
From the peptide array analyses, it could be suggested that there is a 
consensus site for ARHGAP21 binding to β-arrestin of E- (X) 4-KLGEH- (X) 5-E 
(Figure 5.6). However, analyses also showed that βarrestin-ARHGAP21 
interaction appears to involve a strip of acidic amino acids on each protein. 
These observations are somewhat curious as it would be expected that if 
electrostatic interactions were involved in binding then the  key acidic amino 
acids of β-arrestin would be complemented by a strip of basic residues on 
ARHGAP21 and vice versa. Mutagenesis of these identified residues in the 
full-length proteins would be required to define the sites of interaction more 
clearly. It is possible these stretches of acidic amino acids are involved in 
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presenting correctly other key amino acids on each peptide that are important 
for binding but are not affected upon alanine substitution. This needs further 
investigation.  
 
A GAP domain is present in all GAPs of Ras GTPase family including Ras, 
Rho, Rac, Rap, Rab, Arf, Ran and RGS proteins which are GαGAPs 
(Scheffzek and Ahmadian, 2005). Since the GAP domains of most GAPs 
share a high degree of homology, it would be of interest to study the 
interaction of β−arrestin with GAP domains of other Ras proteins. All GAP 
domains are involved in regulating the GTPase activity of GNBPs. GAPs 
enhance the intrinsic GTPase activity of GTPases and, consequently, inhibit 
the GTPase as described in section 1.11.1.3. In one model they either 
stabilise the catalytic domain of GTPases or provide a key arginine residue 
into the catalytic domain of the GTPase (Scheffzek and Ahmadian 1997, 
Moore and Eccleston, 1991). The significance of the second model is better 
explained in that the long side chain of the arginine residue can act as a 
bridge to bring intra-protein distances closer and its guanidium group can act 
like a stabiliser of the transition states involved in GTP hydrolysis by GNBPs. 
However, recent work by Fidyk and Cerione, 2002 has shown that GAPs 
enhance the GTPase activity by both stabilising the catalytic domain as well 
as providing the arginine residue. Given the initial role of GAPs in enhancing 
the GTPase activity of GNBPs and from the data presented on β−arrestin-
ARHGAP21 interaction, it could be argued that binding of β−arrestins to the 
RhoGAP domain might influence GAP activity either by interrupting the 
inherent ability of GAP to enhance the catalytic activity of GTPases or by 
acting as a physical barrier by preventing the ability of GAP to bind its 
respective GTPase altogether, leaving the GTPase in a constitutively active 
state.  
 
To understand the functional outcome of ARHGAP21-β−arrestin interaction, 
functional assays were carried out using a HEK293-AT1ar stable cell line. 
This cell line was chosen to study functional nature of these interactions as 
activation of Rho signalling is shown to be triggered by Angiotensin II 
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treatment of these cells (Barnes et al, 2005). Rho activation assays were 
carried out using these cells as described in section 2.11.3.  A peak transient 
activation of Rho was seen after stimulation with Angiotensin II for 10 min with 
Rho activity returning to basal levels after 20 min (Figure 5.8 a). Confocal 
analyses revealed that the activation of Rho upon incubation of cells with 
Angiotnesin II, induced stress fibre formation (Figure 5.8 b). Rho activation by 
GαQ/11 is mediated either in a phoshpolipase C/PKC dependent manner or 
through activation of tyrosine kinases (Kuwahara and Kuwahara; 2002, 
Hirshman and Emala, 1999). It has been reported that β−arrestin–1-mediated 
activation of Rho, and subsequent actin reorganisation and stress fibre 
formation in angiotensin II-stimulated HEK293-AT1aR cells requires GαQ/G11 
signalling (Barnes et al; 2005). Recruitment of β-arrestin 1 to agonist-activated 
AT1a receptors not only activates Rho, but also regulates β-arrestin-mediated 
activation of the ERK MAP kinase pathway. This regulation is hypothesised to 
be due to competition between the βarrestin1 and 2 for binding sites on At1a 
receptor (Barnes et al; 2005). It has also been proposed that upon receptor 
stimulation, β-arrestin 1 and GαQ/11 co-ordinate to potentiate the activation of 
Rho, which, in turn, activates Rho kinase, ROCK, and thus leads to actin 
rearrangement for the formation of stress fibres (Barnes et al; 2005). Here, 
HEK293-AT1ar cells were transfected with a β-arrestin-1-GFP fusion protein 
and cells were stimulated to attain maximum Rho activation in the cells. Co-
immunoprecipitation studies of cell lysates revealed that interactions were 
unaltered in response to Angiotensin II exposure as compared to non-
stimulated cells (figure 5.9 top panels). Since β−arrestins activate Rho, and if 
they also bind to RhoGAPs, which have an inhibitory affect on Rho, it would 
be logical to assume binding of βarrestin to ARHGAP21 would be augmented 
under conditions of maximum Rho activation. The data suggests that Rho 
activation by β−arrestin is independent of its interaction with the RhoGAP and 
binding of β−arrestin to ARHGAP21 is not affected by Rho activity (Figure 5.9). 
The stable association of β−arrestin 1 with ARHGAP21 in both resting and 
agonist-stimulated cells is perhaps mediated by the RhoGAP domain, 
functioning independently of ARHGAP21. Studies of other ARHGAP21 
interacting proteins has shown that ARHGAP10/21 is able to bind ARF1 (ADP 
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ribosylation factor 1), which allows for the regulation of cdc42 activity at Golgi 
membranes (Dubois et al; 2005). ARHGAP21 interacts with ARF1 through its 
PH domain plus a α-helix motif located towards its C-terminus with switch 
regions of ARF1. Eventhough the PH domain is necessary for this interaction, 
it cannot on its own bind to ARF1 independent of the C-terminal α-helix 
(Menetrey et al; 2007). ARHGAP21/10 acts as GAP for CDC42 recruited to 
Golgi in ARF1-dependent manner and regulates the function of its 
downstream effectors, Arp2/3, which are involved in F-actin dynamics in the 
proximity of the Golgi membranes. Arp2/3 is also implicated in the transport of 
clathrin-coated vesicles via the trans-Golgi network (Dubois et al; 2005).  
 
It is known that β-arrestins play an important role in GPCR desensitisation, 
internalisation and resensitisation (Oakley et al, 1999, Laporte et al; 1999). 
When receptor is internalised in a complex with β-arrestin, dephosphorylation 
of the receptor by phosphatase PP2A, followed by dissociation of β-arrestin 
from the receptor promotes the recycling of receptor from endosomal vesicles 
back to the plasma membrane. If β−arrestin fails to dissociate from the 
receptor, then receptor is targeted to proteasomal degradation thus 
preventing receptor resensitisation (Simaan et al; 2004, Zhang et al; 1999, 
Zhang et al; 1997). β-arrestin dissociation from the lutenising 
hormone/Chorionic gonadotrophin receptor (LH/CGR) has been shown to be 
ARF6-dependent (Mukherjee et al; 2000). Although the role of β−arrestin in 
directly regulating the vesicle transport is poorly understood, given their role in 
receptor desensitisation/resensitisation, and their interaction with ARFs, it 
could be suggested that the β−arrestin-ARHGAP10 complex might function in 
regulating F-actin dynamics at the Golgi thereby regulating the transport of 
clathrin-coated vesicles to plasma membrane surface. β−arrestin has been 
shown to mediate PI3 kinase activation in MEF cells in a manner independent 
of ERK and Gi signalling (DeWire et al; 2007 and Povsic et al; 2003). Most 
RhoGAPs, including ARHGAP21, possess a PH domain, which binds 
phosphotidylinositides, thus altering substrate specificity of the RhoGAP and 
its translocation to plasma membrane (Ligeti and Settleman; 2006, Bernards 
and Settleman; 2004). Given these findings it could be argued that 
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ARHGAP21 might act as a chaperone in response to phosphatidylinositide 
signalling, recruiting β-arrestins to plasma membrane to mediate GPCR 
receptor desensitisation and internalisation.  
 
Considering β−arrestins also function as scaffolds, anchoring proteins 
involved in many signalling pathways, the interaction with ARHGAP10/21 may 
be important for regulating Rho activity associated with these β-arrestin 
complexes in different subcellular locations. β-arrestin complexes have 
previously been shown to mediate β2-AR desensitisation by recruiting PDE4 
isoforms to the plasma membrane. PDE4 binding to β-arrestin regulates PKA 
phosphorylation and consequent the Gs-Gi switching of the receptor (Baillie et 
al; 2003 and Perry et al; 2002). βarrestin recruitment of PDE4 has also been 
shown to occur within lipid rafts of T-cell membranes, regulates T-cell 
activation and cytokine production (Abrahamsen et al, 2004).  
 
Of all PDE4 isoforms, PDE4D5 shows preference for binding to β−arrestin 
due to the presence of an extra site for βarrestin interaction located within its 
isoform-specific N-terminal region (Baillie et al, 2007, Bolger et al; 2003). The 
potential interaction of PDE4D5, with an ARHGAP21/β−arrestin 1 complex 
and its possible role in actin dynamics was therefore investigated. PDE4 has 
previously been shown to be involved in Rho-mediated cell migration (Fleming 
et al; 2004). In REF52 cells, rolipram inhibition of PDE4 resulted in 
suppression of the RhoA-ROCK-Myosin signalling pathway which is required 
for integrin-mediated actin-adhesion spike formation. Furthermore, PDE4 
inhibition led to impaired cell migration (Fleming et al; 2004).  
In this study the HEK293-AT1aR cell line was used to study PDE4D5 
interaction with this complex. Immunoprecipitated ARHGAP21 was shown to 
interact with PDE4D5 both in resting and Angiotensin II stimulated cells 
(Figure 5.10 top panel). As noted previously in β-arrestin/ARHGAP21 co-
immunoprecipitation experiments, interaction of PDE4D5 with ARHGAP21 
was unaltered by activation of Rho. In vitro pull-down assays were performed 
to determine if PDE4D5 is able to bind directly to ARHGAP21 or is the 
interaction observed in vivo mediated by β-arrestin recruitment of the enzyme. 
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Purified recombinant PDE4D5 was found to interact directly with fragments 
RhoGAP domain and ARF binding domains of purified ARHGAP21-GST 
(Figure 5.11 bottom panel). However both the fragments have some 
overlapping regions. Interestingly, PDE4D5, but not β-arrestin, was shown to 
interact with the ARF binding domain of ARHGAP21 (Figure 5.7 top panel and 
Figure 5.11 bottom panel). It could be inferred that PDE4D5 and β-arrestin 
might interact with ARHGAP21 independent of each other. However, both 
proteins are able to interact with the RhoGAP domain of ARHGAP21. It is 
possible that β−arrestin and PDE4D5 compete for binding to the RhoGAP 
domain.  
 
Interaction of PDE4s with some partner proteins can, in certain instances, be 
regulated by cAMP. Elevation of cAMP levels and subsequent activation of 
PKA has been shown to mediate the dissociation of PDE4D3 and PDE4C2 
isoforms from DISC1, a scaffold protein implicated in schizophrenia (Murdoch 
et al; 2007). Furthermore, in neuronal SHSY5Y cells, the interaction of an 
endogenous 71KD DISC1 species with the PDE4B1 isoform is attenuated by 
increased cAMP levels (Millar et al; 2005). 
 
Conversely, the interaction of PDE4D3 with mAKAP has been shown to 
increase in response to elevated cAMP levels, whereby cAMP-mediated PKA 
phosphorylation of PDE4D3 on the Ser13 within its unique N-terminal region, 
increases PDE4D3 affinity for mAKAP (Carlisle et al; 2004).  
It was therefore of interest to assess the functional consequences of elevated 
cAMP levels in the protein-protein interactions of a β−arrestin-ARHGAP21-
PDE4D5 complex. In HEK293-AT1aR cells treated with or without Angiotensin 
II, forskolin/IBMX-induced elevation of cAMP had no impact on the affinities of 
PDE4D5-ARHGAP21 and β−arrestin-ARHGAP21 interactions as revealed in 
co-immunprecipitation experiments (Figure 5.12). Similarly, inhibiting PDE4 
activity with rolipram, in the presence or absence of elevated Rho activity, did 
not alter the interactions of the protein complexes (Figure 5.12). Small 
interfering (si) RNA to knock down ARHGAP21 expression in HEK293-AT1aR 
cells was used to further characterise the interactions of the β-
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arrestin/ARHGAP21/PDE4D5 complex and its role in stress fibre formation. 
However treatment with ARHGAP21 siRNA resulted only in a 15% reduction 
in ARHGAP21 expression in cells, which was insufficient to exploit functionally. 
Further work is therefore required to optimise the transfection efficiency of 
ARHGAP21 siRNA with these cells.  
 
ARHGAP21 is a poorly characterised RhoGAP. Its functional role in signalling 
complexes has yet to be elucidated. Although the cAMP-PKA pathway has 
been shown to be involved in regulation of cell migration and motility (Howe et 
al; 2005, Howe, 2004 and Fleming et al; 2004), the role of PDE4 isoforms in 
these processes is still unclear. As cAMP signalling in cells is 
compartmentalised (Lynch et al; 2006, Houslay and Adams, 2003, Zaccolo 
and Pozzan, 2002), it could be postulated that PDE4D and β−arrestin might 
co-ordinate Rho signalling pathways by interacting with and regulating the 
activity of ARHGAP21. The functional significance of ARHGAP21/β-arrestin, 
ARHGAP21/PDE4D5 and, potentially, ARHGAP21/β-arrestin/PDE4D5 
interactions in these cells needs further investigation.  
 
As it has been shown that both β−arrestin and PDE4D5 bind ARHGAP21 
within its RhoGAP domain, it is possible the two proteins compete for binding 
to ARHGAP21. The amounts of ARHGAP21 complexing with β-arrestin, 
PDE4D5 or both may vary with cell type with the possibility that interactions 
are also altered in response to extracellular stimuli. Considering PDE4D5 also 
binds ARHGAP21 within its ARF binding region, a PDE4D5-ARHGAP21 
complex may be sequestered to different sub-cellular compartments than β-
arrestin-ARHGAP21 and β−arrestin-PDE4D5-ARHGAP21 complexes. Since 
the pull-down assays were not performed with full-length ARHGAP21 protein, 
it is possible that β−arrestin, as well as PDE4D5, might have additional 
binding sites on ARHGAP21 aside from those identified and discussed here.  
Sequence analysis of ARHGAP21/10 using scansite 
(http://scansite.mit.edu/motifscanseq.phtml) identified a potential PKA 
consensus motif within the protein. However, as shown in Figure 5.12, when 
ARHGAP21 was immunoblotted with a PKA substrate-specific antiserum, no 
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phospho-band of the molecular weight of ARHGAP21 was observed in 
precipitates as well as in lysates. However, a 100kD phosphorylated species 
was detected (Fig 5.12) One possible PKA substrate, which migrates at this 
size is PDE4D5. Selective immunoprecipitation of PDE4D5 with PDE4D5-
specific antisera followed by probing with a PKA substrate antibody would 
indicate whether or not the unknown phospho-protein is PDE4D5. 
Notwithstanding this, PDE4D5 is known to be phosphorylated and activated 
by PKA (Baillie et al, 2001).  
In conclusion, these studies suggest ARHGAP21 is a binding partner for both 
β−arrestins and PDE4 isoforms. Investigating these interactions and their 
functional roles may be of importance in the development of therapeutic 
targets in disease states linked to changes in cell migration and cytoskeletal 
rearrangement including tumour metastasis, asthma and COPD.  
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Figure 5.2 Expression and purification of GST-truncates of ARHAGP21 in E coli. 
 
ARHGAP21 and different truncates used in this are schematically represented. ARHGAP21 
contains an N-terminal PDZ domain, a PH domain and a conserved RhoGAP domain. GST 
and different ARHGAP constructs were expressed and purified from E.coli as described in 
chapter 2.4.2.  Purified proteins were analysed by SDS-PAGE and Coommassie staining as 
described in section 2.10.  The gels represent the single successful expression experiment 
undertaken for all the proteins in E.coli 
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Figure 5.4 Alanine-scanning substitution analyses to probe the binding sites for β-
arrestin1-GST in the RhoGAP domain of ARHGAP10/21 
 
ARHGAP21/10 peptide arrays were probed for β-arrestin1–GST binding based upon the 
indicated 25-mer ‘parent’ ARHGAP21/10 peptide, where the indicated amino acids were 
sequentially and individually replaced by alanine. Ct refers to the native peptide and all 
other spots reflect alanine substitutions of individual amino acids in the native spot. The 
peptide array interaction data are from experiments done once. 
N-Domain     C-Domain
ß-arrestin1
peptide array
B10 ARB1 (96-120) P-L-T-R-L-Q-E-R-L-I-K-K-L-G-E-H-A-Y-P-F-T-F-E-I-P
C1 ARB1 (101-125) Q-E-R-L-I-K-K-L-G-E-H-A-Y-P-F-T-F-E-I-P-P-N-L-P-C
C2 ARB1 (106-130) K-K-L-G-E-H-A-Y-P-F-T-F-E-I-P-P-N-L-P-C-S-V-T-L-Q
B10
C1     C2
Probed with 1064-
1346 a.acids of
ARHGAP21-GST
Probed with 885-1096 
a.acids of  
ARHGAP21 GST
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Figure 5.5 Probing a β-arrestin1 array with ARHGAP10/21 (1064-1346) –GST 
 
Beta arrestin-1 is shown schematically with its N and C-domains. Results show 
immobilized peptide ‘spots’ of overlapping 25-mer peptides each shifted along by five 
amino acids in the entire Beta-arrestin-1 sequence probed for interaction with 
ARHGAP21 fragment with 1064-1346 amino acids and detection by immunoblotting. 
Positively interacting peptides generate dark spots, while those that do not interact 
leave white (blank) spots. In all other sections of the array, spots were blank with either 
probe. Spot numbers relate to peptides in the scanned array and whose sequence is 
given as indicated. Arrays probed with a. acids 885-1096 of purified ARHGAP21 GST 
did not yield any spots. Arrays probed with purified GST did not yield any positively 
interacting spots. The peptide array interaction data are from experiments done once. 
GST alone 
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Cont  Q96   E97    R98    L99      I100   K101   K102   L103   G104   E105  H106  A107 Y108
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Probed with 1042-
1346  amino acids 
of ARHGAP21-
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Figure 5.6 Alanine scanning substitution analyses to probe binding sites 
ARHGAP21-GST in the N-domain of β-arrestin 1 
 
β-arrestin1peptide arrays were probed for ARHGAP21/10 binding based upon the 
indicated 25-mer ‘parent’ β-arrestin1 peptide, where the indicated amino acids were 
sequentially and individually replaced by alanine. Ct refers to the native peptide and 
all other spots reflect alanine substitutions of individual amino acids in the native 
spot. The peptide array interaction data are from experiments done once. 
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Chapter 6 Final discussion 
 
PDE4 enzymes play a crucial role in regulating cAMP levels within various 
sub-cellular compartments (Houslay et al; 2007, Zaccolo 2006, Zaccolo et al; 
2006, Lissandron et al; 2006, Terrin et al; 2006, Houslay and Adams, 2003). 
Compartmentalization of cAMP signalling is now well documented due to the 
advent of genetically encoded sensors of cAMP that have allowed for the 
detection of cAMP gradients within live cells (Willoughby and Cooper, 2008, 
Tasken and Aandahl 2004, Zaccolo et al, 2002, Dunn et al; 2006, Dal molin et 
al; 2006, Willoughby and Cooper, 2007). Components of cAMP signalling 
including AKAPs (Dodge-Kafka et al; 2006), adenylate cyclases (Cooper and 
Crossthwaite, 2006) and PDEs (Houslay et al; 2007) are specifically recruited 
to intracellular micro-domains where they respond to and modulate cAMP 
pools.  Proper targeting of these proteins is of critical importance for functional 
cAMP signalling within cells.  
 
To date 21 PDE4 isoforms have been identified, each of which has an isoform 
specific N-terminal region that confers capability to interact with a variety of 
proteins that regulate various signalling molecules and their transduction 
pathways (Houslay et al; 2007, Houslay and Adams, 2003, Lynch et al; 2006). 
Many of these PDE4-signalling scaffold protein complexes are discussed in 
detail in section 1.8.   
 
6.1 SUMOylation of PDE4 isoforms in HEK293 cells 
 
Post-translational modifications of a protein play a major role in regulation of 
its structure, function and subcellular localisation. The most well established 
post-translational modification of PDE4s is phosphorylation, which is 
catalysed by kinases including PKA, ERK, and an as yet unknown kinase 
downstream of PI3 kinase, (Mackenzie et al, 2002, Mackenzie et al, 2000, 
Mackenzie et al; 1998 and Ekholm et al, 1997, Hill et al; 2006). Sections 
1.7.4.2, 4.3 and 4.4 discuss the regulation of PDE4 isoforms by PKA and ERK 
in detail.  
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SUMOylation is relatively a newly identified post-translational modification and 
is known to affect the localisation of proteins, and their functioning (Kerscher, 
O; 2007 and Johnson, E; 2004). SUMO plot (www.abgent.com/doc/sumoplot) 
analysis of PDE4s identified two of the subfamilies as potential SUMO 
substrates. Accordingly, in chapter 3, analysis was performed to characterise 
the SUMO modification of PDE4 isoforms particularly, PDE4D5. Although the 
conditions in which PDE4D5 is SUMOylated were initially unknown. Co-
transfection with PIASy E3 ligase led to conjugation of PDE4D5 with SUMO-1 
whilst co-transfections with other E3 ligases such as PIAS1 and PIAS2 did not 
induce PDE4D5 SUMOylation (Figure 3.2). The SUMO conjugation motif is 
ΨKXE, where Ψ is an aliphatic residue and X is any amino acid (Hay 2005). 
This SUMO conjugation consensus motif is located within the catalytic region 
of PDE4D5. In confirmation of this being the site of SUMOylation within 
PDE4D5, mutation of the lysine residue within this sequence to arginine, 
abrogated SUMOylation of PDE4D5 (Figure 3.2a). Sequence alignment of the 
long isoforms from the four sub-families revealed that only the 4A and 4D sub-
families possess a potential SUMOylation site within their primary structures. 
This was verified in SUMOylation assays whereby HEK293 cells were 
transfected with PDE4A4, 4B1, 4C2 and 4D5 isoforms plus PIASy E3 ligase. 
Only in cells expressing the PDE4D and PDE4A isoforms was SUMOylation 
detected (Figure 3.2 c). It would be of interest to determine whether PDE4 
isoforms are differently conjugated to other SUMO molecules, such as 
SUMO2-4 and if this process is altered under different physiological 
conditions. Identification of the mechanisms regulating SUMOylation would 
offer means to modulate of functioning of the PDE4A and PDE4D subfamilies.  
 
UBC9 is a SUMO E2 ligase (Johnson and Blobel 1997, Johnson et al, 1997). 
Figure 3.3 shows that UBC9 interacts at the FQF ‘multi-functional’ docking 
domain of PDE4D5. The FQF docking domain is conserved in all PDE4 
isoforms. However, only 4A and 4D subfamilies were shown to be 
SUMOylation substrates thus demonstrating that UBC9 binding alone is not 
sufficient for SUMOylation to occur in vivo. The FQF multi-protein docking 
domain of PDE4 isoforms serves as a site for interaction for proteins including 
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 arrestin (Bolger et al, 2006), ERK2 (Mackenzie et al, 2000) and AKAP18δ 
(McSorley et al, 2006). Further analysis is required to characterise the 
interactions of these various partners at the FQF and whether their 
interactions are competitive. If the interactions are dynamic, then, for 
example, would ERK binding to the FQF domain block interaction of UBC9 
with the PDE4 isoform and subsequently preventing it from being 
SUMOylated. Changes in the level of expression of the scaffolds competing 
for binding to this site is likely to have functional consequences for PDE4 
regulation and its subcellular localisation.  
PIAS proteins are Protein inhibitors of activated STAT and possess SUMO E3 
ligase activity (Takahashi et al, 2003). PIAS proteins interact with a variety of 
proteins and act as transcriptional repressors. This repressor activity can 
either be dependent or independent of their SUMO E3 ligase activity 
(Palmivo; 2007). There are four different PIAS proteins PIAS1, PIAS3, PIASx 
and PIASy (Jackson; 2001 and Gross et al; 2001). As co-transfection of 
PIASy and PDE4D5 was shown to induce SUMOylation of the isoform, the 
interaction of PIASy with PDE4D5 was examined in further detail (Figure 3.4). 
Wild type PDE4D5 interacted with PIASy and was SUMOylated. The 
F670A/Q671/F672A mutant of PDE4D5 which was unable to interact with 
UBC9, plus the K323R mutant of PDE4D5 (both of which were still able to 
bind E3 ligase) were not conjugated with SUMO suggesting that a functional 
FQF region as well as a conserved motif for SUMO are necessary for 
SUMOylation (Figure 3.4 a2 and a3). Truncation analyses to identify the 
PIASy binding site(s) on PDE4 revealed that PIASy bound only full-length 
PDE4D5 protein but not to any of the individual PDE4 domains (Figure 3.4 b) 
suggesting that interaction of PIASy with PDE4 is complex and requires more 
than one binding site on the molecule. In support of this, further 
characterisation of the interaction using scanning peptide array analysis 
identified (figure 3.4c) two potential PIASy interaction sites on a PDE4D5 
peptide array (figure 3.4c); one site in close proximity to PKA phosphorylation 
site within the UCR1 region (amino acids 111-145) of PDE4D5 and another 
site within the PDE4D catalytic region (amino acids 486-530).  Confirmation of 
these PDE4D5 regions as binding domains of PIASy, plus the identification of 
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the residues of PIASy required for this interaction, would require further 
mutagenesis studies.   
Other members of the E3 ligase family include the RNBP2/NUP358 and 
polycomb group protein PC2 proteins (Johnson, 2006). The potential role of 
these E3 ligases in SUMOylation of PDE4D5 is still to be determined.  
 
Treatments with various signalling activators and inhibitors were used to 
assess the influence of cell signal transduction on PDE4D5 SUMOylation. 
None of the treatments and associated pathways studied altered the 
SUMOylation status of PDE4D5 under experimental conditions. It therefore 
still remains to be determined which factors drive SUMOylation of PDE4 
enzymes in vivo. SUMOylation patterns of proteins have been shown to be 
variable during different phases of cell cycle (Bischof and Dejean, 2007, 
Bischof et al, 2006). It would therefore be of interest to examine whether 
PDE4 SUMOylation varies during different phases of cell cycle. 
 
SUMOylation of proteins is known to affect their localisation within cells. For 
PDGF-C, conjugation with SUMO-1 targets the protein to the nucleus 
(Reigstad et al; 2006). Nuclear localisation and subcellular fractionation 
studies of SUMOylated and non-SUMOylated PDE4D5 (Figure 3.6a) revealed 
that PDE4D5 remained in soluble fraction of the cells before and after 
SUMOylation. However, a small amount of SUMOylated and non-
SUMOylated PDE4D5 species were present in the P1 cellular fraction, which 
includes both nuclear membranes and unbroken cells. As PDE4D5 
expression appears to be cytosolic within HEK293 cells, the detection of 
PDE4D5 within the P1 fraction is likely due to the presence of unbroken cells 
within this fraction. Although SUMOylation did not effect localisation of 
PDE4D5 in HEK293 cells, it would be of importance to investigate whether the 
localisation PDE4 isoforms is altered upon SUMOylation in other cells types 
and if the localisation is affected by cellular stimuli.  
PDE4 enzyme action is an integral part of cAMP signalling as it is the sole 
means of decreasing cAMP levels within cells. Hence any cellular effects, 
which mediate changes in PDE4 activity, would directly influence cAMP 
signalling. A potential role for SUMOylation in regulating the PDE4 activity 
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was therefore examined. SUMOylation did not affect the activation of PDE4D5 
both in in vitro and in vivo assays. However, it was found that SUMOylation 
potentiated the effect of PKA phosphorylation in activating PDE4D5. 
Furthermore, and somewhat surprisingly, SUMOylation of PDE4D5 appeared 
to negate the inhibitory effect of ERK phosphorylation on PDE4D5 activity in 
vitro (Figure 3.7). A possible explanation for the loss of ERK effect is that 
conjugation of SUMO to the catalytic unit of PDE4D5 induces a 
conformational change affecting its interaction with the UCR1/UCR2 
regulatory module. This is consistent with previous studies showing that PKA 
phosphorylation of UCR1 is able to override the inhibitory effect of ERK 
phosphorylation on PDE4 activity by attenuating the interactions of the 
UCR1/UCR2 module (Beard et al; 1999). Furthermore, the PDE activity of 
short PDE4 isoforms, which lack a UCR1 domain, is not affected by ERK 
phosphorylation.  Further studies are required to assess the ERK response on 
SUMOylated PDE4 in vivo. Based on this novel finding from the in vitro 
studies, it could be suggested that in cells PDE4 SUMOylation functions to 
further compartmentalise cAMP signalling whereby subpopulations of PDE4s 
are able to remain active in the presence of an ERK stimulus.  
 
Although SUMOylation did not affect the overall enzyme activity of PDE4D5, it 
was shown to increase its rolipram sensitivity. SUMOylated PDE4D5 was 
found to be 10 times more sensitive to inhibition by rolipram than its non-
SUMOylated form. PDE4 isoforms exist in two different states of rolipram 
sensitivity, namely HARBS and LARBS (Souness and Rao, 1997). Binding of 
proteins such Src tyrosyl kinases and XAP2, as well as PKA phosphorylation, 
have been reported to induce switching between the LARBS and HARBS 
states (Bolger et al; 2003, McPhee et al, 1996). It is possible that the 
increased sensitivity of rolipram elicited by SUMOylated PDE4D5 is due to 
switching to the HARBS conformational state. Since SUMO is a ~11KD 
molecule, it is possible its conjugation to the PDE4 at the catalytic region 
stabilises the isoform in the HARBS configuration.  
 
PKA phosphorylation of PDE4D5, which evokes a shift from LARBS to 
HARBS, was shown to increase the rolipram sensitivity of both non-
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SUMOylated and SUMOylated PDE4D5 to a similar extent. SUMOylation did 
not appear to enhance the PKA-mediated increase in PDE4D5’s rolipram 
sensitivity as it is likely the SUMOylated form already exists predominantly in 
a HARBS state.  
 
SUMOylated PDE4D5 was completely unaffected by ERK action and its 
rolipram sensitivity was same as that of the non-phosphorylated species 
(Figures 3.8, 3.9 and 3.10). Similar experiments with PDE4D5 binding partner 
RACK1, following earlier findings of Yarwood and co workers (Yarwood et al 
1999) who showed that binding of RACK1 to PDE4D5 N-terminus decreased 
the rolipram sensitivity of the isoform, revealed that both wild type and 
SUMOylated PDE4D5 exhibited a decreased sensitivity to rolipram in the 
presence of purified recombinant RACK1 (figure 3.11). As RACK 1 binds to 
the N-terminal region as well as to the catalytic region (Bolger et al; 2006) and 
SUMO conjugation occurs in the catalytic region, it is possible that the 
HARBS induced by linkage of SUMO is reversed to a certain extent by 
RACK1 binding to the N-terminus and catalytic region of PDE4D5. 
 
The effects of SUMOylation on the binding of PDE4D5 to known interactors 
including RACK1,  arrestins, ERK, AKAP18δ and UBC9 was evaluated both 
in vivo and in vitro. All partners studied exhibited an increased binding to the 
SUMOylated species of PDE4D5 compared to its non-SUMOylated form 
(Figure 3.13 and 3.14). However, the extent by which binding affinities 
increased differed between in vitro and in vivo studies.  In in vivo assays, it is 
likely many other proteins in addition to PDE4D5 are being SUMOylated and 
this may subsequently affect the affinity of PDE4D5 interactions with its 
binding partners.  
 
As only the PDE4A and PDE4D sub-families are SUMOylated, it is possible 
that SUMOylation provides a means for subfamily-specific regulation of PDE4 
signalling within cells. Since cAMP signalling is compartmentalised, 
SUMOylation might offer a way of modulating PDE4 activity within specific 
sub-cellular compartments without altering the PDE4 activity globally. 
Furthermore, the increased affinity of PDE4 interactors for the PDE4 
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SUMOylated species would offer a way of redistributing the cellular PDE4 
population. Future work would entail identifying the processes which drive 
SUMOylation of PDE4 enzymes in an effort to further characterise its 
functional roles. 
For the in vivo experiments performed in this study, both PDE4 isoforms and 
SUMO ligases were overexpressed in the cells. However, given the lability of 
SUMOylated proteins and the ability of SUMO isopeptidases to quickly 
deSUMOylate conjugated proteins, it would be necessary to repeat this study 
focussing on endogenous proteins so as to get a better understanding of 
SUMOylation of PDE4s under normal physiological conditions. It would also 
be of interest to carry out structural analysis to resolve the conformational 
state of SUMOylated PDE4 in an effort to further understand the effects of 
SUMOylation on rolipram sensitivity. As SUMOylation is likely to trigger the 
HARBS conformation of PDE4, PDE4 SUMOylation may eliminate the emetic 
effects caused by PDE4 inhibitors. Compounds or small molecules, which 
trigger PDE4 SUMOylation may therefore be of therapeutic use.  
 
6.2 Rolipram induced foci formation of PDE4A4 
 
PDE4 isoforms in a basal state are known to exist in the LARBS 
conformation. The formation of complexes with proteins such as SRC tyrosyl 
kinases is known to confer switching of PDE4A4 to the HARBS state as 
described in section 1.7.2 (McPhee et al; 1996). PDE4A4 is known to form 
accretion foci in cells subjected to chronic rolipram treatment (Terry et al; 
2003). Chapter 4 describes the process in detail and the experiments carried 
out in an effort to identify the signalling pathways and associated proteins 
involved in the process of PDE4A4 foci formation.  These accretion foci are 
independent of cytoskeletal proteins and sub-cellular organelles such as Golgi 
(Figure 4.1 and table 4.1). cAMP has an inhibitory effect on foci formation and 
quickly disperses any pre-formed foci by competing with rolipram for the 
binding site on PDE4. Similarly, non-foci forming PDE4 selective inhibitors 
similarly antagonise the action of rolipram by displacing it from the active site 
of PDE4A4. Activation/inhibition of the components of cAMP signalling 
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including PKA and EPAC did not have any clear effects on foci formation 
(Figure 4.2). It is therefore likely that the cAMP molecule binding directly to 
the active site of PDE4A4 mediates the effects of cAMP signalling on foci 
formation.  
 
Earlier studies (Terry et al; 2003) proposed a model for foci formation known 
as “inside-out signalling” whereby binding of rolipram to PDE4A4 induces 
conformational changes within the catalytic site that are transferred through 
helix 10/11 and loops 7/8 to the surface of the catalytic unit. This, presumably 
together with the unique N-terminal region of PDE4A4, forms a new 
conformation that interacts with yet unidentified proteins to couple to the 
formation of foci in a process that depends upon active protein synthesis 
(Figure 4.1).  
 
It is widely known that ERK phosphorylation inhibits activity of all long PDE4 
isoforms except those of the PDE4A sub-family, which lack a proline in the 
consensus site for ERK phosphorylation within their catalytic unit (Mackenzie 
et al. 2000). In order to investigate the role of other MAP kinases in foci 
formation and maintenance, various MAP kinase inhibitors were used to treat 
cells stably expressing a GFP fusion protein of PDE4A4B. Inhibition of MEK 
did not affect rolipram-induced foci formation nor did the inhibition of MAPKAP 
kinase2. Inhibition of either kinase did not induce foci formation either. 
 
Activation of MAPKAP kinase-2, via activation of p38 MAPK with anisomycin, 
abrogated rolipram-induced foci formation. However, strangely, the effects of 
anisomycin were not reversed by SB203580, a p38 inhibitor. Anisomycin is 
known to stimulate other effectors, such as JNK (Sampieri et al; 2007). 
However concomitant treatment with the JNK inhibitor did not reverse the 
effects of anisomycin on foci formation (Figure 4.3). Anisomycin can also 
inhibit protein synthesis at concentrations above 10ug/ml (Sampieri et al; 
2007) and it is possible that this might be the process through which it 
attenuates foci formation. However in these studies anisomycin was used at a 
lower concentration concentration. It would be of interest to assess the action 
of anisomycin on protein synthesis in these cells at the concentrations used.  
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The cdk5 inhibitor roscovitine, when used at higher concentrations where it is 
known to affect both cdks and MAP kinases resulted in inhibition of foci thus 
reiterating a potential role of MAP kinases in foci formation (Figure 4.7). 
 
 MAPKAP kinase 2 can also be inhibited by rottlerin, which is also an inhibitor 
of PKC (Blanquet et al, 2003). Rottlerin was found to inhibit foci formation. In 
order to rule out PKC action in this process, treatments were performed with 
PMA and EGCG. Although PMA did not affect foci formation on its own, it 
reversed the effects of rottlerin by increasing the immobile fraction of 
PDE4A4-GFP foci. Inhibition of PKC isoforms PKCα, β1,ε  with RO320432 
(Birchall et al; 1994) and GO6983 to inhibit PKCα, β, γ, δ (Wang et al; 2004) 
increased the levels of foci in cells suggesting the signalling of PKC isoforms 
α, β, γ, δ, or ε  is involved in foci formation. To confirm PKC involvement in foci 
formation future work would entail the selective siRNA-mediated knockdown 
of specific PKC isoforms.  
 
Calcium is an important intracellular messenger regulating many signalling 
pathways. In order to evaluate its effects on foci formation/dispersal, 
treatments were performed with calcium modulators thapsigargin and 
ionomycin (Won and Orth, 1995, Aagaard-tillery and Jelinek, 1995). Both 
ionomycin and thapsigargin inhibited foci formation, indicating an involvement 
of calcium, derived either from intracellular stores or externally, in regulating 
this process.  
 
One effector of calcium signalling is PKC. Only conventional but not novel and 
atypical isoforms of PKC is known to be activated by calcium (Mackay and 
Twelves, 2007). It is possible that such species are indeed involved in foci 
regulation, as PKC inhibition appears to facilitate foci formation. To further 
investigate possible downstream effectors of calcium signalling, inhibitors or 
calmodulin Kinase II (KN62) and calcineurin (Cyclosporin) were used. 
However, both of these had no effect on foci formation (Figure 4.4).  
 
 216 
PDE4A4B can be activated upon stimulation of p70S6 kinase and PI3 Kinase 
in response to growth hormone stimulation in fibroblasts (Mackenzie et al, 
1998). Hence to ascertain the potential role of PI3 kinase pathway in foci 
formation, CHO cells stably expressing PDE4A4GFP were treated with the 
PI3 kinase inhibitors, wortmanin and Ly294002, both of which enhanced the 
foci formation. However, inhibition of p70S6 kinase by rapamycin and GSK3 
by the GSK3β inhibitor had no effect on foci formation thus ruling out the role 
of both of these kinases. PI3 kinase, however, triggers a complex pathway of 
events in cells whereupon it activates a myriad of kinases, including PKC 
(Hirai and Chida; 2003) and ERK (Kim et al; 2007, Xu and Yu, 2007), leaving 
a number of possible actions and thereby routes to pursue in further research, 
thus the downstream targets for PI3 kinase effects have still to be determined 
(Figure 4.5).  
 
PDE4A4 is known to associate with Src tyrosyl kinases (Beard et al, 2002 and 
McPhee et al, 1999). In order to determine the possible involvement of tyrosyl 
kinases in foci formation the general tyrosyl kinase inhibitor genistein was 
used. Genistein treatment was found to abolish foci formation. In order to get 
further insight into a possible role of specific tyrosyl kinases in foci formation 
more inhibitors were assayed. These included inhibitors for Src tryosyl 
kinases (Su6656); EGFR tyrosyl kinases (PD168393) and PDGFR tyrosyl 
kinase (AG17). However, of these only the PDGF receptor Tyrosyl kinase 
inhibitor AG17 inhibited foci formation (Figure 4.6).  This suggests that the 
PDGF receptor may be important in foci formation. In order to address this 
future studies should be done to see if the PDGR receptor accumulates in foci 
or if siRNA-mediated knockdown of the PDGFR inhibits foci formation. The 
PDGF receptor is well known to dimerise upon ligand binding. The bound 
ligand is known to induce transphosphorylation of the intracellular domains of 
the receptors. These phosphorylated intracellular regions are known to initiate 
various signalling responses. Downregulation of PDGF receptor is achieved 
by its internalisation upon ligand binding to the receptor. The receptor is either 
then subjected to proteasomal degradation or recycled back to the surface of 
the receptor (Chiarugi et al; 2002).  
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Researchers have showed that inhibition of PDE4 activity regulates 
immunomodulatory functions (Jin et al, 2005, Jin and Conti 2002). Similarly, 
immunomodulatory functions of thalidomide have been recently established 
(OKafor, 2003, Powell 1999); a potential role of thalidomide in regulating foci 
formation was therefore studied. Thalidomide treatment inhibited foci 
formation. Thalidomide is known to act as an anti-inflammatory agent by 
decreasing the levels of TNFα yet at the same time it is shown to increase the 
production of IFNγ and IL-5 in mononuclear cells (Direskeneli et al; 2007). 
Conversely, PDE4 isoforms have been shown to decrease the production of 
IFNγ and IL-5 in T-cells (Peter et al, 2007). Hence it could be hypothesised 
that foci formation might be a net result of the balance of these two affects, 
the confirmation of which requires further investigation.  
 
It has been suggested that PDE4 isoforms may form oligomers by a process 
involving their regulatory domains UCR1 and UCR2 (Richter and Conti, 2002).  
However, work form our laboratory suggests that whilst this may occur in 
transfected cells overexpressing PDE4 isoforms it is less likely to occur in vivo 
due to the interaction of PDE4 isoforms with partner proteins, which would 
prevent dimerisation occurring. Furthermore, UCR1/2 is conserved amongst 
sub-families implying that heterodimers may occur between different isoforms. 
This very clearly does not occur in vivo as isoforms can be selectively 
immunoprecipitated. Thus dimerisation may only be a feature of 
overexpression systems or exist only under certain cellular conditions. 
 
When it occurs, dimerization has been suggested to regulate the sensitivity of 
PDE4 isoforms to rolipram inhibition (Richter et al 2004). In order to evaluate 
any potential role of oligomerization in foci formation, co-immunoprecipitation 
studies were carried out using differently tagged PDE4A4 species and, in 
separate experiments with differently tagged PDE4D3 species (Figure 4.9). 
Doing this, it was found that overexpressed PDE4D3 oligomerized in cells 
whilst overexpressed PDE4A4 did not appear to show any dimerisation in the 
presence or absence of rolipram. It might be that the residues required for 
oligomerisation are not well conserved in PDE4A4 thus preventing the 
oligomerisation. Another explanation is that PDE4A4 foci formation perhaps 
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requires stabilising factors that are lost upon cell lysis thus disrupting foci. 
However, the role of experimental conditions cannot be ruled out. Further 
investigations are required to identify the key residues as well as their 
conservation in various PDE4 sub-families to understand the role of 
oligomerisation in foci formation.  Although it is clear that foci PDE4A4 
species must co-exist the interaction may not be direct but mediated by a 
linker protein. Perhaps this is the induced species that requires protein 
synthesis and this may be released upon cell disruption.  It may then be 
useful to treat cells with a membrane permeable cross-linker to see if this 
causes the rolipram-induced association of species with PDE4A4. Indeed, this 
may be the route in future to analyse immunoprecipitates by proteomics. 
 
Previous reports (Terry et al; 2003) established that protein synthesis is 
required for foci formation as well as maintenance. To further investigate the 
role of protein turnover in foci formation cells were treated with the protein 
synthesis inhibitor, cycloheximide as well as the protein degradation inhibitor 
MG132 respectively. Both cycloheximide and MG132 strongly inhibited foci 
formation. Also they started dispersing rolipram-preformed foci within 30 
minutes and completely dispersed them by the end of 5 hours. Inhibition of 
total cell protein turnover yielded similar results (Figure 4.10 and 4.11).  
 
PDE4A4 did not show any ubiquitination in the presence or absence of 
rolipram as determined by immunoblotting nor did it co-localise with 
ubiqutinylated proteins in confocal studies. Further studies are required to 
unravel the role of protein turnover in foci stability as well as in formation.  
 
To further ascertain the role of protein turnover in conjunction with signalling 
pathways on foci stability, various inhibitors that were used in foci formation 
assays as described above were assayed. This was based upon the idea of 
trying to discriminate compounds that regulated foci formation from foci 
stabilisation. By blocking protein synthesis and degradation we can observe a 
rate of decay of foci. However, any compounds that accelerated the decay, 
presumably could exert an effect on the machinery that held foci together 
independent of any action of protein synthesis and turnover.  
 219 
 
Thapsigargin caused complete dispersal of foci within 30 minutes in the 
absence of active protein turnover and started dispersing foci within 30 
minutes in the presence of active protein turnover. However by the end of 5 
hours all the foci were dispersed as measured by plate reader assay, whereas  
PKC inhibition with Rottlerin and RO320432 dispersed all foci within 30 
minutes both in the presence and absence of active protein turnover. 
 
Similarly, activation of p38 MAPK by anisomycin dispersed foci completely 
within 30 minutes in the presence or absence of active protein turnover. 
However, inhibition of MEK using UO126 although initially enhanced the 
immobile fraction of GFP eventually stimulated the dispersal of foci (figure 
4.12). It should be noted that anisomycin and UO126 have inhibitory and 
promoting affects on foci formation respectively which reflects their effects on 
foci stability.  
 
The general tyrosine kinase inhibitor, genistein and PI3 kinase inhibitor, 
Ly294002 yielded similar results as anisomycin suggesting an inhibitory effect 
on foci formation (figure 4.13 and 4.14). 
 
In general it could be proposed that these signalling inhibitors and their 
respective signalling complexes could act in three different ways. Firstly, they 
might affect foci formation and stability directly. Secondly, they might alter the 
signals for protein turnover thereby influencing foci indirectly and finally they 
might act to affect foci formation as well as protein turnover thus enhancing or 
slowing foci formation as well as dispersal. Unravelling the components of foci 
formation and the signalling complexes will require further rigorous 
investigations using techniques such as truncation studies and proteomics 
analysis, plus electron microscopy to identify whether foci are confined to 
vesicles or other sub-cellular organelles etc.  
6.3 RhoGAPs, Arrestins and PDE4 isoforms 
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Rho family of GTPases regulate F-actin and microtubule dynamics. These 
GTPases are activated by guanine exchange factors (GEFs) and are inhibited 
by GTPase activating proteins (GAP) and guanine dissociation inhibitors 
(GDI) (Buchsbaum et al; 2007).  arrestins have been shown to be an integral 
part of wide variety of processes like chemotaxis, endocytosis and stress fibre 
formation by interacting or regulating Rho GTPases (Kim and Han, 2007, 
Barnes et al, 2005, Goodman et al, 1996). Similarly, PDE4 isoforms are 
known to regulate cell migration by regulating the activity of Rho GTPases 
(Fleming et al; 2004). Chapter 5 describes these interactions in detail and 
attempts to characterise their functional outcome.  
 
ARHGAP21 is ~1957 amino acid protein and is a novel GTPase activating 
protein (GAP) for Cdc42 comprising PDZ, ARF binding, PH and Rho binding 
domains along with a GAP domain (Menetrey et al; 2007, Dubois et al, 2005, 
Basseres et al, 2002). ARHGAP21 was shown to interact with  arrestins in a 
yeast two-hybrid screen (DeWire et al 2007). In order to characterise the 
interaction of arrestin-ARHGAP21, various truncates of ARHGAP21 were 
used (Figure 5.2). To identify the binding site of  arrestin on ARHGAP21, a 
full length ARHGAP21 peptide array was probed with purified β-arrestin-1 
GST.  arrestin showed strong interaction with the RhoGAP domain (1321-
1360) of the ARHGAP21 peptide array (Figure 5.2). Alanine substitution 
analysis of selected residues within the region revealed key residues 
important for the interaction. In particular, alanine substitution of a series of 
glutamic acid residues, namely E1341, E1342, E1344, and E1345, either 
collectively or individually severely affected β-arrestin interaction (Figure 5.3). 
In reciprocal studies to further characterise the interaction sites of ARHGAP21 
on  arrestins, a peptide array of β-arrestin 1 was probed with truncates 
containing the purified RhoGAP domain of ARHGAP21 (Figure 5.4). The 
RhoGAP domain of ARHGAP21 showed interaction with peptides containing 
residues 96-130, mapping to N-domain of β-arrestin 1. Chapter 5 attempted to 
characterise the interaction with   arrestin1. Understanding the interaction of 
ARHGAP21 with  arrestin 2 comprises a part of future work. Alanine 
substitution scan of binding regions revealed key residues on  arrestin that 
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interact with ARHGAP21. From peptide array analysis, it could be proposed 
that ARHGAP21 interacts with an E-(X) 4-KLGEH-(X) 5-E site on  arrestin 1 
(Figure 5.5 and Figure 5.6).  
 
Pull down assays with purified fragments of ARHGAP21 and  arrestin 1 were 
carried out to ascertain the nature of the interaction. Purified  arrestin 1 
interacted with fragments of ARHGAP21 containing the RhoGAP domain 
(figure 5.7). To further elucidate the interaction, HEK293 cells stably 
expressing the angiotensin AT1A receptor were used. The AT1A receptor 
activates Rho through the Gq/G11 pathway with β-arrestin (Figure 5.8, Barnes 
et al 2005). Hence these cells would prove valuable for understanding the 
interaction of  arrestin with ARHGAP21, a Rho GTPase activating protein. 
 arrestin interacted with ARHGAP21 in basal conditions and the interaction 
did not change even after Gq/G11 activation, suggesting that the interaction is 
governed by factors independent of Gq/G11 pathway (Figure 5.9).  
 
All PDE4 isoforms are known to interact with  arrestins through their 
conserved catalytic unit. In the case of PDE4D5, this interaction leads to 
translocation of  arrestin/PDE4D5 complex to the β2-adrenoceptor and leads 
to consequent desensitisation of the receptor (Perry et al, 2002). Of all the 
PDE4 isoforms studied so far,  arrestins show preferential binding to 
PDE4D5 due an extra binding site present in its isoform specific N-terminal 
region (Bolger et al, 2003). Thus to determine the involvement of PDE4 
isoforms, particularly PDE4D5, in  arrestin/ARHGAP21 interaction, lysates 
the AT1A receptor stable cell line were used for co-immunoprecipitation 
studies. Endogenous ARHGAP21 was found to interact with PDE4D5 (Figure 
5.10). PDE4D5 directly interacted with both the ARF binding domain as well 
as the RhoGAP domain of ARHGAP21 (Figure 5.11). Since only truncates 
were used in this study, it is still not clear if PDE4D5 has other binding sites 
on ARHGAP21. Further investigations are required to identify any extra 
binding sites if any and also the residues involved in the interaction by peptide 
array analysis and through further mutation and truncation analyses. Also, it 
would be of interest to establish whether isoforms from other PDE4 sub-
families are able to interact with ARHGAP21. It should be noted that 
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 arrestins only bind to RhoGAP domain whereas PDE4D5 binds to both ARF 
and RhoGAP domains of ARHGAP21. Whether  arrestin and PDE4D5 
compete with each other for binding to the RhoGAP domain of ARHGAP21 is 
yet to be determined.  
 
PDE4 activation is sometimes known to alter the affinity of these enzymes to 
certain interacting partners. For instance, PKA phosphorylation and activation 
is shown to release PDE4D3 and PDE4C2, but not PDE4B1, from the full-
length DISC1 isoform (Murdoch et al; 2007). Henceforth, the role of PDE4 
activity and PKA phosphorylation in regulating the interaction of ARHGAP21 
with PDE4D5 was determined in the presence or absence of Gq/G11 
activation. Neither PDE4 inhibition in cells nor PKA phosphorylation (with 
subsequent activation of PDE4 activity) affected the interaction of PDE4D5 
with ARHGAP21 (Figure 5.12). It could be inferred from the above results that 
ARHGAP21/PDE4D5/β-arrestin interaction is independent of Gq/G11 activity or 
PKA activity or PDE4 activity. 
 
Future work would involve delineation of binding sites of PDE4s on ARHGAP 
and vice versa along with understanding the dynamics of the interaction 
including the role of signalling pathways, but most importantly, the functional 
outcome of the interaction. Since ARHGAP21 is a novel GAP it is poorly 
characterised and its functions are not fully understood. Dubois and 
coworkers have shown that ARHGAP21/10 acts as a GAP for cdc42 in Golgi 
and regulates the F-actin dynamics (Dubois et al; 2005). Given that  arrestin 
and PDE4D5 bind to the RhoGAP domain of ARHGAP21, it could be 
speculated that either of these proteins, or both, would have an affect the 
GAP activity of ARHGAP21. PDE4 activity is required for cell migration as 
reported previously (Fleming et al. 2004). One possibility is that 
ARHGAP21/PDE4D5 along with   arrestin might play a role in cell migration. 
Also, the PH domains of ARHGAP21 might play a crucial role in membrane 
translocation of this GAP, which might help recruit the  arrestin/PDE4D5 
complex to membrane receptors under the influence of appropriate stimulus 
such as PI3 kinase activity. Since the  arrestin-PDE4D5 complex is involved 
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in receptor desensitisation, ARGAP21 might play a role in endocytosis and 
recycling of the complex to and from Golgi to the plasma membrane.  
 
In conclusion, the  arrestin/PDE4D5/ARHGAP21 interaction is a novel finding 
and needs extensive characterisation to understand the functional outcome. It 
still needs to be determined whether all the three proteins function together or 
in individual complexes.  
 
6.4 Final Conclusion 
 
These studies have given further insight into the complexity of PDE4 
regulation. The identification of effects of SUMOylation on PDE4 function 
paves a way to understand the complex compartmentalisation of cAMP 
signalling. Foci studies attempted to shed light on the role of PDE4 inhibitors 
in regulating the localisation of the PDE4A4 isoform. Identification of β-
arrestin/ARHGAP21/PDE4D5 interaction complex gives further insight into the 
role of cAMP signalling in regulating cell migration which is the basis for 
conditions such as tumour metastasis and wound repair.  
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Appendix I 
 
List of constructs used for Yeast two hybrid screening by Hybrigenics 
for mapping arrestin-Arhagp21 interaction 
 
 
 
 
 
 
 Clone name Type Seq 
 
Start Stop 
1 hgx1193v1_pB27C-48 
 
5p 3p 4743 
 
5274 
 
2 hgx1193v1_pB27C-2 
 
5p 3p 4737 
 
5274 
 
3 hgx1193v1_pB27C-37 
 
5p 3p 4557 
 
5274 
 
4 hgx1193v1_pB27C-8 
 
5p 3p 4557 
 
5274 
 
5 hgx1193v1_pB27C-63 
 
5p 3p 4557 
 
5274 
 
6 hgx1193v1_pB27C-36 
 
5p 3p 4557 
 
5274 
 
7 hgx1193v1_pB27C-27 
 
5p 3p 4557 
 
5274 
 
8 hgx1193v1_pB27C-5 
 
5p 3p 4530 
 
5032 
9 hgx1193v1_pB27C-68 
 
5p 3p 4746 
 
5627 
10 hgx1193v1_pB27C-55 
 
5p 3p 4746 
 
5627 
11 hgx1193v1_pB27C-19 
 
5p 3p 4746 
 
5627 
12 hgx1193v1_pB27C-46 
 
5p 3p 4626 
 
5659 
13 hgx1193v1_pB27C-56 
 
5p 3p 4683 
 
5668 
14 hgx1193v1_pB27C-15 
 
5p 3p 4749 
 
5277 
15 hgx1193v1_pB27C-9 
 
5p 3p 4521 
 
5312 
16 hgx1193v1_pB27C-25 
 
5p 3p 4521 
 
5312 
17 hgx1193v1_pB27C-69 
 
5p 3p 4749 
 
5277 
18 hgx1193v1_pB27C-26 
 
5p 3p 4626 
 
5393 
19 hgx1193v1_pB27C-65 
 
5p 3p 4749 
 
5277 
20 hgx1193v1_pB27C-47 
 
5p 3p 4749 
 
5277 
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Clone 1- hgx1193v1_pB27C-48 
 
5'CATCACCTCAGATTATTCCACCACATCGTCTGCTACATACTTGACTAGC
CTGGACTCCAGTCGACTGAGCCCTGAGGTGCAATCCGTGGCAGAGAGC
AAGGGGGACGAGGCAGATGACGAGAGAAGCGAACTCATCAGTGAAGGG
CGGCCTGTGGAAACCGACAGCGAGAGCGAGTTTCCCGTGTTCCCCACA
GCCTTGACTTCAGAGAGGCTTTTCCGAGGAAAACTGCAAGAAGTGACTA
AGAGCAGCCGGAGAAATTCTGAAGGAAGTGAATTAAGTTGCACCGAGGG
AAGTTTAACATCAAGTTTAGATAGCCGGAGACAGCTCTTCAGTTCCCATA
AACTCATCGAATGTGATACTCTTTCCAGGAAAAAATCAGCTAGATTCAAG
TCAGATAGTGGAAGTCTAGGAGATGCCAAGAATGAGAAAGAAGCACCTT
CGTTAACTAAAGTGTTTGATGTTATGAAAAAAGGAAAGTCAACTGGGAGT
TTACTGACACCCACCAGAGGCGAATCCGAAAAACAGGAACCC-3' 
 
Clone 2- hgx1193v1_pB27C-2 
 
5'CAGCACCATCACCTCAGATTATTCCACCACATCGTCTGCTACATACTTG
ACTAGCCTGGACTCCAGTCGACTGAGCCCTGAGGTGCAATCCGTGGCA
GAGAGCAAGGGGGACGAGGCAGATGACGAGAGAAGCGAACTCATCAGT
GAAGGGCGGCCTGTGGAAACCGACAGCGAGAGCGAGTTTCCCGTGTTC
CCCACAGCCTTGACTTCAGAGAGGCTTTTCCGAGGAAAACTGCAAGAAG
TGACTAAGAGCAGCCGGAGAAATTCTGAAGGAAGTGAATTAAGTTGCAC
CGAGGGAAGTTTAACATCAAGTTTAGATAGCCGGAGACAGCTCTTCAGTT
CCCATAAACTCATCGAATGTGATACTCTTTCCAGGAAAAAATCAGCTAGA
TTCAAGTCAGATAGTGGAAGTCTAGGAGATGCCAAGAATGAGAAAGAAG
CACCTTCGTTAACTAAAGTGTTTGATGTTATGAAAAAAGGAAAGTCAACT
GGGAGTTTACTGACACCCACCAGAGGCGAATCCGAAAAACAGGAACCC-
3' 
 
Clone 3-hgx1193v1_pB27C-37 
 
5'CTTTGCCATCCTGAAAGAGAGCCCCAGGTCACTTCTGGCACAGAAGTC
CTCCCACCTTGAAGAGACAGGCTCTGACTCTGGCACTTTGCTCAGCACG
TCTTCCCAGGCCTCCCTGGCAAGGTTTTCCATGAAGAAATCAACCAGTC
CAGAAACGAAACATAGCGAGTTTTTGGCCAACGTCAGCACCATCACCTC
AGATTATTCCACCACATCGTCTGCTACATACTTGACTAGCCTGGACTCCA
GTCGACTGAGCCCTGAGGTGCAATCCGTGGCAGAGAGCAAGGGGGACG
AGGCAGATGACGAGAGAAGCGAACTCATCAGTGAAGGGCGGCCTGTGG
AAACCGACAGCGAGAGCGAGTTTCCCGTGTTCCCCACAGCCTTGACTTC
AGAGAGGCTTTTCCGAGGAAAACTGCAAGAAGTGACTAAGAGCAGCCGG
AGAAATTCTGAAGGAAGTGAATTAAGTTGCACCGAGGGAAGTTTAACATC
AAGTTTAGATAGCCGGAGACAGCTCTTCAGTTCCCATAAACTCATCGAAT
GTGATACTCTTTCCAGGAAAAAATCAGCTAGATTCAAGTCAGATAGTGGA
AGTCTAGGAGATGCCAAGAATGAGAAAGAGCACCTTCGTTAACTAAAGT
GTTTGATGTTATGAAAAAAGGAAAGTCAACTGGGGAGTTTACTGACACCC
ACCAGAGCGAATCCGAAAAACAGGACCCCTTCGTGG-3' 
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Clone 8-hgx1193v1_pB27C-5 
 
CAACAAGTCACCAACTCTCAGCTGTCGCTTTGCCATCCTGAAAGAGAGC
CCCAGGTCACTTCTGGCACAGAAGTCCTCCCACCTTGAAGAGACAGGCT
CTGACTCTGGCACTTTGCTCAGCACGTCTTCCCAGGCCTCCCTGGCAAG
GTTTTCCATGAAGAAATCAACCAGTCCAGAAACGAAACATAGCGAGTTTT
TGGCCAACGTCAGCACCATCACCTCAGATTATTCCACCACATCGTCTGCT
ACATACTTGACTAGCCTGGACTCCAGTCGACTGAGCCCTGAGGTGCAAT
CCGTGGCAGAGAGCAAGGGGGACGAGGCAGATGACGAGAGAAGCGAA
CTCATCAGTGAAGGGCGGCCTGTGGAAACCGACAGCGAGAGCGAGTTT
CCCGTGTTCCCCACAGCCTTGACTTCAGAGAGGCTTTTCCGAGGAAAAC
TGCAAGAAGTGACTAAGAGCAGCCGGAGAAATTCTGAAGGAAGTGAATT
AAGTTGCACCGAGG 
 
Clone 9- hgx1193v1_pB27C-68 
 
CACCTCAGATTATTCCACCACATCGTCTGCTACATACTTGACTAGCCTGG
ACTCCAGTCGACTGAGCCCTGAGGTGCAATCCGTGGCAGAGAGCAAGG
GGGACGAGGCAGATGACGAGAGAAGCGAACTCATCAGTGAAGGGCGGC
CTGTGGAAACCGACAGCGAGAGCGAGTTTCCCGTGTTCCCCACAGCCTT
GACTTCAGAGAGGCTTTTCCGAGGAAAACTGCAAGAAGTGACTAAGAGC
AGCCGGAGAAATTCTGAAGGAAGTGAATTAAGTTGCACCGAGGGAAGTT
TAACATCAAGTTTAGATAGCCGGAGACAGCTCTTCAGTTCCCATAAACTC
ATCGAATGTGATACTCTTTCCAGGAAAAAATCAGCTAGATTCAAGTCAGA
TAGTGGAAGTCTAGGAGATGCCAAGAATGAGAAAGAAGCACCTTCGTTA
ACTAAAGTGTTTGATGTTATGAAAAAAGGAAAGTCAACTGGGAGTTTACT
GACACCCACCAGAGGCGAATCCGAAAAACAGGAACCCACATGGAAAAC
GAAAATAGCAGATCGGTTAAAACTGAGACCCAGAGCCCCTGCGGATGAC
ATGTTTGGAGTAGGGAATCACAAAGTGAATGCCGAGACTGCTAAAAGGA
AAAGCATCCCGGCGCAGACATACACTAGGAGGGCACAGAGATGCTACC
GAAATCAGCGTTTTGAATTTTTGGGAAAGTGCATGAGCA 
 
Clone 12- hgx1193v1_pB27C-46 
 
CTCTGACTCTGGCACTTTGCTCAGCACGTCTTCCCAGGCCTCCCTGGCA
AGGTTTTCCATGAAGAAATCAACCAGTCCAGAAACGAAACATAGCGAGTT
TTTGGCCAACGTCAGCACCATCACCTCAGATTATTCCACCACATCGTCTG
CTACATACTTGACTAGCCTGGACTCCAGTCGACTGAGCCCTGAGGTGCA
ATCCGTGGCAGAGAGCAAGGGGGACGAGGCAGATGACGAGAGAAGCG
AACTCATCAGTGAAGGGCGGCCTGTGGAAACCGACAGCGAGAGCGAGT
TTCCCGTGTTCCCCACAGCCTTGACTTCAGAGAGGCTTTTCCGAGGAAA
ACTGCAAGAAGTGACTAAGAGCAGCCGGAGAAATTCTGAAGGAAGTGAA
TTAAGTTGCACCGAGGGAAGTTTAACATCAGTTTTACAATGCTTGGAGAC
GGCGGGAAAGTTCTTTTATTCCCCTAAAACCTGGAAGGGGATACCCTTTC
CGGGCAAAATAGCTCAGTTCAATTCAGAGAAGGCATGCAGGAGCAGCCC
ACGATGAAAAAGAACCCCCTCGTTAACTAACTGTTTATATTTTTTGGTAAG
AAAAGAAAACAGAGAGTGTGTTGTGT 
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Clone 13-hgx1193v1_pB27C-56 
 
CATGAAGAAATCAACCAGTCCAGAAACGAAACATAGCGAGTTTTTGGCCA
ACGTCAGCACCATCACCTCAGATTATTCCACCACATCGTCTGCTACATAC
TTGACTAGCCTGGACTCCAGTCGACTGAGCCCTGAGGTGCAATCCGTGG
CAGAGAGCAAGGGGGACGAGGCAGATGACGAGAGAAGCGAACTCATCA
GTGAAGGGCGGCCTGTGGAAACCGACAGCGAGAGCGAGTTTCCCGTGT
TCCCCACAGCCTTGACTTCAGAGAGGCTTTTCCGAGGAAAACTGCAAGA
AGTGACTAAGAGCAGCCGGAGAAATTCTGAAGGAAGTGAATTAAGTTGC
ACCGAGGGAAGTTTAACATCAAGTTTAGATAGCCGGAGACAGCTCTTCA
GTTCCCATAAACTCATCGAATGTGATACTCTTTCCAGGAAAAAATCAGCT
AGATTCAAGTCAGATAGTGGAAGTCTAGGAGATGCCAAGAATGAGAAAG
AAGCACCTTCGTTAACTAAAGTGTTTGATGTTATGAAAAAAGGAAAGTCA
ACTGGGAGTTTACTGACACCCACCAGAGGCGAATCCGAAAAACAGGAAC
CCACATGGAAAACGAAAATAGCAGATCGGTTAAAACTGAGACCCAGAGC
CCCTGCGGATGACATGTTTGGAGTAGGGAATCACAAAGTGAATGCCGAG
ACTGCTAAAAGGAAAAGCATCCCGCG  
 
Clone 14-hgx1193v1_pB27C-15 
 
CTCAGATTATTCCACCACATCGTCTGCTACATACTTGACTAGCCTGGACT
CCAGTCGACTGAGCCCTGAGGTGCAATCCGTGGCAGAGAGCAAGGGGG
ACGAGGCAGATGACGAGAGAAGCGAACTCATCAGTGAAGGGCGGCCTG
TGGAAACCGACAGCGAGAGCGAGTTTCCCGTGTTCCCCACAGCCTTGAC
TTCAGAGAGGCTTTTCCGAGGAAAACTGCAAGAAGTGACTAAGAGCAGC
CGGAGAAATTCTGAAGGAAGTGAATTAAGTTGCACCGAGGGAAGTTTAA
CATCAAGTTTAGATAGCCGGAGACAGCTCTTCAGTTCCCATAAACTCATC
GAATGTGATACTCTTTCCAGGAAAAAATCAGCTAGATTCAAGTCAGATAG
TGGAAGTCTAGGAGATGCCAAGAATGAGAAAGAAGCACCTTCGTTAACT
AAAGTGTTTGATGTTATGAAAAAAGGAAAGTCAACTGGGAGTTTTACTGA
CACCCACCAGAGGCGAATCCGAAAAACAGGAACCCACGT 
 
Clone 15- hgx1193v1_pB27C-9 
 
CTCAAAACACAACAAGTCACCAACTCTCAGCTGTCGCTTTGCCATCCTGA
AAGAGAGCCCCAGGTCACTTCTGGCACAGAAGTCCTCCCACCTTGAAGA
GACAGGCTCTGACTCTGGCACTTTGCTCAGCACGTCTTCCCAGGCCTCC
CTGGCAAGGTTTTCCATGAAGAAATCAACCAGTCCAGAAACGAAACATAG
CGAGTTTTTGGCCAACGTCAGCACCATCACCTCAGATTATTCCACCACAT
CGTCTGCTACATACTTGACTAGCCTGGACTCCAGTCGACTGAGCCCTGA
GGTGCAATCCGTGGCAGAGAGCAAGGGGGACGAGGCAGATGACGAGA
GAAGCGAACTCATCAGTGAAGGGCGGCCTGTGGAAACCGACAGCGAGA
GCGAGTTTCCCGTGTTCCCCACAGCCTTGACTTCAGAGAGGCTTTTCCG
AGGAAAACTGCAAGAAGTGACTAAGAGCAGCCGGAGAAATTCTGAAGGA
AGTGAATTAAGTTGCACCGAGGGAAGTTTAACATCAAGTTTAGATAGCCG
GAGACAGCTCTTCAGTTCCCATAAACTCATCGAATGTGATACTCTTTCCA
GAAAAAAATCAGCTAGATTCAAGTCAGATAGTGAAGTCTAGGAGATGCCA
AGAATGAGAAAGAGCACCTTCGTTAACTAAAGTGTTTGATGTTATGAAAA
AAGGAAAGTCAACTGGGGAGTTTACTGACCCCCCACCAG 
Clone 17-hgx1193v1_pB27C-69 
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CTCAGATTATTCCACCACATCGTCTGCTACATACTTGACTAGCCTGGACT
CCAGTCGACTGAGCCCTGAGGTGCAATCCGTGGCAGAGAGCAAGGGGG
ACGAGGCAGATGACGAGAGAAGCGAACTCATCAGTGAAGGGCGGCCTG
TGGAAACCGACAGCGAGAGCGAGTTTCCCGTGTTCCCCACAGCCTTGAC
TTCAGAGAGGCTTTTCCGAGGAAAACTGCAAGAAGTGACTAAGAGCAGC
CGGAGAAATTCTGAAGGAAGTGAATTAAGTTGCACCGAGGGAAGTTTAA
CATCAAGTTTAGATAGCCGGAGACAGCTCTTCAGTTCCCATAAACTCATC
GAATGTGATACTCTTTCCAGGAAAAAATCAGCTAGATTCAAGTCAGATAG
TGGAAGTCTAGGAGATGCCAAGAATGAGAAAGAAGCACCTTCGTTAACT
AAAGTGTTTGATGTTATGAAAAAGGAAAGTCAACTGGGAGTTTACTGACA
CCCACCAGAGGCGAATCCCGAAAAACAGGAACCCACCGTTTCGGGGGC
CCCTGGGGCCCCTCGAGTAGCCTAGTGTCTAGAGGCCCGGGTCCCCAT
TTGGCCCTAATGTGAGGTCGGAATAACAATTCATTGGGCGTGCCTTTTTG
CAA 
 
Clone 18-hgx1193v1_pB27C-26 
 
CTCTGACTCTGGCACTTTGCTCAGCACGTCTTCCCAGGCCTCCCTGGCA
AGGTTTTCCATGAAGAAATCAACCAGTCCAGAAACGAAACATAGCGAGTT
TTTGGCCAACGTCAGCACCATCACCTCAGATTATTCCACCACATCGTCTG
CTACATACTTGACTAGCCTGGACTCCAGTCGACTGAGCCCTGAGGTGCA
ATCCGTGGCAGAGAGCAAGGGGGACGAGGCAGATGACGAGAGAAGCG
AACTCATCAGTGAAGGGCGGCCTGTGGAAACCGACAGCGAGAGCGAGT
TTCCCGTGTTCCCCACAGCCTTGACTTCAGAGAGGCTTTTCCGAGGAAA
ACTGCAAGAAGTGACTAAGAGCAGCCGGAGAAATTCTGAAGGAAGTGAA
TTAAGTTGCACCGAGGGAAGTTTAACATCAAGTTTAGATAGCCGGAGACA
GCTCTTCAGTTCCCATAAACTCATCGAATGTGATACTCTTTCCAGGAAAA
AATCAGCTAGATTCAAGTCAGATAGTGGAAGTCTAGGAGATGCCAAGAAT
GAGAAAGAAGCACCTTCGTTAACTAAAGTGTTTTGATGTTATGAAAAAAG
GAAAGTCAACTGGGGAGTTTACTGACACCCACCAGAGGCGAATCCGAAA
AACAGGAACCCACATGGGAAAACGAAAATAGCAGATCGGTTAAAACTGA
GACCCAGAGCCCCTGCGGATGACATGTTTGGGAGTAGGGATCACA 
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Appendix II 
 
Section II.I  
 
Structure-activity relationship of PDE4 inhibitors- A preliminary study 
 
Rolipram is an active site directed inhibitor and is classified as first generation 
PDE4 selective inhibitor along with Ro 20-1724. Second generation of PDE4 
inhibitors include Ariflo® and Roflumilast®.  Third generation PDE4 inhibitors 
include Xanthine derivatives. Rolipram inhibits isoforms of all PDE4 
subfamilies and is not subfamily specific (Houslay and Adams, 2003, 
Lugnier,et al 1986, Lugnier, 2006). It is widely known that the side effects like 
nausea and emesis caused by rolipram have limited the use of rolipram as a 
therapeutic agent (Houslay et al; 2005).  
 
It has been shown (Terry et al, 2003) that PDE4A4 and its orthologue 
PDE4A5 when subjected to chronic rolipram treatment (10-18hrs) can 
undergo redistribution in cells and form accretion foci. In that study it was 
proposed that various of the side-effects caused by rolipram may be mediated 
through cAMP-independent foci formation due to the redistribution of PDE4A4 
and associated proteins within the cell (Terry et al; 2003). 
 
This concept was formulated from observing that various of the PDE4 
inhibitors that are known to have pronounced side effects induce foci 
formation (example; Rolipram, RO 20-17240), whereas, other PDE4 inhibitors 
like Ariflo® do not induce foci formation of PDE4A4 and have lesser effects 
(Terry et al; 2003).  
 
I set out to gain further insight into this by screening a large panel of PDE4 
inhibitors using a plate reader assay to identify inhibitors that allowed foci 
formation and to quantify their action, as described in section 2.15.  
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All PDE4 inhibitors that induce foci were then to be analysed by our 
collaborator, Dr David Adams (Herriot-Watt University, Dept Chemistry) so 
that their structures can be compared in order to try and identify features that 
might potentially contribute to foci formation. In so doing we hoped to gain 
novel insight into an approach that would allow us to design a novel PDE4 
inhibitor that is devoid of side effects. This section of appendix presents 
various compounds that have been studied as a part of structure-activity 
relationship.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rolipram 
Ro 20-1724 
Ariflo (Cilomilast) Roflumilast 
Denbufylline 
Figure II.I: Chemical structures of various PDE4 inhibitors. Chemical structures 
taken from Houslay et al; 2005 
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Compound                   IC50                      Induces foci                       Inhibits foci  
RS-33793 (10mg/ml)         ---                                Yes                                        No   
 
YM-907 (10mg/ml)             ---                                No                                        Yes 
 
YM-976 (20mM)               2.2nM                           No                                         Yes 
  
Roflumilast (50mM)          1nM                              No                                         Yes  
 
CDP-40 (50mM)                4nM                             No                                         Yes    
 
ICI-63,197 (1mM)              4.6uM                          No                                         Yes 
 
Denbufylline (50mM)         1uM                             No                                         Yes 
 
Zardaverine (5mM)            2.5uM                         No                                         Yes 
 
Trequensin (1mM)             500nM                        No                                         Yes 
 
Milrinone (50mM)               1uM                           No                                          No  
 
CC-1069 (50mM)               10uM                         No                                         Yes 
 
CC-1003 (50mM)               10uM                         No                                          No 
 
CC-1104 (2.5mM)              2.5uM                        No                                          Yes 
 
CC-1018 (1mM)                  5uM                          No                                         Yes 
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CC-1115 (50mM)                1uM                          No                                   No 
 
CC-9088 (50mM)               10uM                         No                                   Yes 
 
CC-7034 (50mM)               50nM                         No                                   Yes 
 
Enoximone (10mM)            0.25uM                      No                                   Yes 
 
Amrinone (10mM)             5uM                      No                                          Yes 
 
Papverine (10mM)            10uM                    No                                          Yes 
 
CP-80633 (20mg/ml)         1.5uM                  No                                           Yes 
 
AH-8883 (200mM)             8uM                    Yes                                           No 
 
Z-15370A (20mg/ml)          ----                      No                                            Yes   
 
CH-4259 (50mm)               1uM                     No                                            Yes 
 
CT-2396 (20mM)               2uM                     Yes                                           No 
 
NCS-613 (100mM)             1uM                     No                                            Yes 
 
ICI-118,233 (20mg/ml)        ----                       No                                            No 
 
PMNPQ (100mM)                1uM                    Yes                                           No 
Cinpanfylline (100mM)         1uM                    Yes                                           No 
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APF-1 (50mM)                      5uM                   Yes                                           No 
 
APF-2 (20mM)                      2uM                    No                                          Yes 
 
RO-1067146 (4mM)              0.5uM                 Yes                                          No 
 
Pyradizanone  I (250mM)      2.0uM                  No                                          Yes 
 
Pyradizanone II  (250mM)      2.0uM                 No                                          Yes          
 
RWJ-22867 (50mM)              1uM                     No                                          No 
 
RO-458, 2640 (10mM)           1uM                     Yes                                        No 
 
Table II.I: A table showing various PDE4 inhibitors, stock concentrations and 
their IC/EC50 values for foci induction and inhibition as determined in a foci plate 
reader assay described in section 2.15 
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Figure II.II The effect of various PDE4 inhibitors on Rolipram induced foci of PDE4A4
Various PDE4 inhibitors were tested for their affects on rolipram (3uM) induced foci formation of GFP fusion protein of PDE4A4
in CHO cells using a florescent plate reader assay as described in section 2.15
Figure II.III Sequence alignment of human PDE4A4 and PDE4B2.
Sequence alignment was performed using ClustalW (Larkin et al; 2007).
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Figure II.IV: Crystal structure of catalytic domain of PDE4B2B
Image showing chain A of the dimeric PDE4B2B with rolipram bound. (1R06.pdb). Xu,
R.X., et al. (2004) Crystal structures of the catalytic domain of phosphodiesterase 4B
complexed with rolipram and AMP and the corresponding amino acids of PDE4A4 are
shown in the parentheses. JMB. 337. 355-365. Images were made using Chimera
(Petterson et al; 2004).
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Leptomycin
 No Rolipram                                Rolipram
Phospho tyrosine
No Rolipram                              Rolipram
Ubiquitin
 No Rolipram                                 Rolipram
DISC1
 No Rolipram                                     Rolipram
PYK2
 No Rolipram                                 Rolipram
Actin
No Rolipram                                Rolipram
Tubulin
 No Rolipram                              Rolipram
Rab 11
 No Rolipram                                  Rolipram
Rab 9
 No Rolipram                                Rolipram
mdm2
 No Rolipram                                 Rolipram
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Mitochondria
 No Rolipram                               Rolipram
UBC9
 No Rolipram                                 Rolipram
Calpastatin
 No Rolipram                            Rolipram
 No Rolipram                                 Rolipram
Lysosomes
Figure II.V: Immunocytochemical studies of foci interacting proteins
Immunocytochemical analysis of CHO cells stably expressing PDE4A4-GFP treated
with and without rolipram (10uM-16hrs) and stained for various proteins and various
sub-cellular organelles. All data shown are representatives of the results obtained
from three separate experiments.
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